Phenotypes associated with this allele

• Allele Symbol: Cd19⁺
• Allele Name: wild type
• Allele ID: MGI:2158247
• Summary: 165 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Cd19^tm1.1Oao/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5521195
cn2	Cd19^tm1(cre)Cgn/Cd19^+ Ifnar1^tm1Uka/Ifnar1^tm1Uka	B6.129P2-Cd19^tm1(cre)Cgn Ifnar1^tm1Uka	MGI:3829380
cn3	Cd19^tm1(cre)Cgn/Cd19^+ Fas^tm1Cgn/Fas^tm1Cgn	B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn	MGI:3690548
cn4	Cd19^tm1(cre)Cgn/Cd19^+ Wac^em2Cya/Wac^em2Cya	B6.Cg-Cd19^tm1(cre)Cgn Wac^em2Cya	MGI:7783621
cn5	Cd19^tm1(cre)Cgn/Cd19^+ Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben	B6.Cg-Cd1d1^tm1.1Aben Cd19^tm1(cre)Cgn	MGI:5318544
cn6	Fas^tm1Cgn/Fas^tm1Cgn Cd19^tm1(cre)Cgn/Cd19^+ Tg(Cd4-cre)1Cwi/0	B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn	MGI:3690549
cn7	Cd19^tm1(cre)Cgn/Cd19^+ Gna11^tm1Soff/Gna11^tm1Soff Gnaq^tm2Soff/Gnaq^tm2Soff	B6N.129-Cd19^tm1(cre)Cgn Gna11^tm1Soff Gnaq^tm2Soff	MGI:3699321
cn8	Cd19^tm1(cre)Cgn/Cd19^+ Klhl6^tm2Sato/Klhl6^tm2Sato	either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1)	MGI:3605618
cn9	Gt(ROSA)26Sor^tm1(gp80)Eces/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)	MGI:5004802
cn10	Ezh2^tm1.1Nesh/Ezh2^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:6393679
cn11	Ezh2^tm1.1Nesh/Ezh2^tm1.1Nesh Cd19^tm1(cre)Cgn/Cd19^+	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:6393694
cn12	Tnf^tm1.1Sned/Tnf^tm1.1Sned Cd19^tm1(cre)Cgn/Cd19^+	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:3527259
cn13	Prelid1^tm1Hmva/Prelid1^tm1Hmva Cd19^tm1(cre)Cgn/Cd19^+	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:5437512
cn14	Cd19^tm1(cre)Cgn/Cd19^+ Slc3a2^tm1.1Mgin/Slc3a2^tm1Yai	involves: 129 * C57BL/6 * SJL	MGI:3843277
cn15	Cd19^tm1(cre)Cgn/Cd19^+ Slc3a2^tm1.1Mgin/Slc3a2^tm1.1Mgin	involves: 129 * C57BL/6 * SJL	MGI:3843276
cn16	Cd19^tm1(cre)Cgn/Cd19^+ Igbp1^tm1Imku/Y	involves: 129P2/OlaHsd	MGI:3603798
cn17	Gt(ROSA)26Sor^tm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5574113
cn18	Cd19^tm1(cre)Cgn/Cd19^+ Derl2^tm1.1Hpl/Derl2^tm1.1Hpl	involves: 129P2/OlaHsd	MGI:4947223
cn19	Cd19^tm1(cre)Cgn/Cd19^+ Tnfaip3^tm1.1Awai/Tnfaip3^tm1.1Awai	involves: 129P2/OlaHsd	MGI:5291647
cn20	Cxcr4^tm2Yzo/Cxcr4^tm3.1Yzo Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:4878990
cn21	Pgap3^tm1Ymra/Pgap3^tm1Ymra Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5538667
cn22	Brca2^tm1Brn/Brca2^tm1Brn Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5495980
cn23	Brca2^tm1Brn/Brca2^tm1Brn Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5495979
cn24	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm1(ITK/SYK)Jrld/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd	MGI:4460905
cn25	Cd19^tm1(cre)Cgn/Cd19^+ Ltbr^tm1Avt/Ltbr^tm1Avt Tg(Lck-cre)I57Jxm/0	involves: 129P2/OlaHsd	MGI:4453323
cn26	Cd19^tm1(cre)Cgn/Cd19^+ Ltbr^tm1Avt/Ltbr^tm1Avt	involves: 129P2/OlaHsd	MGI:4453321
cn27	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd	MGI:5908453
cn28	Casp8^tm1Hed/Casp8^tm1Hed Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:3697395
cn29	Cd19^tm1(cre)Cgn/Cd19^+ Il10^tm1Roer/Il10^tm1Roer	involves: 129P2/OlaHsd	MGI:4355202
cn30	Srf^tm2Nor/Srf^tm2Nor Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:3843267
cn31	Bcl10^tm1Mak/Bcl10^tm1Mak Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd	MGI:5908454
cn32	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor^+ Malt1^tm1Mak/Malt1^tm1Mak	involves: 129P2/OlaHsd	MGI:5908455
cn33	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd	MGI:3055676
cn34	Cxcr4^tm2Yzo/Cxcr4^tm2Yzo Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:3526527
cn35	Cd19^tm1(cre)Cgn/Cd19^+ Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous	involves: 129P2/OlaHsd * 129S1/Sv	MGI:4839186
cn36	Pik3cd^tm1Tnr/Pik3cd^tm1Tnr Pten^tm2.1Ppp/Pten^tm2.1Ppp Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6	MGI:3796508
cn37	Del(14Trim13-Rnaseh2b)6Rdf/+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6	MGI:5305096
cn38	Is(14)1Rdf/Is(14)1Rdf Is(14)5Rdf/Is(14)5Rdf Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6	MGI:5305097
cn39	Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6	MGI:5305095
cn40	Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6	MGI:4437062
cn41	Cd19^tm1(cre)Cgn/Cd19^+ Mirc30^tm1.1Rdf/Mirc30^tm1.1Rdf	involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6	MGI:4437066
cn42	Cd19^tm1(cre)Cgn/Cd19^+ Prdm1^tm1Clme/Prdm1^tm1Clme	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:3606173
cn43	Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm1Sjk/Bax^tm2Sjk Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:3608659
cn44	Cd19^tm1(cre)Cgn/Cd19^+ Trp53^tm1Yjc/Trp53^tm1Yjc	involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6	MGI:5476680
cn45	Cd19^tm1(cre)Cgn/Cd19^+ Pax5^tm1Mbu/Pax5^tm3Mbu	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:3720352
cn46	Nle1^tm1Cba/Nle1^tm1.1Cota Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:5553374
cn47	Gt(ROSA)26Sor^tm10(Lmp1)Rsky/Gt(ROSA)26Sor^+ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ	MGI:5314093
cn48	Gt(ROSA)26Sor^tm10(Lmp1)Rsky/Gt(ROSA)26Sor^+ Tcrb^tm1Mom/Tcrb^+ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ	MGI:5314090
cn49	Gt(ROSA)26Sor^tm11(Lmp1)Rsky/Gt(ROSA)26Sor^+ Tcrb^tm1Mom/Tcrb^+ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5314091
cn50	Cd19^tm1(cre)Cgn/Cd19^+ Ell2^tm2.1Cmil/Ell2^tm2.1Cmil	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5793062
cn51	Cd19^tm1(cre)Cgn/Cd19^+ Ell2^tm1.1Cmil/Ell2^tm1.1Cmil	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5793061
cn52	Cd19^tm1(cre)Cgn/Cd19^+ Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc Traf2^tm1Rbr/Traf2^tm1Rbr	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:3777352
cn53	Gt(ROSA)26Sor^tm11(Lmp1)Rsky/Gt(ROSA)26Sor^+ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5314096
cn54	Itgav^tm2Hyn/Itgav^tm2.1Hyn Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB	MGI:3759846
cn55	Cd19^tm1(cre)Cgn/Cd19^+ Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL	MGI:3839883
cn56	Cd19^tm1(cre)Cgn/Cd19^+ Inpp5d^tm1Rav/Inpp5d^tm1Rav Pten^tm1Hwu/Pten^tm1Hwu	involves: 129P2/OlaHsd * 129S4/SvJae	MGI:5013951
cn57	Cd19^tm1(cre)Cgn/Cd19^+ Pten^tm1Hwu/Pten^tm1Hwu	involves: 129P2/OlaHsd * 129S4/SvJae	MGI:4829791
cn58	Cd19^tm1(cre)Cgn/Cd19^+ Rac1^tm1Tyb/Rac1^tm1Tyb	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:2684441
cn59	Cd19^tm1(cre)Cgn/Cd19^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5007685
cn60	Rbbp8^tm1Whl/Rbbp8^tm1.1Thl Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S4/SvJaeSor	MGI:5484529
cn61	Palb2^tm1.1Dli/Palb2^tm1.1Dli Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6	MGI:5495974
cn62	Zc3h12c^tm2c(EUCOMM)Hmgu/Zc3h12c^tm2c(EUCOMM)Hmgu Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N	MGI:6359749
cn63	Brca1^tm2Cxd/Brca1^tm2Cxd Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:5495977
cn64	Cd19^tm1(cre)Cgn/Cd19^+ Pbx1^tm2Mlc/Pbx1^tm2Mlc	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:3783742
cn65	Brca1^tm2Cxd/Brca1^tm2Cxd Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:5495978
cn66	Blm^tm4Ches/Blm^tm4Ches Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:5484530
cn67	Myc^tm2Fwa/Myc^tm2Fwa Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:2385667
cn68	Cd19^tm1(cre)Cgn/Cd19^+ Ptpn11^tm1Ckq/Ptpn11^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J	MGI:5295466
cn69	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J	MGI:5301628
cn70	Traf3^tm1Bshp/Traf3^tm1Bshp Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL	MGI:3722773
cn71	Blm^tm4Ches/Blm^tm4Ches Cd19^tm1(cre)Cgn/Cd19^+ Nsmce2^tm2.1Ofc/Nsmce2^tm2.1Ofc	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL	MGI:5906762
cn72	Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL	MGI:5485996
cn73	Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S * C57BL/6	MGI:6694201
cn74	Fas^lpr/Fas^lpr Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp	MGI:6694199
cn75	Cd19^tm1(cre)Cgn/Cd19^+ Rac1^tm1Tyb/Rac1^tm1Tyb Rac2^tm1Mddw/Rac2^tm1Mddw	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6	MGI:2684442
cn76	Cd19^tm1(cre)Cgn/Cd19^+ Tnf^tm2.1Gkl/Tnf^tm2.1Gkl	involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J	MGI:3629600
cn77	Cd19^tm1(cre)Cgn/Cd19^+ Mcl1^tm2Sjk/Mcl1^tm3Sjk	involves: 129P2/OlaHsd * 129X1/SvJ	MGI:2684157
cn78	Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+ Rev3l^tm1.1Diaz/Rev3l^tm1.1Diaz	involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac	MGI:5442608
cn79	Cd19^tm1(cre)Cgn/Cd19^+ Gna12^tm1Citb/Gna12^tm1Citb Gna13^tm2.1Soff/Gna13^tm2.1Soff	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N	MGI:3699320
cn80	Cd19^tm1(cre)Cgn/Cd19^+ Srsf3^tm1Pjln/Srsf3^tm1Pjln	involves: 129P2/OlaHsd * BALB/c	MGI:3687457
cn81	Cd19^tm1(cre)Cgn/Cd19^+ Tgfbr2^tm1Roes/Tgfbr2^tm1Roes	involves: 129P2/OlaHsd * BALB/c	MGI:3051965
cn82	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm1Uzs/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * BALB/c	MGI:3811554
cn83	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm1(CTNNB1)Nerl/Gt(ROSA)26Sor^tm1(CTNNB1)Nerl	involves: 129P2/OlaHsd * BALB/c	MGI:3706810
cn84	Cd19^tm1(cre)Cgn/Cd19^+ Fas^tm1Ach/Fas^tm1Ach	involves: 129P2/OlaHsd * BALB/c	MGI:3720605
cn85	Cd19^tm1(cre)Cgn/Cd19^+ Il10ra^tm1.1Jack/Il10ra^tm1.1Jack	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:4437331
cn86	Gt(ROSA)26Sor^tm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:5567931
cn87	Nfkb2^Lym1/Nfkb2^+ Otub1^tm1c(EUCOMM)Hmgu/Otub1^tm1c(EUCOMM)Hmgu Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N	MGI:6387024
cn88	Gt(ROSA)26Sor^tm10(Lmp1)Rsky/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * BALB/cJ	MGI:5314103
cn89	Gt(ROSA)26Sor^tm10(Lmp1)Rsky/Gt(ROSA)26Sor^+ Klrk1^tm1Dhr/Klrk1^tm1Dhr Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * BALB/cJ * C57BL/6	MGI:5314085
cn90	Dhx15^tm1c(EUCOMM)Wtsi/Dhx15^tm1c(EUCOMM)Wtsi Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C3H * C57BL/6N	MGI:6393270
cn91	Gt(ROSA)26Sor^tm1(Ptpn22*)Draw/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5517353
cn92	Cd19^tm1(cre)Cgn/Cd19^+ Rbpj^tm1Hon/Rbpj^tm1Hon	involves: 129P2/OlaHsd * C57BL/6	MGI:2654061
cn93	Cd19^tm1(cre)Cgn/Cd19^+ Cxcr4^tm1Tng/Cxcr4^tm2Tng	involves: 129P2/OlaHsd * C57BL/6	MGI:3639683
cn94	Cd19^tm1(cre)Cgn/Cd19^+ Ube2n^tm1Aki/Ube2n^tm1Aki	involves: 129P2/OlaHsd * C57BL/6	MGI:3656029
cn95	Cd19^tm1(cre)Cgn/Cd19^+ Map3k7^tm1Aki/Map3k7^tm1.1Aki	involves: 129P2/OlaHsd * C57BL/6	MGI:3664610
cn96	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm4(Ikbkb)Rsky/Gt(ROSA)26Sor^+ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass	involves: 129P2/OlaHsd * C57BL/6	MGI:3687509
cn97	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm4(Ikbkb)Rsky/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * C57BL/6	MGI:3687542
cn98	Cd19^tm1(cre)Cgn/Cd19^+ Spi1^tm2Dgt/Spi1^tm2Dgt	involves: 129P2/OlaHsd * C57BL/6	MGI:3688724
cn99	Cd19^tm1(cre)Cgn/Cd19^+ Pdia3^tm1Gjh/Pdia3^tm1Gjh	involves: 129P2/OlaHsd * C57BL/6	MGI:3702091
cn100	Cd19^tm1(cre)Cgn/Cd19^+ Ptpn6^tm1Rsky/Ptpn6^tm1Rsky	involves: 129P2/OlaHsd * C57BL/6	MGI:3720197
cn101	Cd19^tm1(cre)Cgn/Cd19^+ Ltb^tm1Avt/Ltb^tm1Avt	involves: 129P2/OlaHsd * C57BL/6	MGI:3768340
cn102	Cd19^tm1(cre)Cgn/Cd19^+ Ltb^tm1Avt/Ltb^tm1Avt Tg(Lck-cre)1Jtak/?	involves: 129P2/OlaHsd * C57BL/6	MGI:3768341
cn103	Sh2d1a^tm2Vei/Sh2d1a^tm2Vei Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:3775442
cn104	Cd19^tm1(cre)Cgn/Cd19^+ Traf2^tm1Rbr/Traf2^tm1Rbr	involves: 129P2/OlaHsd * C57BL/6	MGI:3777342
cn105	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm5(Map3k14)Rsky/Gt(ROSA)26Sor^tm5(Map3k14)Rsky	involves: 129P2/OlaHsd * C57BL/6	MGI:3809748
cn106	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm6(Map3k14*)Rsky/Gt(ROSA)26Sor^tm6(Map3k14*)Rsky	involves: 129P2/OlaHsd * C57BL/6	MGI:3809749
cn107	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm5(Map3k14)Rsky/Gt(ROSA)26Sor^tm5(Map3k14)Rsky Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass	involves: 129P2/OlaHsd * C57BL/6	MGI:3809750
cn108	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm6(Map3k14*)Rsky/Gt(ROSA)26Sor^tm6(Map3k14*)Rsky Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass	involves: 129P2/OlaHsd * C57BL/6	MGI:3809751
cn109	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm2(Cd74/MOG)Awai/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * C57BL/6	MGI:3814891
cn110	Cd19^tm1(cre)Cgn/Cd19^+ Gt(ROSA)26Sor^tm2(Cd74/MOG)Awai/Gt(ROSA)26Sor^+ Il10^tm1Roer/Il10^tm1Roer	involves: 129P2/OlaHsd * C57BL/6	MGI:3814893
cn111	Cd19^tm1(cre)Cgn/Cd19^+ Ikbkb^tm1Cgn/Ikbkb^tm1.1Cgn	involves: 129P2/OlaHsd * C57BL/6	MGI:3851693
cn112	Cd19^tm1(cre)Cgn/Cd19^+ Ikbkb^tm2Cgn/Ikbkb^tm2.1Cgn	involves: 129P2/OlaHsd * C57BL/6	MGI:3851694
cn113	Cd19^tm1(cre)Cgn/Cd19^+ Ikbkg^tm1.1Mpa/Y	involves: 129P2/OlaHsd * C57BL/6	MGI:3851695
cn114	Tnfaip3^tm2Ama/Tnfaip3^tm2Ama Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4831002
cn115	Cd19^tm1(cre)Cgn/Cd19^+ Tnfaip3^tm2Ama/Tnfaip3^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4831003
cn116	Pik3cd^tm2.1Tnr/Pik3cd^tm2.1Tnr Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4850098
cn117	Cd19^tm1(cre)Cgn/Cd19^+ Irf8^tm1.1Hm/Irf8^tm1.1Hm	involves: 129P2/OlaHsd * C57BL/6	MGI:4939594
cn118	Gt(ROSA)26Sor^tm11(Lmp1)Rsky/Gt(ROSA)26Sor^+ Klrk1^tm1Dhr/Klrk1^tm1Dhr Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5314087
cn119	Gt(ROSA)26Sor^tm11(Lmp1)Rsky/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5314104
cn120	Nabp2^tm1.1Kkha/Nabp2^tm1.1Kkha Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5502352
cn121	Tab2^tm2.1Aki/Tab2^tm2.1Aki Tab3^tm1Aki/Tab3^tm1Aki Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5502699
cn122	Kmt2d^tm1.1Kaig/Kmt2d^tm1.1Kaig Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5780067
cn123	Kmt2d^tm1.1Kaig/Kmt2d^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5780069
cn124	Tcf3^tm1(PBX1)Mlc/Tcf3^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5825356
cn125	Pax5^tm3Mbu/Pax5^+ Tcf3^tm1(PBX1)Mlc/Tcf3^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5825360
cn126	Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:6731079
cn127	Adam10^tm1.1Dhc/Adam10^tm1.1Dhc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL	MGI:4438893
cn128	Cd19^tm1(cre)Cgn/Cd19^+ Tcf3^tm1Mbu/Tcf3^tm1.2Mbu Tg(Vav-BCL2)69Jad/0	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL	MGI:3804187
cn129	Otub1^tm1c(EUCOMM)Hmgu/Otub1^tm1c(EUCOMM)Hmgu Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N	MGI:6387015
cn130	Pdap1^em1Rkuhn/Pdap1^em1Rkuhn Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N	MGI:6717128
cn131	Map3k14^tm1.1Gne/Map3k14^tm1.1Gne Otub1^tm1c(EUCOMM)Hmgu/Otub1^tm1c(EUCOMM)Hmgu Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac	MGI:6387022
cn132	Rnaseh2b^tm1c(EUCOMM)Wtsi/Rnaseh2b^tm1c(EUCOMM)Wtsi Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL	MGI:5911410
cn133	Map3k14^tm1.1Gne/Map3k14^tm1.1Gne Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac	MGI:6387020
cn134	Cd19^tm1(cre)Cgn/Cd19^+ Rbpj^tm1Hon/Rbpj^tm1Hon Spen^tm2.1Hon/Spen^tm2.1Hon	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3710554
cn135	Cd19^tm1(cre)Cgn/Cd19^+ Spen^tm2.1Hon/Spen^tm2.1Hon	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3710553
cn136	Pcid2^tm1Imku/Pcid2^tm1Imku Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:4843145
cn137	Cd19^tm1(cre)Cgn/Cd19^+ Notch2^tm2Hhi/Notch2^tm1.1Hhi	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:2663723
cn138	Mcm3ap^tm1Imku/Mcm3ap^tm1Imku Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3584126
cn139	Cd19^tm1(cre)Cgn/Cd19^+ Notch2^tm1.1Hhi/Notch2^+	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:4360762
cn140	Cd19^tm1(cre)Cgn/Cd19^+ Fas^lpr/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL	MGI:3690553
cn141	Nabp2^tm1.1Nfel/Nabp2^tm1.2Nfel Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL	MGI:5448645
cn142	Bod1l^em1Bltn/Bod1l^em1Bltn Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6J	MGI:7540616
cn143	Gt(ROSA)26Sor^tm11(Lmp1)Rsky/Gt(ROSA)26Sor^+ Cd19^tm1(cre/ERT2)Rsky/Cd19^+	involves: 129P2/OlaHsd * C57BL/6J	MGI:5614487
cn144	Cd19^tm1(cre)Cgn/Cd19^+ Tbl1xr1^tm1c(EUCOMM)Hmgu/Tbl1xr1^tm1c(EUCOMM)Hmgu Tg(Vav-BCL2)69Jad/0	involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N	MGI:7550775
cn145	Cd19^tm1(cre)Cgn/Cd19^+ Fas^lpr/Fas^tm1Cgn	involves: 129P2/OlaHsd * C57BL/6 * MRL	MGI:3690552
cn146	Cd19^tm1(cre/ERT2)Rsky/Cd19^+ Myd88^em1.1Rsky/Myd88^+	involves: 129P2/OlaHsd * C57BL/6NTac	MGI:7281485
cn147	Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1Rbr/Birc3^tm1Rbr Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * NZB	MGI:5013716
cn148	Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1.1Rbr/Birc3^tm1.1Rbr Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * NZB	MGI:5013717
cn149	Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1.1Rbr/Birc3^tm1.1Rbr Cd19^tm1(cre)Cgn/Cd19^+ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass	involves: 129P2/OlaHsd * C57BL/6 * NZB	MGI:5013718
cn150	Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL	MGI:5301604
cn151	Cd19^tm1(cre)Cgn/Cd19^+ Traf2^tm1Rbr/Traf2^tm1Rbr Traf3^tm1Rbr/Traf3^tm1Rbr	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:3777347
cn152	Cd19^tm1(cre)Cgn/Cd19^+ Traf3^tm1Rbr/Traf3^tm1Rbr	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:3777344
cn153	Cd19^tm1(cre)Cgn/Cd19^+ Tcf3^tm1Mbu/Tcf3^tm1.2Mbu	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:3804190
cn154	Cd19^tm1(cre)Cgn/Cd19^+ Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5795711
cn155	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5316373
cn156	H2-Ab1^b-tm1Wug/H2-Ab1^b-tm1Wug Cd19^tm1(cre)Cgn/Cd19^+	involves: 129S2/SvPas * C57BL/6	MGI:5543897
cn157	Lmo2^tm3Thr/Lmo2^tm4Thr Cd19^tm1(cre)Thr/Cd19^+	involves: 129S/SvEv	MGI:3584440
cn158	Cd19^tm1(cre)Cgn/Cd19^+ Ikbkb^tm2Mka/Ikbkb^tm2Mka	involves: 129/Sv * 129P2/OlaHsd * C57BL/6	MGI:2657004
cn159	Cd19^tm1(cre)Cgn/Cd19^+ Ep300^tm2Reck/Ep300^+	involves: 129/Sv * 129P2/OlaHsd * C57BL/6	MGI:3843174
cn160	Cd19^tm1(cre)Cgn/Cd19^+ Ep300^tm2Reck/Ep300^+	involves: 129/Sv * 129P2/OlaHsd * FVB/N	MGI:3843175
cn161	Tbk1^tm1Arte/Tbk1^tm1Arte Map3k14^tm1Rds/Map3k14^tm1Rds Cd19^tm1(cre)Cgn/Cd19^+	involves: 129/SvEv * 129P2/OlaHsd * C57BL/6	MGI:5446431
cn162	Tbk1^tm1Arte/Tbk1^tm1Arte Cd19^tm1(cre)Cgn/Cd19^+	involves: 129/SvEv * 129P2/OlaHsd * C57BL/6	MGI:5446428
cn163	Cd19^tm1(cre)Cgn/Cd19^+ Myd88^em1.1Rsky/Myd88^em1.1Rsky	involves: C57BL/6NTac	MGI:7281480
cn164	Cd19^tm1(cre)Cgn/Cd19^+ Myd88^em1.1Rsky/Myd88^+	involves: C57BL/6NTac	MGI:7281482
cx165	Cd19^tm1(cre)Cgn/Cd19^+ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass	involves: 129P2/OlaHsd * C57BL/6	MGI:5013719

Genotype
MGI:5521195

ht1

• Allelic Composition: Cd19^tm1.1Oao/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:202574 )

• mice are phenotypically normal and do not display alterations of thymus, spleen or lymph nodes, or develop tumors

Genotype
MGI:3829380

cn2

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ifnar1^tm1Uka/Ifnar1^tm1Uka
• Genetic Background: B6.129P2-Cd19^tm1(cre)Cgn Ifnar1^tm1Uka

immune system

decreased IgG1 level ( J:129128 )

• serum IgG1 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgG2a level ( J:129128 )

• serum IgG2a levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgG3 level ( J:129128 )

• serum IgG3 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgM level ( J:129128 )

• serum IgM levels are markedly decreased compared to controls 10- days after immunization with soluble antigen + IFNalpha stimulation

hematopoietic system

decreased IgG1 level ( J:129128 )

• serum IgG1 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgG2a level ( J:129128 )

• serum IgG2a levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgG3 level ( J:129128 )

• serum IgG3 levels are markedly decreased compared to controls 10- and 35- days after immunization with soluble antigen + IFNalpha stimulation

decreased IgM level ( J:129128 )

• serum IgM levels are markedly decreased compared to controls 10- days after immunization with soluble antigen + IFNalpha stimulation

Genotype
MGI:3690548

cn3

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^tm1Cgn/Fas^tm1Cgn
• Genetic Background: B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn

immune system

increased anti-single stranded DNA antibody level ( J:114948 )

• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fas^tm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Fas^lpr homozygotes

Genotype
MGI:7783621

cn4

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Wac^em2Cya/Wac^em2Cya
• Genetic Background: B6.Cg-Cd19^tm1(cre)Cgn Wac^em2Cya

immune system

decreased B cell proliferation ( J:345327 )

• after LPS stimulation, splenic B cells show significantly reduced BrdU incorporation relative to wild-type cells

• under in vitro plasma cell (PC) differentiation conditions, proliferation of CFSE-labeled B cells is halted at division 2-4 upon 5 and 20 ug/mL LPS stimulation

abnormal plasma cell differentiation ( J:345327 )

• however, LPS-induced B cell activation is unaffected, as indicated by normal upregulation of various activation markers

• moreover, expression of master transcription factors essential for PC differentiation is largely normal

• 3 days after stimulation with LPS, isolated splenic B cells show a 50% reduction of in vitro PC differentiation

decreased plasma cell number ( J:345327 )

• significant decrease in NP-specific IgG1 antibody-secreting plasma cells in the spleen and bone marrow on day 10 after NP-CGG immunization

• significant decrease in the frequencies of NP-specific IgM and IgG3 antibody-secreting plasma cells in the spleen on day 5 after NP-LPS immunization

• however, the frequencies and numbers of B220+Fas+CD38- germinal center (GC) B cells in spleen are normal on day 10 after NP-CGG immunization

decreased IgG1 level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG1 at all time points after NP-CGG immunization

decreased IgG2b level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG2b on days 7, 14 and 21 after NP-CGG immunization

decreased IgG3 level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG3 at all time points after NP-CGG immunization

• significant decrease in serum levels of NP-specific IgG3 on days 7, 14 and 21 after NP-LPS immunization

decreased IgM level ( J:345327 )

• slight but significant decrease in serum levels of NP-specific IgM on days 21 and 28, but not on days 7 14, after NP-CGG immunization

• significant decrease in serum levels of NP-specific IgM on days 7, 14 and 21 after NP-LPS immunization

impaired humoral immune response ( J:345327 )

• severely compromised T cell-dependent and T cell-independent antibody responses

hematopoietic system

hematopoietic system phenotype ( J:345327 )

N • 6- to 14-week-old mice show normal B cell development in the bone marrow and no significant changes in peripheral B cell populations in spleen relative to wild-type controls

decreased B cell proliferation ( J:345327 )

• after LPS stimulation, splenic B cells show significantly reduced BrdU incorporation relative to wild-type cells

• under in vitro plasma cell (PC) differentiation conditions, proliferation of CFSE-labeled B cells is halted at division 2-4 upon 5 and 20 ug/mL LPS stimulation

abnormal plasma cell differentiation ( J:345327 )

• however, LPS-induced B cell activation is unaffected, as indicated by normal upregulation of various activation markers

• moreover, expression of master transcription factors essential for PC differentiation is largely normal

• 3 days after stimulation with LPS, isolated splenic B cells show a 50% reduction of in vitro PC differentiation

decreased plasma cell number ( J:345327 )

• significant decrease in NP-specific IgG1 antibody-secreting plasma cells in the spleen and bone marrow on day 10 after NP-CGG immunization

• significant decrease in the frequencies of NP-specific IgM and IgG3 antibody-secreting plasma cells in the spleen on day 5 after NP-LPS immunization

• however, the frequencies and numbers of B220+Fas+CD38- germinal center (GC) B cells in spleen are normal on day 10 after NP-CGG immunization

decreased IgG1 level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG1 at all time points after NP-CGG immunization

decreased IgG2b level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG2b on days 7, 14 and 21 after NP-CGG immunization

decreased IgG3 level ( J:345327 )

• significant decrease in serum levels of NP-specific IgG3 at all time points after NP-CGG immunization

• significant decrease in serum levels of NP-specific IgG3 on days 7, 14 and 21 after NP-LPS immunization

decreased IgM level ( J:345327 )

• slight but significant decrease in serum levels of NP-specific IgM on days 21 and 28, but not on days 7 14, after NP-CGG immunization

• significant decrease in serum levels of NP-specific IgM on days 7, 14 and 21 after NP-LPS immunization

cellular

decreased B cell proliferation ( J:345327 )

• after LPS stimulation, splenic B cells show significantly reduced BrdU incorporation relative to wild-type cells

• under in vitro plasma cell (PC) differentiation conditions, proliferation of CFSE-labeled B cells is halted at division 2-4 upon 5 and 20 ug/mL LPS stimulation

abnormal epigenetic regulation of gene expression ( J:345327 )

• significant decrease in histone H2B ubiquitination (ubH2B) levels in resting B cells, LPS-stimulated B220+CD138- B cells, and B220^lo CD138+ LPS-induced plasma cells

• reduction in ubH2B is correlated with downregulated expression of several metabolism-related genes in LPS-stimulated B cells

Genotype
MGI:5318544

cn5

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben
• Genetic Background: B6.Cg-Cd1d1^tm1.1Aben Cd19^tm1(cre)Cgn

immune system

immune system phenotype ( J:183087 )

N • mice exhibit normal development, distribution and activation of NK T cells

Genotype
MGI:3690549

cn6

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Cd19^tm1(cre)Cgn/Cd19⁺; Tg(Cd4-cre)1Cwi/0
• Genetic Background: B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn

immune system

increased anti-single stranded DNA antibody level ( J:114948 )

• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fas^tm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Fas^lpr homozygotes

Genotype
MGI:3699321

cn7

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gna11^tm1Soff/Gna11^tm1Soff; Gnaq^tm2Soff/Gnaq^tm2Soff
• Genetic Background: B6N.129-Cd19^tm1(cre)Cgn Gna11^tm1Soff Gnaq^tm2Soff

hematopoietic system

hematopoietic system phenotype ( J:117663 )

N • double deficient B cells do not show abnormalities is lysophospholipid-induced adhesion

Genotype
MGI:3605618

cn8

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Klhl6^tm2Sato/Klhl6^tm2Sato
• Genetic Background: either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1)

immune system

abnormal B cell differentiation ( J:101363 )

• impaired development past the immature stage

decreased B cell number ( J:101363 )

• reduced number of B220+ and CD3- B lymphocytes in spleen and peripheral blood

abnormal lymph node germinal center morphology ( J:101363 )

• impaired germinal center formation

hematopoietic system

abnormal B cell differentiation ( J:101363 )

• impaired development past the immature stage

decreased B cell number ( J:101363 )

• reduced number of B220+ and CD3- B lymphocytes in spleen and peripheral blood

Genotype
MGI:5004802

cn9

• Allelic Composition: Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)

A representative tumor in the nose of a Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mouse

growth/size/body

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

mortality/aging

decreased tumor-free survival time ( J:172031 )

• mice succumb to tumors between 7 and 19 months of age

immune system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

neoplasm

increased tumor incidence ( J:172031 )

• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region

increased sarcoma incidence ( J:172031 )

• histocytic/dendritic cell sarcoma

increased histiocytic sarcoma incidence ( J:172031 )

hematopoietic system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

cellular

decreased B cell apoptosis ( J:172031 )

• FAS-induced

Genotype
MGI:6393679

cn10

• Allelic Composition: Ezh2^tm1.1Nesh/Ezh2⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6

mortality/aging

premature death ( J:239472 )

• median survival of 1 year

neoplasm

increased leukemia incidence ( J:239472 )

• about 50% of mice show frank leukemia and/or hepatic involvement

increased B cell derived lymphoma incidence ( J:239472 )

• mice develop B cell lymphoma with a median survival of 1 year

• tumors show a CD45+B220+CD19+IgM+CD43+CD5+ immunophenotype

• mice treated with JQEZ5, an S-5'adenosyl-l-methionine (SAM)-competitive pyridinone inhibitor, for 6 days show completely cleared malignant population from the spleen without depleting normal B cells

immune system

abnormal spleen morphology ( J:239472 )

• tumor-bearing mice show disruption of the splenic architecture

enlarged spleen ( J:239472 )

abnormal spleen white pulp morphology ( J:239472 )

• tumor-bearing mice show expansion of abnormal, large lymphoid cells in the white pulp

enlarged lymph nodes ( J:239472 )

hematopoietic system

abnormal spleen morphology ( J:239472 )

• tumor-bearing mice show disruption of the splenic architecture

enlarged spleen ( J:239472 )

abnormal spleen white pulp morphology ( J:239472 )

• tumor-bearing mice show expansion of abnormal, large lymphoid cells in the white pulp

growth/size/body

enlarged spleen ( J:239472 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
B-cell lymphoma		DOID:707		J:239472

Genotype
MGI:6393694

cn11

• Allelic Composition: Ezh2^tm1.1Nesh/Ezh2^tm1.1Nesh; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6

neoplasm

increased B cell derived lymphoma incidence ( J:239472 )

• development of B cell lymphoma with kinetics and tumor immunophenotype nearly identical to heterozygous conditional mutants

immune system

enlarged spleen ( J:239472 )

enlarged lymph nodes ( J:239472 )

• lymphadenopathy with an infiltration of abnormal B220^lowMac2^low B cells

hematopoietic system

enlarged spleen ( J:239472 )

growth/size/body

enlarged spleen ( J:239472 )

Genotype
MGI:3527259

cn12

• Allelic Composition: Tnf^tm1.1Sned/Tnf^tm1.1Sned; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:95684 )

N • susceptibility to LPS, S. aureus, and Listeria monocytoegenes infection and liver injury was not different from wild-type and no differences in serum TNF levels were detected, indicating that B cell derived Tnf does not play a role in toxicity, host defense, or autoimmunity

Genotype
MGI:5437512

cn13

• Allelic Composition: Prelid1^tm1Hmva/Prelid1^tm1Hmva; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6

normal phenotype

no abnormal phenotype detected ( J:187294 )

• viable and fertile with no discernible B cell abnormalities

Genotype
MGI:3843277

cn14

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Slc3a2^tm1.1Mgin/Slc3a2^tm1Yai
• Genetic Background: involves: 129 * C57BL/6 * SJL

immune system

decreased IgG3 level ( J:148000 )

• decrease in antigen specific levels of IgG3

decreased IgM level ( J:148000 )

• decrease in antigen specific levels of IgM

hematopoietic system

decreased IgG3 level ( J:148000 )

• decrease in antigen specific levels of IgG3

decreased IgM level ( J:148000 )

• decrease in antigen specific levels of IgM

Genotype
MGI:3843276

cn15

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Slc3a2^tm1.1Mgin/Slc3a2^tm1.1Mgin
• Genetic Background: involves: 129 * C57BL/6 * SJL

immune system

immune system phenotype ( J:148000 )

N • despite Cre mediated deletion in B cells, mice have normal pre-B, pro-B, immature and mature B cell numbers and normal splenic architecture

abnormal plasma cell differentiation ( J:148000 )

• defect in the ability of LPS stimulated isolated B cells to differentiate into plasma cells

• however, in a small percentage of cells where Cre mediated recombination did not take place plasma cell differentiation is normal

decreased germinal center B cell number ( J:148000 )

• decrease in germinal center B cell and plasma cell numbers 1 week after immunization

• however, by 2 - 3 weeks after immunization antigen specifc antibody titers are similar to controls suggesting strong selection in germinal centers for the few cells that escaped Cre mediated recombination and expression analysis confirms the presence of B cells expressing SLC3A2 in the germinal centers

abnormal B cell physiology ( J:148000 )

• impaired antibody secretion following LPS stimulation

abnormal class switch recombination ( J:148000 )

• impaired class switching following LPS stimulation

abnormal B cell activation ( J:148000 )

• activated B cells fail to spread after antibody mediated ligation of integrins

decreased B cell proliferation ( J:148000 )

• minimal proliferation in response to anti-IgM antibody stimulation

• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells

decreased IgG level ( J:148000 )

• decrease in basal and antigen specific levels of IgG

decreased IgM level ( J:148000 )

• decrease in antigen specific levels of IgM

• however, basal IgM levels are similar to controls

hematopoietic system

abnormal plasma cell differentiation ( J:148000 )

• defect in the ability of LPS stimulated isolated B cells to differentiate into plasma cells

• however, in a small percentage of cells where Cre mediated recombination did not take place plasma cell differentiation is normal

decreased germinal center B cell number ( J:148000 )

• decrease in germinal center B cell and plasma cell numbers 1 week after immunization

• however, by 2 - 3 weeks after immunization antigen specifc antibody titers are similar to controls suggesting strong selection in germinal centers for the few cells that escaped Cre mediated recombination and expression analysis confirms the presence of B cells expressing SLC3A2 in the germinal centers

abnormal B cell physiology ( J:148000 )

• impaired antibody secretion following LPS stimulation

abnormal class switch recombination ( J:148000 )

• impaired class switching following LPS stimulation

abnormal B cell activation ( J:148000 )

• activated B cells fail to spread after antibody mediated ligation of integrins

decreased B cell proliferation ( J:148000 )

• minimal proliferation in response to anti-IgM antibody stimulation

• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells

decreased IgG level ( J:148000 )

• decrease in basal and antigen specific levels of IgG

decreased IgM level ( J:148000 )

• decrease in antigen specific levels of IgM

• however, basal IgM levels are similar to controls

cellular

decreased B cell proliferation ( J:148000 )

• minimal proliferation in response to anti-IgM antibody stimulation

• in vivo, B cells carrying the recombined allele fail to proliferate; however, cells that escape Cre mediated recombination do proliferate and go on to form plasma cells

Genotype
MGI:3603798

cn16

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Igbp1^tm1Imku/Y
• Genetic Background: involves: 129P2/OlaHsd

immune system

abnormal somatic hypermutation frequency ( J:74619 )

♂ • no somatic hypermutation takes place

decreased B cell number ( J:74619 )

♂ • decreased B220+ cells but cells have a normal maturation phenotype

♂ • decreased numbers involve IgM+ IgD^hi

decreased follicular B cell number ( J:74619 )

♂ • CD23+IgM+ follicular cells in the spleen were reduced as were CD40+ cells

decreased pre-B cell number ( J:74619 )

♂ • reduced in numbers although normal numbers of pro B cells are present in bone marrow

abnormal spleen germinal center morphology ( J:74619 )

♂ • germinal center formation is impaired

abnormal B cell physiology ( J:74619 )

♂

decreased B cell proliferation ( J:74619 )

♂ • impaired proliferative responses, failure of G1/S transition

decreased immunoglobulin level ( J:74619 )

♂ • stimulated antibody production is low

♂ • T cell dependent antibody production more affected than T cell independent production

hematopoietic system

abnormal somatic hypermutation frequency ( J:74619 )

♂ • no somatic hypermutation takes place

decreased B cell number ( J:74619 )

♂ • decreased B220+ cells but cells have a normal maturation phenotype

♂ • decreased numbers involve IgM+ IgD^hi

decreased follicular B cell number ( J:74619 )

♂ • CD23+IgM+ follicular cells in the spleen were reduced as were CD40+ cells

decreased pre-B cell number ( J:74619 )

♂ • reduced in numbers although normal numbers of pro B cells are present in bone marrow

abnormal spleen germinal center morphology ( J:74619 )

♂ • germinal center formation is impaired

abnormal B cell physiology ( J:74619 )

♂

decreased B cell proliferation ( J:74619 )

♂ • impaired proliferative responses, failure of G1/S transition

decreased immunoglobulin level ( J:74619 )

♂ • stimulated antibody production is low

♂ • T cell dependent antibody production more affected than T cell independent production

cellular

decreased B cell proliferation ( J:74619 )

♂ • impaired proliferative responses, failure of G1/S transition

Genotype
MGI:5574113

cn17

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bcl3,-EGFP)Hoev}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

immune system

decreased B cell apoptosis ( J:208980 )

• of follicular II B cells in the spleen

decreased B cell proliferation ( J:208980 )

• of follicular I and follicular II B cells in the spleen

• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro

enlarged spleen ( J:208980 )

abnormal B cell differentiation ( J:208980 )

• impaired marginal zone B cell differentiation

abnormal class switch recombination ( J:208980 )

• reduced number of class switched IgG1 B cells in the Peyer's patch

• almost complete block of class switch to IgA, IgG1, IgG2b and IgG3

decreased immature B cell number ( J:208980 )

• in the spleen

decreased transitional stage T1 B cell number ( J:208980 )

• in the spleen

abnormal transitional stage T3 B cell morphology ( J:208980 )

• increased percent

decreased B-1 B cell number ( J:208980 )

decreased B-1a cell number ( J:208980 )

decreased marginal zone B cell number ( J:208980 )

absent marginal zone B cells ( J:208980 )

• absence of the marginal zone B cells peripheral to follicles in the spleen

increased lymphocyte cell number ( J:208980 )

• in the spleen

abnormal B-2 B cell morphology ( J:208980 )

• increased percentage in the peritoneal cavity

abnormal follicular B cell morphology ( J:208980 )

• decreased follicular II B cell compartment and increase in follicular I B cell numbers in the spleen

decreased IgG1 level ( J:208980 )

• following immunization with NP-CG antigen

• however, levels in naive mice are normal

decreased IgG2b level ( J:208980 )

• following immunization with NP-CG antigen

decreased IgG3 level ( J:208980 )

• in naive mice and following immunization with NP-Ficoll

decreased IgM level ( J:208980 )

• in naive mice and following immunization with NP-Ficoll

• however, levels are normal following immunization with NP-CG antigen

abnormal Peyer's patch germinal center morphology ( J:208980 )

• reduced development with reduced number of class switched IgG1 B cells in the Peyer's patch

cellular

decreased B cell apoptosis ( J:208980 )

• of follicular II B cells in the spleen

decreased B cell proliferation ( J:208980 )

• of follicular I and follicular II B cells in the spleen

• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro

hematopoietic system

decreased B cell apoptosis ( J:208980 )

• of follicular II B cells in the spleen

decreased B cell proliferation ( J:208980 )

• of follicular I and follicular II B cells in the spleen

• of B cells stimulated with LPS, CpG or anti-IgM F(ab)'2 in vivo or in vitro

enlarged spleen ( J:208980 )

abnormal B cell differentiation ( J:208980 )

• impaired marginal zone B cell differentiation

abnormal class switch recombination ( J:208980 )

• reduced number of class switched IgG1 B cells in the Peyer's patch

• almost complete block of class switch to IgA, IgG1, IgG2b and IgG3

decreased immature B cell number ( J:208980 )

• in the spleen

decreased transitional stage T1 B cell number ( J:208980 )

• in the spleen

abnormal transitional stage T3 B cell morphology ( J:208980 )

• increased percent

decreased B-1 B cell number ( J:208980 )

decreased B-1a cell number ( J:208980 )

decreased marginal zone B cell number ( J:208980 )

absent marginal zone B cells ( J:208980 )

• absence of the marginal zone B cells peripheral to follicles in the spleen

increased lymphocyte cell number ( J:208980 )

• in the spleen

abnormal B-2 B cell morphology ( J:208980 )

• increased percentage in the peritoneal cavity

abnormal follicular B cell morphology ( J:208980 )

• decreased follicular II B cell compartment and increase in follicular I B cell numbers in the spleen

decreased IgG1 level ( J:208980 )

• following immunization with NP-CG antigen

• however, levels in naive mice are normal

decreased IgG2b level ( J:208980 )

• following immunization with NP-CG antigen

decreased IgG3 level ( J:208980 )

• in naive mice and following immunization with NP-Ficoll

decreased IgM level ( J:208980 )

• in naive mice and following immunization with NP-Ficoll

• however, levels are normal following immunization with NP-CG antigen

growth/size/body

enlarged spleen ( J:208980 )

Genotype
MGI:4947223

cn18

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Derl2^tm1.1Hpl/Derl2^tm1.1Hpl
• Genetic Background: involves: 129P2/OlaHsd

immune system

immune system phenotype ( J:170650 )

N • B cell development and antibody secretion are normal

Genotype
MGI:5291647

cn19

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tnfaip3^tm1.1Awai/Tnfaip3^tm1.1Awai
• Genetic Background: involves: 129P2/OlaHsd

immune system

increased B cell proliferation ( J:175422 )

enlarged spleen ( J:175422 )

decreased mature B cell number ( J:175422 )

• in the bone marrow

decreased B-1a cell number ( J:175422 )

decreased B-1b cell number ( J:175422 )

decreased marginal zone B cell number ( J:175422 )

increased B cell number ( J:175422 )

• in the spleen and lymph nodes

increased germinal center B cell number ( J:175422 )

• in mesenteric lymph nodes and Peyer's patches

increased follicular B cell number ( J:175422 )

increased T cell number ( J:175422 )

• in the spleen and lymph nodes

increased splenocyte number ( J:175422 )

increased IgA level ( J:175422 )

increased IgG2a level ( J:175422 )

• in unstimulated and NP-CG-stimulated mice

increased IgM level ( J:175422 )

• in unstimulated and NP-CG-stimulated mice

increased anti-nuclear antigen antibody level ( J:175422 )

hematopoietic system

increased B cell proliferation ( J:175422 )

enlarged spleen ( J:175422 )

decreased mature B cell number ( J:175422 )

• in the bone marrow

decreased B-1a cell number ( J:175422 )

decreased B-1b cell number ( J:175422 )

decreased marginal zone B cell number ( J:175422 )

increased B cell number ( J:175422 )

• in the spleen and lymph nodes

increased germinal center B cell number ( J:175422 )

• in mesenteric lymph nodes and Peyer's patches

increased follicular B cell number ( J:175422 )

increased T cell number ( J:175422 )

• in the spleen and lymph nodes

increased splenocyte number ( J:175422 )

increased IgA level ( J:175422 )

increased IgG2a level ( J:175422 )

• in unstimulated and NP-CG-stimulated mice

increased IgM level ( J:175422 )

• in unstimulated and NP-CG-stimulated mice

growth/size/body

enlarged spleen ( J:175422 )

cellular

increased B cell proliferation ( J:175422 )

Genotype
MGI:4878990

cn20

• Allelic Composition: Cxcr4^tm2Yzo/Cxcr4^tm3.1Yzo; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

hematopoietic system

abnormal B cell differentiation ( J:167314 )

• B cell precursors are released into the peripheral blood and reduced in the spleen unlike in wild-type mice but not as severely as in Cxcr4^tm1Yzo homozygotes

immune system

abnormal B cell differentiation ( J:167314 )

• B cell precursors are released into the peripheral blood and reduced in the spleen unlike in wild-type mice but not as severely as in Cxcr4^tm1Yzo homozygotes

Genotype
MGI:5538667

cn21

• Allelic Composition: Pgap3^tm1Ymra/Pgap3^tm1Ymra; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

immune system

immune system phenotype ( J:203443 )

N • mice do not develop anti-DNA antibodies

Genotype
MGI:5495980

cn22

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53bp1^tm1Jc/Trp53bp1^tm1Jc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

cellular

chromosome breakage ( J:197442 )

• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with cells from Brca2^tm1Brn/Brca2^tm1Brn Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn mice

Genotype
MGI:5495979

cn23

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

cellular

chromosome breakage ( J:197442 )

• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with untreated cells

Genotype
MGI:4460905

cn24

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd

Enlarged spleen and solid organ infiltration with abnormally proliferating T cells in Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mice

mortality/aging

premature death ( J:160931 )

• mice develop lethal wasting and die by 60 weeks of age unlike wild-type mice

immune system

increased T cell derived lymphoma incidence ( J:160931 )

• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice

• lymphomas consists of enlarged, activated, and highly proliferative T cells

enlarged spleen ( J:160931 )

• at 50 weeks

abnormal T cell activation ( J:160931 )

• lymphomas consists of enlarged, activated, and highly proliferative T cells

increased T cell proliferation ( J:160931 )

• lymphomas consists of enlarged, activated, and highly proliferative T cells

neoplasm

increased T cell derived lymphoma incidence ( J:160931 )

• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice

• lymphomas consists of enlarged, activated, and highly proliferative T cells

growth/size/body

cachexia ( J:160931 )

• mice develop lethal wasting unlike wild-type mice

enlarged spleen ( J:160931 )

• at 50 weeks

hematopoietic system

increased T cell derived lymphoma incidence ( J:160931 )

• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice

• lymphomas consists of enlarged, activated, and highly proliferative T cells

enlarged spleen ( J:160931 )

• at 50 weeks

abnormal T cell activation ( J:160931 )

• lymphomas consists of enlarged, activated, and highly proliferative T cells

increased T cell proliferation ( J:160931 )

• lymphomas consists of enlarged, activated, and highly proliferative T cells

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:160931 )

• mice develop infiltrating lymphocytes into multiple organs unlike in wild-type mice

• lymphomas consists of enlarged, activated, and highly proliferative T cells

cellular

increased T cell proliferation ( J:160931 )

• lymphomas consists of enlarged, activated, and highly proliferative T cells

Genotype
MGI:4453323

cn25

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ltbr^tm1Avt/Ltbr^tm1Avt; Tg(Lck-cre)I57Jxm/0
• Genetic Background: involves: 129P2/OlaHsd

immune system

immune system phenotype ( J:158663 )

N • susceptibility to Citrobacter rodentium infection is similar to wild-type controls

Genotype
MGI:4453321

cn26

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ltbr^tm1Avt/Ltbr^tm1Avt
• Genetic Background: involves: 129P2/OlaHsd

immune system

immune system phenotype ( J:158663 )

N • susceptibility to Citrobacter rodentium infection is similar to wild-type controls

Genotype
MGI:5908453

cn27

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd

mortality/aging

postnatal lethality, complete penetrance ( J:228288 )

• all die by P6

neoplasm

increased B cell derived lymphoma incidence ( J:228288 )

• blastoid cells that infiltrate solid organs are seen indicating high-grade lymphoma

• blastoid B cells express low levels of IL7 or CD25 indicating the disease does not resemble acute B-cell lineage leukemia

immune system

increased B cell number ( J:228288 )

increased plasma cell number ( J:228288 )

• B cells in the spleen and bone marrow are CD138+ B220^int or CD138+ B220^low indicating these consist of plasmablasts and plasma cells

abnormal plasmablast number ( J:228288 )

• B cells in the spleen and bone marrow are CD138+ B220^int or CD138+ B220^low indicating these consist of plasmablasts and plasma cells

abnormal spleen morphology ( J:228288 )

• spleens contain homogenous populations of large cells with prominent nucleoli and high proliferation indices

enlarged spleen ( J:228288 )

• massive

spleen hyperplasia ( J:228288 )

• high proliferation indices

abnormal B cell activation ( J:228288 )

• recombined B cells exhibit an activated phenotype with high CD80 and Sca-1 expression and elevated CD43 levels

increased B cell proliferation ( J:228288 )

• B cells proliferate vigorously in the absence of any specific B cell survival or mitogenic factors for at least 10 days in culture

• high proliferation indices in the spleen

enlarged lymph nodes ( J:228288 )

hematopoietic system

abnormal bone marrow cell number ( J:228288 )

• massive reduction in the B220+ IgM- compartment in the bone marrow indicating infiltration by peripheral blastoid B cells

increased B cell number ( J:228288 )

increased plasma cell number ( J:228288 )

• B cells in the spleen and bone marrow are CD138+ B220^int or CD138+ B220^low indicating these consist of plasmablasts and plasma cells

abnormal plasmablast number ( J:228288 )

• B cells in the spleen and bone marrow are CD138+ B220^int or CD138+ B220^low indicating these consist of plasmablasts and plasma cells

abnormal spleen morphology ( J:228288 )

• spleens contain homogenous populations of large cells with prominent nucleoli and high proliferation indices

enlarged spleen ( J:228288 )

• massive

spleen hyperplasia ( J:228288 )

• high proliferation indices

abnormal B cell activation ( J:228288 )

• recombined B cells exhibit an activated phenotype with high CD80 and Sca-1 expression and elevated CD43 levels

increased B cell proliferation ( J:228288 )

• B cells proliferate vigorously in the absence of any specific B cell survival or mitogenic factors for at least 10 days in culture

• high proliferation indices in the spleen

cellular

increased B cell proliferation ( J:228288 )

• B cells proliferate vigorously in the absence of any specific B cell survival or mitogenic factors for at least 10 days in culture

• high proliferation indices in the spleen

growth/size/body

enlarged spleen ( J:228288 )

• massive

spleen hyperplasia ( J:228288 )

• high proliferation indices

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
diffuse large B-cell lymphoma		DOID:0050745		J:228288

Genotype
MGI:3697395

cn28

• Allelic Composition: Casp8^tm1Hed/Casp8^tm1Hed; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

immune system

decreased B cell number ( J:116713 )

decreased B-1 B cell number ( J:116713 )

• modest reduction in B1 cells (~10%) in peritoneal cavity is seen

decreased marginal zone B cell number ( J:116713 )

• reduction in percentage of marginal zone B cells is observed

spleen hypoplasia ( J:116713 )

• spleen cell number is increased ~30% compared to wild-type

abnormal adaptive immunity ( J:116713 )

decreased B cell proliferation ( J:116713 )

• in response to LPS and dsRNA, B cells have decreased proliferative response

• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells

abnormal immunoglobulin level ( J:116713 )

• mice mount an inferior IgM response to LPS immunization

hematopoietic system

decreased B cell proliferation ( J:116713 )

• in response to LPS and dsRNA, B cells have decreased proliferative response

• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells

decreased B cell number ( J:116713 )

decreased B-1 B cell number ( J:116713 )

• modest reduction in B1 cells (~10%) in peritoneal cavity is seen

decreased marginal zone B cell number ( J:116713 )

• reduction in percentage of marginal zone B cells is observed

spleen hypoplasia ( J:116713 )

• spleen cell number is increased ~30% compared to wild-type

abnormal immunoglobulin level ( J:116713 )

• mice mount an inferior IgM response to LPS immunization

cellular

increased apoptosis ( J:116713 )

• cells treated with LPS or dsRNA show decreased survival (increased apoptosis) compared to controls at 24 hours, with decreased viability starting at 12 hours

• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells

decreased B cell proliferation ( J:116713 )

• in response to LPS and dsRNA, B cells have decreased proliferative response

• cells stimulated through Tlr9 or antigen receptor show similar proliferation and apoptosis to wild-type cells

Genotype
MGI:4355202

cn29

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Il10^tm1Roer/Il10^tm1Roer
• Genetic Background: involves: 129P2/OlaHsd

immune system

increased B cell number ( J:151551 )

• increased B cell numbers are observed after immunization with anti-IgD antibody compared to immunized controls

increased plasma cell number ( J:151551 )

• plasma cell numbers are 2-fold larger than controls seven days after infection with MCMV

increased CD4-positive, alpha-beta T cell number ( J:151551 )

• are observed after immunization with anti-IgD antibody compared to immunized controls

abnormal myeloid leukocyte morphology ( J:151551 )

• increased myeloid numbers are observed after immunization with anti-IgD antibody compared to immunized controls

abnormal CD8-positive, alpha-beta T cell physiology ( J:151551 )

• MCMV-specific CD8 ⁺ T cell numbers are about twice as numerous as controls 7 days after infection with MCMV

decreased circulating interleukin-10 level ( J:151551 )

• IL-10 levels are half that of wild-type controls when immunized with anti-IgD antibodies

homeostasis/metabolism

decreased circulating interleukin-10 level ( J:151551 )

• IL-10 levels are half that of wild-type controls when immunized with anti-IgD antibodies

hematopoietic system

increased B cell number ( J:151551 )

• increased B cell numbers are observed after immunization with anti-IgD antibody compared to immunized controls

increased plasma cell number ( J:151551 )

• plasma cell numbers are 2-fold larger than controls seven days after infection with MCMV

increased CD4-positive, alpha-beta T cell number ( J:151551 )

• are observed after immunization with anti-IgD antibody compared to immunized controls

abnormal myeloid leukocyte morphology ( J:151551 )

• increased myeloid numbers are observed after immunization with anti-IgD antibody compared to immunized controls

abnormal CD8-positive, alpha-beta T cell physiology ( J:151551 )

• MCMV-specific CD8 ⁺ T cell numbers are about twice as numerous as controls 7 days after infection with MCMV

Genotype
MGI:3843267

cn30

• Allelic Composition: Srf^tm2Nor/Srf^tm2Nor; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

immune system

decreased B cell number ( J:124767 )

• overall reduction of CD19+ B cells in bone marrow

abnormal mature B cell morphology ( J:124767 )

• reduced surface expression of IgM in cells from the spleen, lymph nodes, bone marrow and blood

• surface expression of IgD is not affected

decreased B-1 B cell number ( J:124767 )

• CD19+ IgM+ CD5+ peritoneal B cells are decreased in number

absent marginal zone B cells ( J:124767 )

• in spite of normal follicular architecture

hematopoietic system

decreased B cell number ( J:124767 )

• overall reduction of CD19+ B cells in bone marrow

decreased B-1 B cell number ( J:124767 )

• CD19+ IgM+ CD5+ peritoneal B cells are decreased in number

absent marginal zone B cells ( J:124767 )

• in spite of normal follicular architecture

abnormal mature B cell morphology ( J:124767 )

• reduced surface expression of IgM in cells from the spleen, lymph nodes, bone marrow and blood

• surface expression of IgD is not affected

Genotype
MGI:5908454

cn31

• Allelic Composition: Bcl10^tm1Mak/Bcl10^tm1Mak; Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd

mortality/aging

mortality/aging ( J:228288 )

N • absence of Bcl10 expression rescues the early lethality seen in mutant mice wild-type for Bcl10

immune system

immune system phenotype ( J:228288 )

N • absence of Bcl10 expression rescues the pathological B-cell activation, differentiation, and malignant proliferation seen in mutant mice wild-type for Bcl10

Genotype
MGI:5908455

cn32

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺; Malt1^tm1Mak/Malt1^tm1Mak
• Genetic Background: involves: 129P2/OlaHsd

mortality/aging

mortality/aging ( J:228288 )

N • absence of Malt1 expression rescues the early lethality seen in mutant mice wild-type for Malt1

immune system

immune system phenotype ( J:228288 )

N • absence of Malt1 expression rescues the pathological B-cell activation, differentiation, and malignant proliferation seen in mutant mice wild-type for Malt1

Genotype
MGI:3055676

cn33

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd

hematopoietic system

decreased B cell number ( J:92789 )

• B cell but not T cell numbers are reduced in the bone marrow and spleen to 65% and 50% of control, respectively

• B cell turn over is also increased in double mutants

immune system

decreased B cell number ( J:92789 )

• B cell but not T cell numbers are reduced in the bone marrow and spleen to 65% and 50% of control, respectively

• B cell turn over is also increased in double mutants

Genotype
MGI:3526527

cn34

• Allelic Composition: Cxcr4^tm2Yzo/Cxcr4^tm2Yzo; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

hematopoietic system

abnormal B cell differentiation ( J:94911 )

• B cell precursors are found in the blood

• a large number of the B cell precursors die before they can complete the differentiation process

decreased mature B cell number ( J:94911 )

• the total number of mature B cells in the spleen is reduced to about 65% of wild-type

decreased B-1 B cell number ( J:94911 )

• the peritoneal B1 cell population is reduced in young and old mutants

decreased B-2 B cell number ( J:94911 )

• the peritoneal B2 cell population is reduced only in older mutants

decreased plasma cell number ( J:94911 )

• a greater than 20-fold reduction in the number of T cell independent antigen-specific plasma cells in the bone marrow is seen after immunization with Ficoll

• the number of antibody-secreting cells is reduced in the bone marrow and increased in the spleen 9 days after immunization, however long-term antibody production is not impaired

decreased immunoglobulin level ( J:94911 )

• basal levels of serum IG of all isotypes are reduced

immune system

abnormal B cell differentiation ( J:94911 )

• B cell precursors are found in the blood

• a large number of the B cell precursors die before they can complete the differentiation process

decreased mature B cell number ( J:94911 )

• the total number of mature B cells in the spleen is reduced to about 65% of wild-type

decreased B-1 B cell number ( J:94911 )

• the peritoneal B1 cell population is reduced in young and old mutants

decreased B-2 B cell number ( J:94911 )

• the peritoneal B2 cell population is reduced only in older mutants

decreased plasma cell number ( J:94911 )

• a greater than 20-fold reduction in the number of T cell independent antigen-specific plasma cells in the bone marrow is seen after immunization with Ficoll

• the number of antibody-secreting cells is reduced in the bone marrow and increased in the spleen 9 days after immunization, however long-term antibody production is not impaired

decreased immunoglobulin level ( J:94911 )

• basal levels of serum IG of all isotypes are reduced

abnormal Peyer's patch follicle morphology ( J:94911 )

• B cell follicles are more dispersed, frequently occur deep in the lamina propria, and some have enlarged T cell zones

Genotype
MGI:4839186

cn35

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv

hematopoietic system

hematopoietic system phenotype ( J:165879 )

N • mice exhibit normal adult hematopoiesis

immune system

immune system phenotype ( J:165879 )

N • mice exhibit normal B cell and T cell development

Genotype
MGI:3796508

cn36

• Allelic Composition: Pik3cd^tm1Tnr/Pik3cd^tm1Tnr; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6

immune system

immune system phenotype ( J:130950 )

N • unlike in Pten deficient mice, B1 B cell numbers are normal in the spleen and peritoneum

abnormal class switch recombination ( J:130950 )

• defects in class switch recombination associated with Pten deficiency are partially reversed

increased marginal zone B cell number ( J:130950 )

• mice exhibit an increase in marginal zone B cells that is not as great as in Pten null mice but more than in wild-type mice

hematopoietic system

abnormal class switch recombination ( J:130950 )

• defects in class switch recombination associated with Pten deficiency are partially reversed

increased marginal zone B cell number ( J:130950 )

• mice exhibit an increase in marginal zone B cells that is not as great as in Pten null mice but more than in wild-type mice

Genotype
MGI:5305096

cn37

• Allelic Composition: Del(14Trim13-Rnaseh2b)6Rdf/+; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6

mortality/aging

premature death ( J:179879 )

• 70% of mice die by 20 months

neoplasm

increased chronic lymphocytic leukemia incidence ( J:179879 )

increased lymphoma incidence ( J:179879 )

• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

increased small lymphocytic lymphoma incidence ( J:179879 )

immune system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 25% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

hematopoietic system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 25% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
chronic lymphocytic leukemia		DOID:1040	OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559	J:179879

Genotype
MGI:5305097

cn38

• Allelic Composition: Is(14)1Rdf/Is(14)1Rdf; Is(14)5Rdf/Is(14)5Rdf; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6

mortality/aging

premature death ( J:179879 )

neoplasm

increased chronic lymphocytic leukemia incidence ( J:179879 )

increased lymphoma incidence ( J:179879 )

• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

increased small lymphocytic lymphoma incidence ( J:179879 )

immune system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 67% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

hematopoietic system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 67% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
chronic lymphocytic leukemia		DOID:1040	OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559	J:179879

Genotype
MGI:5305095

cn39

• Allelic Composition: Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6

mortality/aging

premature death ( J:179879 )

neoplasm

increased chronic lymphocytic leukemia incidence ( J:179879 )

increased lymphoma incidence ( J:179879 )

• mice develop B cell clonal lymphoproliferations, chronic lymphocytic leukemia , small cell lymphomas, and CD5- non-Hodgkin lymphomas

increased small lymphocytic lymphoma incidence ( J:179879 )

immune system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 42% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

hematopoietic system

abnormal lymphopoiesis ( J:179879 )

• mice exhibit lymphoproliferation in the peripheral blood (IgM+CD5+B220^lo) with characteristics of chronic lymphocytic leukemia

• 42% of mice develop clonal lymphoproliferations

increased B cell number ( J:179879 )

• IgM+CD5+B220^lo

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
chronic lymphocytic leukemia		DOID:1040	OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559	J:179879

Genotype
MGI:4437062

cn40

• Allelic Composition: Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6

hematopoietic system

increased B cell number ( J:156946 )

• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age

increased B-1a cell number ( J:156946 )

• at 15-18 months increased clonal population in the peripheral blood

increased spleen white pulp amount ( J:156946 )

• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

immune system

increased B cell number ( J:156946 )

• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age

increased B-1a cell number ( J:156946 )

• at 15-18 months increased clonal population in the peripheral blood

increased spleen white pulp amount ( J:156946 )

• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

neoplasm

increased leukemia incidence ( J:156946 )

• a fraction of mice have histological features of small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL)

increased B cell derived lymphoma incidence ( J:156946 )

• some of the CD5 negative tumors showed a mature B cell phenotype histologically reminiscent of human diffuse large B cell lymphoma, non-Hodgkin lymphoma

• a minority of CD5 negative tumors showed plasmacytic features similar to lymphoplasmacytic lymphoma

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
chronic lymphocytic leukemia		DOID:1040	OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559	J:156946

Genotype
MGI:4437066

cn41

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Mirc30^tm1.1Rdf/Mirc30^tm1.1Rdf
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6

neoplasm

increased leukemia incidence ( J:156946 )

• fraction of mice have histological features of small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL)

increased B cell derived lymphoma incidence ( J:156946 )

• some of the CD5 negative tumors showed a mature B cell phenotype histologically reminiscent of human diffuse large B cell lymphoma, non-Hodgkin lymphoma

• a minority of CD5 negative tumors showed plasmacytic features similar to lymphoplasmacytic lymphoma

hematopoietic system

increased B cell number ( J:156946 )

• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age

increased B-1a cell number ( J:156946 )

• at 15-18 months increased clonal population in the peripheral blood

increased spleen white pulp amount ( J:156946 )

• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

immune system

increased B cell number ( J:156946 )

• monoclonal B cell lymphocytosis in some mice at 15 - 18 months of age

increased B-1a cell number ( J:156946 )

• at 15-18 months increased clonal population in the peripheral blood

increased spleen white pulp amount ( J:156946 )

• expansion or accumulation of small lymphocytes, with a pattern similar small cell lymphocytic leukemia (SLL) or B cell chronic lymphocytic leukemia (CLL) and with characteristic 'smudge' cells in some mice

Genotype
MGI:3606173

cn42

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Prdm1^tm1Clme/Prdm1^tm1Clme
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

immune system

abnormal B cell differentiation ( J:101890 )

• following immunization a severe decrease in the number of antigen-specific IgM secreting cells is seen compared to wild-type mice

• a larger increase in CD138-B220+NP+ B cells expressing GL7 is seen at 7 and 14 days after immunization

abnormal plasma cell differentiation ( J:101890 )

• the development of both short-lived and post-germinal center long-lived plasma cells is blocked in mutants

abnormal memory B cell number ( J:101890 )

• pre-plasma memory B-cells are reduced by 75% in the spleen and 95% in the bone marrow, and CD138-B220+NP+ cells comprise the majority of memory B cells

abnormal plasma cell morphology ( J:101890 , J:114881 )

• antibody stimulating cell development is completely inhibited in cultures of stimulated B cells, however stimulation of B cells with LPS or LPS and IL-4 results in increased class switch recombination (J:114881)

decreased plasma cell number ( J:101890 )

• very few CD138+B220+/- plasma cells are seen at any time before or after immunization

• 5 days after re-challenge a 99% reduction in CD138+ B220+/- NP+ plasma cells is seen

increased spleen germinal center number ( J:101890 )

• more numerous germinal centers are seen after immunization

increased spleen germinal center size ( J:101890 )

• larger germinal centers are seen after immunization

decreased immunoglobulin level ( J:101890 )

• serum Ig levels are reduced in unimmunized mice

decreased IgG level ( J:101890 )

• in mice immunized with NP-Ficoll serum IgG1 and IgG2a levels are significantly lower in mutants compared to wild-type mice and mutant mice fail to secrete Ig in a recall response

decreased IgM level ( J:101890 )

• in mice immunized with NP-Ficoll serum IgM levels are significantly lower in mutants compared to wild-type mice and homozygous mice fail to secrete Ig in a recall response

hematopoietic system

abnormal B cell differentiation ( J:101890 )

• following immunization a severe decrease in the number of antigen-specific IgM secreting cells is seen compared to wild-type mice

• a larger increase in CD138-B220+NP+ B cells expressing GL7 is seen at 7 and 14 days after immunization

abnormal plasma cell differentiation ( J:101890 )

• the development of both short-lived and post-germinal center long-lived plasma cells is blocked in mutants

abnormal memory B cell number ( J:101890 )

• pre-plasma memory B-cells are reduced by 75% in the spleen and 95% in the bone marrow, and CD138-B220+NP+ cells comprise the majority of memory B cells

abnormal plasma cell morphology ( J:101890 , J:114881 )

• antibody stimulating cell development is completely inhibited in cultures of stimulated B cells, however stimulation of B cells with LPS or LPS and IL-4 results in increased class switch recombination (J:114881)

decreased plasma cell number ( J:101890 )

• very few CD138+B220+/- plasma cells are seen at any time before or after immunization

• 5 days after re-challenge a 99% reduction in CD138+ B220+/- NP+ plasma cells is seen

increased spleen germinal center number ( J:101890 )

• more numerous germinal centers are seen after immunization

increased spleen germinal center size ( J:101890 )

• larger germinal centers are seen after immunization

decreased immunoglobulin level ( J:101890 )

• serum Ig levels are reduced in unimmunized mice

decreased IgG level ( J:101890 )

• in mice immunized with NP-Ficoll serum IgG1 and IgG2a levels are significantly lower in mutants compared to wild-type mice and mutant mice fail to secrete Ig in a recall response

decreased IgM level ( J:101890 )

• in mice immunized with NP-Ficoll serum IgM levels are significantly lower in mutants compared to wild-type mice and homozygous mice fail to secrete Ig in a recall response

Genotype
MGI:3608659

cn43

• Allelic Composition: Bak1^tm1Thsn/Bak1^tm1Thsn; Bax^tm1Sjk/Bax^tm2Sjk; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

immune system

increased pro-B cell number ( J:100463 )

• 4-fold increase in the number of CD43⁺IgM^- Pro-B cells

abnormal B cell number ( J:100463 )

decreased marginal zone B cell number ( J:100463 )

• relative number of CD21^highCD23^low marginal zone B cells is decreased

increased B cell number ( J:100463 )

• increase in the number of B cells at all stages of development in the bone marrow and spleen

increased transitional stage B cell number ( J:100463 )

• a 3-5 fold increase in the numbers of transitional B cells

increased B-2 B cell number ( J:100463 )

• an increase in B-2 cell number, but not B-1 cells, from the peritoneal cavity

increased follicular B cell number ( J:100463 )

• an increase in CD21^intCD23^high follicular B cells

increased pre-B cell number ( J:100463 )

• a 4-fold increase in the number of IgM⁺ immature B cells

abnormal B cell physiology ( J:100463 )

• B cells are highly resistant to multiple cell death stimuli, including cytokine withdrawal, BCR crosslinking, steroid treatment, and DNA damage

• cell cycle progression of splenic B cells is impaired after stimulation with mitogens LPS and anti-IgM, but not CpG-DNA

increased immunoglobulin level ( J:100463 )

• all isotypes were 5-10 times higher than controls

increased IgA level ( J:100463 )

increased IgG level ( J:100463 )

• increased IgG1, IgG2, IgG2b and IgG3

increased IgM level ( J:100463 )

hematopoietic system

increased pro-B cell number ( J:100463 )

• 4-fold increase in the number of CD43⁺IgM^- Pro-B cells

increased bone marrow cell number ( J:100463 )

• 2-fold increase in total cellularity of bone marrow cells, due to accumulation of developing B cells

abnormal B cell number ( J:100463 )

decreased marginal zone B cell number ( J:100463 )

• relative number of CD21^highCD23^low marginal zone B cells is decreased

increased B cell number ( J:100463 )

• increase in the number of B cells at all stages of development in the bone marrow and spleen

increased transitional stage B cell number ( J:100463 )

• a 3-5 fold increase in the numbers of transitional B cells

increased B-2 B cell number ( J:100463 )

• an increase in B-2 cell number, but not B-1 cells, from the peritoneal cavity

increased follicular B cell number ( J:100463 )

• an increase in CD21^intCD23^high follicular B cells

increased pre-B cell number ( J:100463 )

• a 4-fold increase in the number of IgM⁺ immature B cells

abnormal B cell physiology ( J:100463 )

• B cells are highly resistant to multiple cell death stimuli, including cytokine withdrawal, BCR crosslinking, steroid treatment, and DNA damage

• cell cycle progression of splenic B cells is impaired after stimulation with mitogens LPS and anti-IgM, but not CpG-DNA

increased immunoglobulin level ( J:100463 )

• all isotypes were 5-10 times higher than controls

increased IgA level ( J:100463 )

increased IgG level ( J:100463 )

• increased IgG1, IgG2, IgG2b and IgG3

increased IgM level ( J:100463 )

Genotype
MGI:5476680

cn44

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Trp53^tm1Yjc/Trp53^tm1Yjc
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6

neoplasm

neoplasm ( J:195018 )

N • mice do not develop B cell lymphomas

Genotype
MGI:3720352

cn45

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pax5^tm1Mbu/Pax5^tm3Mbu
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

immune system

abnormal B cell differentiation ( J:75504 )

• LPS-stimulated lymph node B cells exhibit a low frequency of and a delay in increased cell size relative to wild-type cells

abnormal class switch recombination ( J:75504 )

• IgG class switching is decreased

decreased immature B cell number ( J:75504 )

• short-lived IgM-B220^lo and IgM+B220^lo immature B cells are slightly lower in number

decreased mature B cell number ( J:75504 )

• there is a 3-fold reduction in the number of long-lived mature B cells

• mice lack recirculating IgM+IgD+B220^hi cells in the bone marrow

decreased pre-B cell number ( J:75504 )

• short-lived IgM-B220^lo B cells are slightly lower in number

decreased immunoglobulin level ( J:75504 )

• total immunoglobin is reduced 3-fold compared to control mice

decreased IgG level ( J:75504 )

• IgG levels are decreased ranging from a 9.4-fold decrease of IgG1 to a 2-fold decrease in IgG3 levels

decreased IgG1 level ( J:75504 )

decreased IgG3 level ( J:75504 )

hematopoietic system

abnormal B cell differentiation ( J:75504 )

• LPS-stimulated lymph node B cells exhibit a low frequency of and a delay in increased cell size relative to wild-type cells

abnormal class switch recombination ( J:75504 )

• IgG class switching is decreased

decreased immature B cell number ( J:75504 )

• short-lived IgM-B220^lo and IgM+B220^lo immature B cells are slightly lower in number

decreased mature B cell number ( J:75504 )

• there is a 3-fold reduction in the number of long-lived mature B cells

• mice lack recirculating IgM+IgD+B220^hi cells in the bone marrow

decreased pre-B cell number ( J:75504 )

• short-lived IgM-B220^lo B cells are slightly lower in number

decreased immunoglobulin level ( J:75504 )

• total immunoglobin is reduced 3-fold compared to control mice

decreased IgG level ( J:75504 )

• IgG levels are decreased ranging from a 9.4-fold decrease of IgG1 to a 2-fold decrease in IgG3 levels

decreased IgG1 level ( J:75504 )

decreased IgG3 level ( J:75504 )

Genotype
MGI:5553374

cn46

• Allelic Composition: Nle1^tm1Cba/Nle1^tm1.1Cota; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

hematopoietic system

hematopoietic system phenotype ( J:204063 )

N • mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells

N • mice exhibit normal survival, proliferation and maturation of restricted progenitors

immune system

immune system phenotype ( J:204063 )

N • mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells

N • mice exhibit normal survival, proliferation and maturation of restricted progenitors

Genotype
MGI:5314093

cn47

• Allelic Composition: Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Tcrb^tm1Mom/Tcrb^tm1Mom; Tcrd^tm1Mom/Tcrd^tm1Mom; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

liver/biliary system

enlarged liver ( J:181546 )

• occasionally

neoplasm

increased B cell derived lymphoma incidence ( J:181546 )

• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

increased plasmacytoma incidence ( J:181546 )

• in 3 of 9 mice

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged liver ( J:181546 )

• occasionally

enlarged spleen ( J:181546 )

Genotype
MGI:5314090

cn48

• Allelic Composition: Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Tcrb^tm1Mom/Tcrb⁺; Tcrd^tm1Mom/Tcrd^tm1Mom; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged spleen ( J:181546 )

Genotype
MGI:5314091

cn49

• Allelic Composition: Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Tcrb^tm1Mom/Tcrb⁺; Tcrd^tm1Mom/Tcrd^tm1Mom; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged spleen ( J:181546 )

Genotype
MGI:5793062

cn50

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ell2^tm2.1Cmil/Ell2^tm2.1Cmil
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

hematopoietic system

decreased mature B cell number ( J:234692 )

• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells

decreased immunoglobulin level ( J:234692 )

• decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotypes is found in naive mice as compared to controls

decreased IgA level ( J:234692 )

decreased IgG1 level ( J:234692 )

decreased IgM level ( J:234692 )

immune system

decreased mature B cell number ( J:234692 )

• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells

decreased immunoglobulin level ( J:234692 )

• decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotypes is found in naive mice as compared to controls

decreased IgA level ( J:234692 )

decreased IgG1 level ( J:234692 )

decreased IgM level ( J:234692 )

Genotype
MGI:5793061

cn51

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ell2^tm1.1Cmil/Ell2^tm1.1Cmil
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

immune system

decreased transitional stage T1 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen

decreased transitional stage T2 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen

decreased transitional stage T3 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T3 cells are observed in spleen

increased immature B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) percentage of immature B cells in bone marrow is increased as compared to control

increased pro-B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH)

decreased mature B cell number ( J:234692 )

• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells

decreased plasma cell number ( J:234692 )

• 4 fold decrease in LPS-treated B220^loCD138⁺ splenic B cells

• decline in CD138+ cells in immunized mice

increased follicular B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) percentage of recirculating B cells in bone marrow is increased as compared to control

increased pre-B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH)

decreased immunoglobulin level ( J:234692 )

• 2 fold decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotopes is found in naive mice as compared to controls

decreased IgA level ( J:234692 )

decreased IgG1 level ( J:234692 )

decreased IgM level ( J:234692 )

impaired humoral immune response ( J:234692 )

• specific antibody responses are impaired for both T cell dependent and independent antigens

• mice immunized with NP-Ficoll exhibit less anti-NP antibody of the IgM, IgG2b and IgG3 isotypes

• mice immunized with NP-KLH exhibit less anti-NP antibody of the IgM, IgG1, IgG2c and IgG3 isotopes

• following restimulation, recall response is less than controls

hematopoietic system

decreased transitional stage T1 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen

decreased transitional stage T2 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T1 and T2 type B cells are observed in spleen

decreased transitional stage T3 B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) fewer T3 cells are observed in spleen

increased immature B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) percentage of immature B cells in bone marrow is increased as compared to control

increased pro-B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH)

decreased mature B cell number ( J:234692 )

• decrease in IgG1-producing cells in bone marrow from unimmunized mice; these cells may represent either plasma cells or memory B cells

decreased plasma cell number ( J:234692 )

• 4 fold decrease in LPS-treated B220^loCD138⁺ splenic B cells

• decline in CD138+ cells in immunized mice

increased follicular B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH) percentage of recirculating B cells in bone marrow is increased as compared to control

increased pre-B cell number ( J:234692 )

• following antigen challenge (NP-Ficoll or NP-KLH)

decreased immunoglobulin level ( J:234692 )

• 2 fold decrease in serum levels of secreted IgM, IgG1, IgA and all other IgG isotopes is found in naive mice as compared to controls

decreased IgA level ( J:234692 )

decreased IgG1 level ( J:234692 )

decreased IgM level ( J:234692 )

cellular

abnormal endoplasmic reticulum morphology ( J:234692 )

• ER found in LPS-treated B220^loCD138⁺ cells is dilated and fragmented

Genotype
MGI:3777352

cn52

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc; Traf2^tm1Rbr/Traf2^tm1Rbr
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

immune system

increased follicular B cell number ( J:132877 )

• there is about a 4-fold increase in the number of follicular B cells found in the spleen compared to controls

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

hematopoietic system

increased follicular B cell number ( J:132877 )

• there is about a 4-fold increase in the number of follicular B cells found in the spleen compared to controls

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

Genotype
MGI:5314096

cn53

• Allelic Composition: Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Tcrb^tm1Mom/Tcrb^tm1Mom; Tcrd^tm1Mom/Tcrd^tm1Mom; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

liver/biliary system

enlarged liver ( J:181546 )

• occasionally

neoplasm

increased B cell derived lymphoma incidence ( J:181546 )

• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

increased plasmacytoma incidence ( J:181546 )

• in 3 of 9 mice

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged liver ( J:181546 )

• occasionally

enlarged spleen ( J:181546 )

Genotype
MGI:3759846

cn54

• Allelic Composition: Itgav^tm2Hyn/Itgav^tm2.1Hyn; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB

digestive/alimentary system

digestive/alimentary phenotype ( J:125508 )

N • mice do not develop colitis unlike Itgav^tm2Hyn Itgav^tm2.1Hyn Tg(Tek-cre)1Ywa mice

Genotype
MGI:3839883

cn55

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL

immune system

immune system phenotype ( J:147265 )

N • mice exhibit normally differentiating T, B, and myeloid cells

Genotype
MGI:5013951

cn56

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Inpp5d^tm1Rav/Inpp5d^tm1Rav; Pten^tm1Hwu/Pten^tm1Hwu
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae

behavior/neurological

lethargy ( J:166155 )

• mutants exhibit lethargy by 4 months of age

hunched posture ( J:166155 )

• mutants exhibit a hunched posture by 4 months of age

growth/size/body

weight loss ( J:166155 )

• mutants exhibit weight loss by 4 months of age

enlarged spleen ( J:166155 )

• mutants exhibit splenomegaly by 4 months of age

hematopoietic system

enlarged spleen ( J:166155 )

• mutants exhibit splenomegaly by 4 months of age

abnormal B cell morphology ( J:166155 )

• CD19+ B cells are larger than B cells from wild-type mice

• B cell neoplasia

decreased B cell number ( J:166155 )

• reduction in the frequency of B cells in asymptomatic double mutant mice as compared to controls or either single mutant mouse

increased B cell number ( J:166155 )

• mutants older than 6 months of age have a 3-fold increase in the percentage of recirculating B cells in the blood, concurrent with onset of disease

abnormal myeloid leukocyte morphology ( J:166155 )

• tissues containing the expanded B cell population also display an expansion of CD11b+ myeloid cells

increased spleen white pulp amount ( J:166155 )

• spleens of mutants over 6 months of age exhibit an expansion of CD19+ B cells, resulting in enlarged white pulp areas that often infiltrate and compress the red pulp

abnormal B cell physiology ( J:166155 )

• B cells exhibit enhanced survival

increased B cell proliferation ( J:166155 )

• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not

• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

immune system

enlarged spleen ( J:166155 )

• mutants exhibit splenomegaly by 4 months of age

abnormal B cell morphology ( J:166155 )

• CD19+ B cells are larger than B cells from wild-type mice

• B cell neoplasia

decreased B cell number ( J:166155 )

• reduction in the frequency of B cells in asymptomatic double mutant mice as compared to controls or either single mutant mouse

increased B cell number ( J:166155 )

• mutants older than 6 months of age have a 3-fold increase in the percentage of recirculating B cells in the blood, concurrent with onset of disease

abnormal myeloid leukocyte morphology ( J:166155 )

• tissues containing the expanded B cell population also display an expansion of CD11b+ myeloid cells

increased spleen white pulp amount ( J:166155 )

• spleens of mutants over 6 months of age exhibit an expansion of CD19+ B cells, resulting in enlarged white pulp areas that often infiltrate and compress the red pulp

abnormal B cell physiology ( J:166155 )

• B cells exhibit enhanced survival

increased B cell proliferation ( J:166155 )

• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not

• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

integument

abnormal coat appearance ( J:166155 )

• mutants exhibit ruffled fur by 4 months of age

mortality/aging

premature death ( J:166155 )

• severe morbidity and death occurs in all mutants by 1 year of age

neoplasm

increased lymphoma incidence ( J:166155 )

• mutants develop marginal zone lymphoma, and less frequently, follicular B cell lymphoma or centroblastic lymphoma

increased follicular lymphoma incidence ( J:166155 )

increased splenic marginal zone lymphoma incidence ( J:166155 )

• mutants develop spontaneous and lethal mature B cell neoplasms consistent with marginal zone lymphoma

increased malignant tumor incidence ( J:166155 )

• lymphoma infiltrates are seen in nonlymphoid tissues, including liver, lung, heart, and kidney

increased plasmacytoma incidence ( J:166155 )

cellular

increased B cell proliferation ( J:166155 )

• B cells proliferate to the prosurvival factor B cell activating factor (BAFF) while wild-type B cells do not

• B cells show a more robust proliferative response to LPS or anti-CD40 than wild-type mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
B-cell lymphoma		DOID:707		J:166155

Genotype
MGI:4829791

cn57

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pten^tm1Hwu/Pten^tm1Hwu
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae

hematopoietic system

abnormal B cell negative selection ( J:155314 )

• bone marrow cultured with IL-7 over a 6 day period to promote selective expansion of pre-B cells exhibits an approximate 7-fold enhancement in the frequency of activated immature mutant B cells relative to immature wild-type B cells

• gating on activated B cells shows that immature mutant B cells proliferate to a much greater extent than immature wild-type B cells

• these experiments show that upon BCR engagement, immature B cells are activated and proliferate rather than being inhibited and undergoing anergy

increased B cell number ( J:83213 )

• increase in the absolute number of splenic B cells, attributed mainly to the expansion/accumulation of MZ B cells

increased B-1 B cell number ( J:83213 )

• expansion of the B1 cell population

increased marginal zone B cell number ( J:83213 )

• expansion of the MZ B cell compartment

abnormal plasma cell morphology ( J:114881 )

• increase in numbers of IgM^hi antibody secreting cells and decrease in numbers of IgG^hi antibody secreting cells

decreased spleen germinal center number ( J:83213 )

• reduction in germinal center formation in response to sheep red blood cell immunization and in response to environmental antigens

abnormal B cell physiology ( J:83213 )

• B cells are responsive to chemotactic stimuli but show reduced directed movement toward the stimulus

increased B cell apoptosis ( J:83213 )

• cultured B cells show increased apoptosis

increased B cell proliferation ( J:83213 , J:155314 )

• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)

• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)

• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)

abnormal class switch recombination ( J:114881 )

• impaired class-switch recombination in antibody secreting cells in response to a T-dependent antigen; B cells fail to undergo class-switch recombination to IgG3 or IgG1 in the presence of LPS or LPS plus IL-4, respectively

• however, well-formed germinal centers are observed in spleen after immunization

decreased IgG level ( J:114881 )

• decrease in IgG after TNP-OVA immunization

increased IgM level ( J:114881 )

• increase in IgM after TNP-OVA immunization

immune system

abnormal B cell negative selection ( J:155314 )

• bone marrow cultured with IL-7 over a 6 day period to promote selective expansion of pre-B cells exhibits an approximate 7-fold enhancement in the frequency of activated immature mutant B cells relative to immature wild-type B cells

• gating on activated B cells shows that immature mutant B cells proliferate to a much greater extent than immature wild-type B cells

• these experiments show that upon BCR engagement, immature B cells are activated and proliferate rather than being inhibited and undergoing anergy

increased B cell number ( J:83213 )

• increase in the absolute number of splenic B cells, attributed mainly to the expansion/accumulation of MZ B cells

increased B-1 B cell number ( J:83213 )

• expansion of the B1 cell population

increased marginal zone B cell number ( J:83213 )

• expansion of the MZ B cell compartment

abnormal plasma cell morphology ( J:114881 )

• increase in numbers of IgM^hi antibody secreting cells and decrease in numbers of IgG^hi antibody secreting cells

decreased spleen germinal center number ( J:83213 )

• reduction in germinal center formation in response to sheep red blood cell immunization and in response to environmental antigens

abnormal B cell physiology ( J:83213 )

• B cells are responsive to chemotactic stimuli but show reduced directed movement toward the stimulus

increased B cell apoptosis ( J:83213 )

• cultured B cells show increased apoptosis

increased B cell proliferation ( J:83213 , J:155314 )

• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)

• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)

• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)

abnormal class switch recombination ( J:114881 )

• impaired class-switch recombination in antibody secreting cells in response to a T-dependent antigen; B cells fail to undergo class-switch recombination to IgG3 or IgG1 in the presence of LPS or LPS plus IL-4, respectively

• however, well-formed germinal centers are observed in spleen after immunization

decreased IgG level ( J:114881 )

• decrease in IgG after TNP-OVA immunization

increased IgM level ( J:114881 )

• increase in IgM after TNP-OVA immunization

cellular

increased B cell apoptosis ( J:83213 )

• cultured B cells show increased apoptosis

increased B cell proliferation ( J:83213 , J:155314 )

• B cells are hyperproliferative in response to mitogenic stimuli and exhibit a lower threshold for activation through the B cell antigen receptor (J:83213)

• B cells exhibit altered cell cycle progression, with an increase in the percentage of cells in S and G2-M stages (J:83213)

• neonatal B cells proliferate strongly in response to both LPS and anti-IgM F(ab')2 unlike wild-type B cells which show a modest proliferation in response to LPS and no proliferation in response to the anti-IgM F(ab')2 (J:155314)

Genotype
MGI:2684441

cn58

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Rac1^tm1Tyb/Rac1^tm1Tyb
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

immune system

immune system phenotype ( J:86765 )

N • B lineage cells were normal in bone marrow, spleen, and lymph nodes

Genotype
MGI:5007685

cn59

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

immune system

abnormal peripheral B cell anergy ( J:155314 )

• failed tolerance induction resulting in abundant autoantibody production, indicating that B cells are prevented from acquiring an anergic state

• B cells have about 10 fold lower bound HEL than in mutants with intact Pten, suggesting that receptor occupancy is reduced on mutant autoreactive B cells and that less HEL is available in adults for inducing and sustaining anergy

• increasing the concentration of free self-antigen confers an anergic phenotype on mutant B cells, but they remain long-lived

Genotype
MGI:5484529

cn60

• Allelic Composition: Rbbp8^tm1Whl/Rbbp8^tm1.1Thl; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor

immune system

immune system phenotype ( J:194603 )

N • B cells exhibit normal class switching and microhomology at Smu-Sgamma1 junctions

Genotype
MGI:5495974

cn61

• Allelic Composition: Palb2^tm1.1Dli/Palb2^tm1.1Dli; Trp53bp1^tm1Jc/Trp53bp1^tm1Jc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6

cellular

chromosome breakage ( J:197442 )

• the number of chromosomal aberrations (chromatid breaks, chromosome breaks and radial chromosomes) in B lymphocytes is increased by treatment with KU0058949 (PARP inhibitor) compared to in wild-type mice

Genotype
MGI:6359749

cn62

• Allelic Composition: Zc3h12c^{tm2c(EUCOMM)Hmgu}/Zc3h12c^{tm2c(EUCOMM)Hmgu}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N

immune system

immune system phenotype ( J:277714 )

N • mice exhibit normal B cell numbers and lymph node size

Genotype
MGI:5495977

cn63

• Allelic Composition: Brca1^tm2Cxd/Brca1^tm2Cxd; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

cellular

chromosome breakage ( J:197442 )

• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with wild-type cells

Genotype
MGI:3783742

cn64

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pbx1^tm2Mlc/Pbx1^tm2Mlc
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

normal phenotype

no abnormal phenotype detected ( J:132963 )

• mice have normal numbers of B cells

Genotype
MGI:5495978

cn65

• Allelic Composition: Brca1^tm2Cxd/Brca1^tm2Cxd; Trp53bp1^tm1Jc/Trp53bp1^tm1Jc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

cellular

cellular phenotype ( J:197442 )

N • chromosomal damage induced by PARP-inhibition is rescued compared to in cells from Brca1^tm2Cxd/Brca1^tm2Cxd Cd19^tm1(cre)Cgn/Cd19⁺ mice

Genotype
MGI:5484530

cn66

• Allelic Composition: Blm^tm4Ches/Blm^tm4Ches; Trp53bp1^tm1Jc/Trp53bp1^tm1Jc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

immune system

abnormal class switch recombination ( J:194603 )

• increased switching to a small extent compared with Trp53bp1^tm1Jc homozygotes

hematopoietic system

abnormal class switch recombination ( J:194603 )

• increased switching to a small extent compared with Trp53bp1^tm1Jc homozygotes

Genotype
MGI:2385667

cn67

• Allelic Composition: Myc^tm2Fwa/Myc^tm2Fwa; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

immune system

decreased B cell proliferation ( J:67222 )

• impaired proliferation response to stimulation; cells do not undergo activation

hematopoietic system

decreased B cell proliferation ( J:67222 )

• impaired proliferation response to stimulation; cells do not undergo activation

cellular

decreased B cell proliferation ( J:67222 )

• impaired proliferation response to stimulation; cells do not undergo activation

Genotype
MGI:5295466

cn68

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ptpn11^tm1Ckq/Ptpn11⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J

mortality/aging

premature death ( J:177285 )

neoplasm

increased acute lymphoblastic leukemia incidence ( J:177285 )

• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice

increased B cell derived lymphoma incidence ( J:177285 )

• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice

Genotype
MGI:5301628

cn69

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J

immune system

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

increased spleen weight ( J:179036 )

abnormal B cell differentiation ( J:179036 )

• B cell development in the spleen is altered

• however, mice exhibit normal B cell development in the bone marrow

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased B cell number ( J:179036 )

• in re-circulating B cells

• slightly in the spleen

decreased B-1a cell number ( J:179036 )

• in the peritoneal cavity

decreased B-2 B cell number ( J:179036 )

• in the peritoneal cavity

decreased follicular B cell number ( J:179036 )

• 5 times

increased T cell number ( J:179036 )

• doubled in the spleen

decreased spleen B cell follicle size ( J:179036 )

• diminished in size

decreased spleen germinal center number ( J:179036 )

• after NP-CGG stimulation with diminished NP-specific IgM and IgG1

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged in size

increased marginal zone B cell number ( J:179036 )

• 7 times

decreased IgG1 level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

decreased IgG3 level ( J:179036 )

• after NP-Ficoll stimulation

decreased IgM level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

abnormal marginal zone B cell physiology ( J:179036 )

• enlarged in response to anti-CD40 antibodies and IL4

hematopoietic system

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

increased spleen weight ( J:179036 )

abnormal B cell differentiation ( J:179036 )

• B cell development in the spleen is altered

• however, mice exhibit normal B cell development in the bone marrow

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased B cell number ( J:179036 )

• in re-circulating B cells

• slightly in the spleen

decreased B-1a cell number ( J:179036 )

• in the peritoneal cavity

decreased B-2 B cell number ( J:179036 )

• in the peritoneal cavity

decreased follicular B cell number ( J:179036 )

• 5 times

increased T cell number ( J:179036 )

• doubled in the spleen

decreased spleen B cell follicle size ( J:179036 )

• diminished in size

decreased spleen germinal center number ( J:179036 )

• after NP-CGG stimulation with diminished NP-specific IgM and IgG1

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged in size

increased marginal zone B cell number ( J:179036 )

• 7 times

decreased IgG1 level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

decreased IgG3 level ( J:179036 )

• after NP-Ficoll stimulation

decreased IgM level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

abnormal marginal zone B cell physiology ( J:179036 )

• enlarged in response to anti-CD40 antibodies and IL4

growth/size/body

increased spleen weight ( J:179036 )

cellular

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

Genotype
MGI:3722773

cn70

• Allelic Composition: Traf3^tm1Bshp/Traf3^tm1Bshp; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL

immune system

abnormal leukocyte morphology ( J:124329 )

increased B cell number ( J:124329 )

• B cell numbers are increased in adult spleen and lymph nodes

• the number of T2 transitional, follicular and marginal zone B cells is increased in the spleen

increased transitional stage B cell number ( J:124329 )

• the number of T2 transitional B cells is increased in the spleen

• the number of T1 transitional B cells in slightly increased (1.4-fold)

increased follicular B cell number ( J:124329 )

increased marginal zone B cell number ( J:124329 )

• the percent and number of marginal zone B cells is increased

decreased T cell number ( J:124329 )

• in adult mice

abnormal immune system organ morphology ( J:124329 )

enlarged spleen ( J:124329 )

• adult mice have splenomegaly

abnormal spleen germinal center morphology ( J:124329 )

• spontaneous germinal centers form

increased spleen white pulp amount ( J:124329 )

• white pulp is enlarged

abnormal lymph node B cell domain morphology ( J:124329 )

• adult mice have an increased in the size and number of lymphoid follicles

enlarged lymph nodes ( J:124329 )

• adult mice have enlarged lymph nodes

abnormal immune system physiology ( J:124329 )

abnormal adaptive immunity ( J:124329 )

• when challenged with TNP-Ficoll, mice generate higher titers of TNO-specific IgM, igG1, IgG2a, IgG2b, and IgG3 compared to wild-type mice

• when challenged with T dependent antigen (TNP-KLH), mice only show an increase in TNP-specific IgM response

• the T-I antibody response in increased while the T-D IgG1 response is normal

decreased B cell apoptosis ( J:124329 )

• unstimulated ex vivo B cell survive longer than for wild-type B cells with 30% of B cells alive after 16 days in culture when control cells were no longer alive

• B cell activating factor did not enhance ex vivo survival

• B cell do not undergo apoptosis ex vivo as wild-type B cells do

increased IgA level ( J:124329 )

• serum IgA is elevated 2- to 5-fold

increased IgG level ( J:124329 )

• germinal center B cells express more surface IgG

• serum IgG2a, IgG2b and IgG3 are elevated 2- to 5-fold

increased IgG2a level ( J:124329 )

increased IgG2b level ( J:124329 )

increased IgG3 level ( J:124329 )

increased IgM level ( J:124329 )

• germinal center B cells express more surface IgM

• serum IgM is elevated 2- to 5-fold

autoimmune response ( J:124329 )

• mice display autoimmune manifestations such as double stranded DNA antibodies and the presence of lymphocyte infiltrate in the kidney and liver

increased anti-double stranded DNA antibody level ( J:124329 )

• in 80% of mice

homeostasis/metabolism

decreased physiological sensitivity to xenobiotic ( J:124329 )

• mice do not exhibit a reduction in spleen weight or depletion of B cells in response to administration of TACI-Ig (an inhibitor or B cell activating factor and a proliferation-inducing ligand)

liver/biliary system

abnormal liver morphology ( J:124329 )

• 3 of 4 mice contain lymphocyte infiltration at multiple locations in the kidney and liver

renal/urinary system

abnormal kidney morphology ( J:124329 )

• 3 of 4 mice contain lymphocyte infiltration at multiple locations in the kidney and liver

hematopoietic system

decreased B cell apoptosis ( J:124329 )

• unstimulated ex vivo B cell survive longer than for wild-type B cells with 30% of B cells alive after 16 days in culture when control cells were no longer alive

• B cell activating factor did not enhance ex vivo survival

• B cell do not undergo apoptosis ex vivo as wild-type B cells do

enlarged spleen ( J:124329 )

• adult mice have splenomegaly

abnormal leukocyte morphology ( J:124329 )

increased B cell number ( J:124329 )

• B cell numbers are increased in adult spleen and lymph nodes

• the number of T2 transitional, follicular and marginal zone B cells is increased in the spleen

increased transitional stage B cell number ( J:124329 )

• the number of T2 transitional B cells is increased in the spleen

• the number of T1 transitional B cells in slightly increased (1.4-fold)

increased follicular B cell number ( J:124329 )

increased marginal zone B cell number ( J:124329 )

• the percent and number of marginal zone B cells is increased

decreased T cell number ( J:124329 )

• in adult mice

abnormal spleen germinal center morphology ( J:124329 )

• spontaneous germinal centers form

increased spleen white pulp amount ( J:124329 )

• white pulp is enlarged

increased IgA level ( J:124329 )

• serum IgA is elevated 2- to 5-fold

increased IgG level ( J:124329 )

• germinal center B cells express more surface IgG

• serum IgG2a, IgG2b and IgG3 are elevated 2- to 5-fold

increased IgG2a level ( J:124329 )

increased IgG2b level ( J:124329 )

increased IgG3 level ( J:124329 )

increased IgM level ( J:124329 )

• germinal center B cells express more surface IgM

• serum IgM is elevated 2- to 5-fold

cellular

decreased B cell apoptosis ( J:124329 )

• unstimulated ex vivo B cell survive longer than for wild-type B cells with 30% of B cells alive after 16 days in culture when control cells were no longer alive

• B cell activating factor did not enhance ex vivo survival

• B cell do not undergo apoptosis ex vivo as wild-type B cells do

growth/size/body

enlarged spleen ( J:124329 )

• adult mice have splenomegaly

Genotype
MGI:5906762

cn71

• Allelic Composition: Blm^tm4Ches/Blm^tm4Ches; Cd19^tm1(cre)Cgn/Cd19⁺; Nsmce2^tm2.1Ofc/Nsmce2^tm2.1Ofc
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL

immune system

abnormal B cell morphology ( J:227197 )

• striking increase in B cell size coincident with the presence of large and irregular multilobulated nuclei indicating severe segregation defects

decreased B cell number ( J:227197 )

• acute loss of B cells that is not seen in either single conditional mutant

small spleen ( J:227197 )

abnormal B cell physiology ( J:227197 )

• increase in spontaneous sister chromatid exchange levels in B cells

cellular

elevated level of mitotic sister chromatid exchange ( J:227197 )

• increase in spontaneous sister chromatid exchange levels in B cells

hematopoietic system

abnormal B cell morphology ( J:227197 )

• striking increase in B cell size coincident with the presence of large and irregular multilobulated nuclei indicating severe segregation defects

decreased B cell number ( J:227197 )

• acute loss of B cells that is not seen in either single conditional mutant

small spleen ( J:227197 )

abnormal B cell physiology ( J:227197 )

• increase in spontaneous sister chromatid exchange levels in B cells

Genotype
MGI:5485996

cn72

• Allelic Composition: Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL

hematopoietic system

hematopoietic system phenotype ( J:194929 )

N • mice exhibit normal myeloid, T lymphoid and B lymphoid lineages and cell cycle of lineage progenitors

immune system

immune system phenotype ( J:194929 )

N • mice exhibit normal myeloid, T lymphoid and B lymphoid lineages and cell cycle of lineage progenitors

Genotype
MGI:6694201

cn73

• Allelic Composition: Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S * C57BL/6

immune system

abnormal class switch recombination ( J:303927 )

• impaired

abnormal somatic hypermutation frequency ( J:303927 )

• reduced

decreased plasma cell number ( J:303927 )

• reduced TACI+CD138+B220-CD19^int early cells and TACI+CD138+B220-CD19- mature cells in the spleen, lymph nodes and bone marrow

• reduced LPS-induced TACI+CD138+B220-CD19^int early plasma cells and TACI+CD138+B220-CD19- mature plasma cells

• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasma cells

abnormal plasmablast number ( J:303927 )

• decreased TACI+CD138+B220^intCD19^int cells

• decreased plasmablasts in LPS-treated mice

• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasmablasts

abnormal humoral immune response ( J:303927 )

• mice treated with NP-Ficoll and NP-KLH exhibit reduced NP-specific IgM, IgG, IgG1, IgG2b, IgG2c, IgG3, IgA, and IgE antibodies

decreased IgA level ( J:303927 )

• at baseline

decreased IgE level ( J:303927 )

• at baseline

decreased IgG level ( J:303927 )

• at baseline or mice treated with sheep red blood cells

decreased IgG1 level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG2b level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG2c level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG3 level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgM level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased autoantibody level ( J:303927 )

• in mice treated with pristane compared with similarly treated control mice

renal/urinary system

increased urine protein level ( J:303927 )

• in mice treated with pristane that is not as high as in control mice

homeostasis/metabolism

increased urine protein level ( J:303927 )

• in mice treated with pristane that is not as high as in control mice

decreased susceptibility to injury ( J:303927 )

• mice treated with hydrocarbon oil 2, 6, 10, 14-tetramethylpentadecane (TMPD or pristane) to induce systemic lupus erythematosus exhibit reduced increase in autoantibody levels and proteinuria compared with control mice

hematopoietic system

abnormal class switch recombination ( J:303927 )

• impaired

abnormal somatic hypermutation frequency ( J:303927 )

• reduced

decreased plasma cell number ( J:303927 )

• reduced TACI+CD138+B220-CD19^int early cells and TACI+CD138+B220-CD19- mature cells in the spleen, lymph nodes and bone marrow

• reduced LPS-induced TACI+CD138+B220-CD19^int early plasma cells and TACI+CD138+B220-CD19- mature plasma cells

• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasma cells

abnormal plasmablast number ( J:303927 )

• decreased TACI+CD138+B220^intCD19^int cells

• decreased plasmablasts in LPS-treated mice

• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasmablasts

decreased IgA level ( J:303927 )

• at baseline

decreased IgE level ( J:303927 )

• at baseline

decreased IgG level ( J:303927 )

• at baseline or mice treated with sheep red blood cells

decreased IgG1 level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG2b level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG2c level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgG3 level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

decreased IgM level ( J:303927 )

• at baseline and in LPS- or sheep red blood cell-treated mice

Genotype
MGI:6694199

cn74

• Allelic Composition: Fas^lpr/Fas^lpr; Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp

immune system

decreased susceptibility to systemic lupus erythematosus ( J:303927 )

• mice exhibit reduced increase in autoantibody levels and proteinuria levels compared with control mice

decreased autoantibody level ( J:303927 )

• compared with Fas^lpr homozygotes

renal/urinary system

increased urine protein level ( J:303927 )

• not as severe as in Fas^lpr homozygotes

homeostasis/metabolism

increased urine protein level ( J:303927 )

• not as severe as in Fas^lpr homozygotes

Genotype
MGI:2684442

cn75

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Rac1^tm1Tyb/Rac1^tm1Tyb; Rac2^tm1Mddw/Rac2^tm1Mddw
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6

hematopoietic system

arrested B cell differentiation ( J:86765 )

• development blocked at the T1 stage

decreased B cell number ( J:86765 )

decreased transitional stage B cell number ( J:86765 )

• diminished splenic T1 and T2 cells

decreased B-1 B cell number ( J:86765 )

• peritoneal B cells (B1) also reduced

decreased follicular B cell number ( J:86765 )

• diminished recirculating follicular B cells

decreased marginal zone B cell number ( J:86765 )

• splenic marginal B cells were reduced

immune system

arrested B cell differentiation ( J:86765 )

• development blocked at the T1 stage

decreased B cell number ( J:86765 )

decreased transitional stage B cell number ( J:86765 )

• diminished splenic T1 and T2 cells

decreased B-1 B cell number ( J:86765 )

• peritoneal B cells (B1) also reduced

decreased follicular B cell number ( J:86765 )

• diminished recirculating follicular B cells

decreased marginal zone B cell number ( J:86765 )

• splenic marginal B cells were reduced

Genotype
MGI:3629600

cn76

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tnf^tm2.1Gkl/Tnf^tm2.1Gkl
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J

immune system

immune system phenotype ( J:108572 )

N • unlike mice with recombination in T cells, mice do not develop inflammatory bowel disease

Genotype
MGI:2684157

cn77

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Mcl1^tm2Sjk/Mcl1^tm3Sjk
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ

hematopoietic system

increased B cell apoptosis ( J:86906 )

• increased apoptosis at pro-B cell stage

abnormal B cell differentiation ( J:86906 )

absent early pro-B cells ( J:86906 )

absent late pro-B cells ( J:86906 )

arrested B cell differentiation ( J:86906 )

• arrested at pro-B cell stage

decreased B cell number ( J:86906 )

• decrease in peripheral B cells

• 88% reduction of splenic B cells relative to controls

• near absence of lymph node B cells

• detected peripheral B cells did not undergo cre-mediated recombination

absent pre-B cells ( J:86906 )

immune system

increased B cell apoptosis ( J:86906 )

• increased apoptosis at pro-B cell stage

abnormal B cell differentiation ( J:86906 )

absent early pro-B cells ( J:86906 )

absent late pro-B cells ( J:86906 )

arrested B cell differentiation ( J:86906 )

• arrested at pro-B cell stage

decreased B cell number ( J:86906 )

• decrease in peripheral B cells

• 88% reduction of splenic B cells relative to controls

• near absence of lymph node B cells

• detected peripheral B cells did not undergo cre-mediated recombination

absent pre-B cells ( J:86906 )

cellular

increased B cell apoptosis ( J:86906 )

• increased apoptosis at pro-B cell stage

Genotype
MGI:5442608

cn78

• Allelic Composition: Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺; Rev3l^tm1.1Diaz/Rev3l^tm1.1Diaz
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac

immune system

immune system phenotype ( J:188723 )

N • mice exhibit normal B cell development in the bone marrow and spleen

decreased B cell proliferation ( J:188723 )

• following with activation LPS, less so when activated with LPS plus IL4

abnormal class switch recombination ( J:188723 )

• following activated with LPS and IL4, mice exhibit decreased IgG1+ cells, indicating reduced class switch recombination, compared with wild-type mice

abnormal somatic hypermutation frequency ( J:188723 )

• following immunization with NP-CGG in alum, splenic B cells exhibit reduced mutation frequency in the rearranged Vh186.2 H chains compared with wild-type cells

• Peyer's patch B cells exhibit reduced accumulation of mutation at the intron downstream of rearranged V genes compared with wild-type cells

hematopoietic system

decreased B cell proliferation ( J:188723 )

• following with activation LPS, less so when activated with LPS plus IL4

abnormal class switch recombination ( J:188723 )

• following activated with LPS and IL4, mice exhibit decreased IgG1+ cells, indicating reduced class switch recombination, compared with wild-type mice

abnormal somatic hypermutation frequency ( J:188723 )

• following immunization with NP-CGG in alum, splenic B cells exhibit reduced mutation frequency in the rearranged Vh186.2 H chains compared with wild-type cells

• Peyer's patch B cells exhibit reduced accumulation of mutation at the intron downstream of rearranged V genes compared with wild-type cells

cellular

decreased B cell proliferation ( J:188723 )

• following with activation LPS, less so when activated with LPS plus IL4

Genotype
MGI:3699320

cn79

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gna12^tm1Citb/Gna12^tm1Citb; Gna13^tm2.1Soff/Gna13^tm2.1Soff
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N

hematopoietic system

decreased marginal zone B cell number ( J:117663 )

• marginal zone B cell numbers are strongly reduced compared to controls

abnormal B cell physiology ( J:117663 )

• lysophospholipid-induced induced adhesion is completely abrogated in marginal zone mutant B cells and is reduced in follicular B cells

• lysophospholipid-induced induced LFA-1 (integrin) clustering is abolished in mutant B cells

immune system

decreased marginal zone B cell number ( J:117663 )

• marginal zone B cell numbers are strongly reduced compared to controls

abnormal B cell physiology ( J:117663 )

• lysophospholipid-induced induced adhesion is completely abrogated in marginal zone mutant B cells and is reduced in follicular B cells

• lysophospholipid-induced induced LFA-1 (integrin) clustering is abolished in mutant B cells

Genotype
MGI:3687457

cn80

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Srsf3^tm1Pjln/Srsf3^tm1Pjln
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

decreased B cell number ( J:113645 )

• there is only a mild effect on B cell numbers

hematopoietic system

decreased B cell number ( J:113645 )

• there is only a mild effect on B cell numbers

Genotype
MGI:3051965

cn81

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tgfbr2^tm1Roes/Tgfbr2^tm1Roes
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

hematopoietic system

absent plasma cells ( J:90558 )

• IgA expressing plasma cells are virtually absent from the spleen and bone marrow of mutants

increased leukocyte cell number ( J:90558 )

• a 3 fold increase in leukocyte numbers is seen

abnormal B-1 B cell morphology ( J:90558 )

abnormal B-1 B cell number ( J:90558 )

• increased proliferation of mature splenic B cells is seen, however a decrease in B-1 cell proliferation and increase in B-1 cell survival time are also seen

abnormal B cell physiology ( J:90558 )

• more activated B cells are found in mutants

• sera from 9 week or 8 month old mutants shows increased binding to double stranded DNA indicating impaired control of B cell activation

decreased IgA level ( J:90558 )

• serum IgA levels are reduced by about 10 fold and are not increased in response to antigens

increased IgG level ( J:90558 )

• serum levels of all IgG subclasses are increased with IgG1 showing the largest increase (16 fold)

• IgG3 antigen-induced expression is greatly increased

increased IgM level ( J:90558 )

• serum IgM levels and IgM expression by peripheral B cells are increased

immune system

absent plasma cells ( J:90558 )

• IgA expressing plasma cells are virtually absent from the spleen and bone marrow of mutants

increased leukocyte cell number ( J:90558 )

• a 3 fold increase in leukocyte numbers is seen

abnormal B-1 B cell morphology ( J:90558 )

abnormal B-1 B cell number ( J:90558 )

• increased proliferation of mature splenic B cells is seen, however a decrease in B-1 cell proliferation and increase in B-1 cell survival time are also seen

abnormal B cell physiology ( J:90558 )

• more activated B cells are found in mutants

• sera from 9 week or 8 month old mutants shows increased binding to double stranded DNA indicating impaired control of B cell activation

decreased IgA level ( J:90558 )

• serum IgA levels are reduced by about 10 fold and are not increased in response to antigens

increased IgG level ( J:90558 )

• serum levels of all IgG subclasses are increased with IgG1 showing the largest increase (16 fold)

• IgG3 antigen-induced expression is greatly increased

increased IgM level ( J:90558 )

• serum IgM levels and IgM expression by peripheral B cells are increased

enlarged Peyer's patches ( J:90558 )

• Peyer's patches are larger and more distinct

Genotype
MGI:3811554

cn82

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^tm1Uzs/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

immune system phenotype ( J:130768 )

N • mice exhibit a normal B cell compartment

Genotype
MGI:3706810

cn83

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}/Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

immune system phenotype ( J:112660 )

N • induction of recombination in pre-B cells does not produce an altered phenotype

Genotype
MGI:3720605

cn84

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^tm1Ach/Fas^tm1Ach
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

enlarged spleen ( J:123556 )

• splenomegaly results from

increased lymphocyte cell number ( J:123556 )

• extensive lympho-proliferation of both T and B cells results in splenomegaly

increased immunoglobulin level ( J:123556 )

• mice have hyperimmunoglobulinemia

increased anti-nuclear antigen antibody level ( J:123556 )

hematopoietic system

enlarged spleen ( J:123556 )

• splenomegaly results from

increased lymphocyte cell number ( J:123556 )

• extensive lympho-proliferation of both T and B cells results in splenomegaly

increased immunoglobulin level ( J:123556 )

• mice have hyperimmunoglobulinemia

growth/size/body

enlarged spleen ( J:123556 )

• splenomegaly results from

Genotype
MGI:4437331

cn85

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Il10ra^tm1.1Jack/Il10ra^tm1.1Jack
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

immune system phenotype ( J:157787 )

N • mice exhibit a normal response to LPS injection and T. muris infection

Genotype
MGI:5567931

cn86

• Allelic Composition: Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mice develop mono- and oligoclonal lymphomas

immune system

enlarged spleen ( J:137122 )

• at 8 weeks

• extreme in mice older than 12 months showing signs of disease

increased spleen weight ( J:137122 )

• 3.5-fold at 8 weeks

• 20- to 40-fold in mice older than 12 months showing signs of disease

increased B cell number ( J:137122 )

• 8 times more in the spleen

• 4-fold in lymph nodes

• increased percent of IgM+IgD+ B cells in the spleen and lymph nodes

• however, absolute numbers in the bone marrow are normal

increased follicular B cell number ( J:137122 )

increased marginal zone B cell number ( J:137122 )

increased T cell number ( J:137122 )

• 3 times more in the spleen

increased spleen B cell follicle size ( J:137122 )

• enlarged

abnormal B cell physiology ( J:137122 )

• prolonged survival in vitro

abnormal class switch recombination ( J:137122 )

• Ig class switch recombination is achieved in the presence of IL4 indicating constitutive CD40 signaling

abnormal B cell activation ( J:137122 )

• activated B cells in the spleen and lymph node

increased B cell proliferation ( J:137122 )

• spontaneous

abnormal T cell activation ( J:137122 )

• activated T cells with a shift toward activated and memory-type T cells

enlarged inguinal lymph nodes ( J:137122 )

• in mice older than 12 months showing signs of disease

abnormal humoral immune response ( J:137122 )

• following immunization with hapten conjugated to the carrier chicken gammaglobulin, mice exhibit reduced recruitment/maintenance of B cells within the germinal centers of the spleen compared with wild-type mice

neoplasm

increased B cell derived lymphoma incidence ( J:137122 )

• with extreme splenomegaly, enlarged inguinal lymph nodes, hepatomegaly and nodular infiltrates in the kidney, lung and liver in mice older than 12 months showing signs of disease

liver/biliary system

enlarged liver ( J:137122 )

• in mice older than 12 months showing signs of disease

hematopoietic system

enlarged spleen ( J:137122 )

• at 8 weeks

• extreme in mice older than 12 months showing signs of disease

increased spleen weight ( J:137122 )

• 3.5-fold at 8 weeks

• 20- to 40-fold in mice older than 12 months showing signs of disease

increased B cell number ( J:137122 )

• 8 times more in the spleen

• 4-fold in lymph nodes

• increased percent of IgM+IgD+ B cells in the spleen and lymph nodes

• however, absolute numbers in the bone marrow are normal

increased follicular B cell number ( J:137122 )

increased marginal zone B cell number ( J:137122 )

increased T cell number ( J:137122 )

• 3 times more in the spleen

increased spleen B cell follicle size ( J:137122 )

• enlarged

abnormal B cell physiology ( J:137122 )

• prolonged survival in vitro

abnormal class switch recombination ( J:137122 )

• Ig class switch recombination is achieved in the presence of IL4 indicating constitutive CD40 signaling

abnormal B cell activation ( J:137122 )

• activated B cells in the spleen and lymph node

increased B cell proliferation ( J:137122 )

• spontaneous

abnormal T cell activation ( J:137122 )

• activated T cells with a shift toward activated and memory-type T cells

growth/size/body

enlarged liver ( J:137122 )

• in mice older than 12 months showing signs of disease

enlarged spleen ( J:137122 )

• at 8 weeks

• extreme in mice older than 12 months showing signs of disease

increased spleen weight ( J:137122 )

• 3.5-fold at 8 weeks

• 20- to 40-fold in mice older than 12 months showing signs of disease

cellular

increased B cell proliferation ( J:137122 )

• spontaneous

Genotype
MGI:6387024

cn87

• Allelic Composition: Nfkb2^Lym1/Nfkb2⁺; Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N
• Cell Lines: HEPD0539_8_A05

immune system

immune system phenotype ( J:280549 )

N • mice show rescue of the defect in peripheral B cells, with an increase in total peripheral B cells, mature B cells, and follicular and MZ B cells

Genotype
MGI:5314103

cn88

• Allelic Composition: Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/cJ

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

immune system

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal immune system physiology ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

hematopoietic system

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

cellular

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

growth/size/body

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

Genotype
MGI:5314085

cn89

• Allelic Composition: Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Klrk1^tm1Dhr/Klrk1^tm1Dhr; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/cJ * C57BL/6

neoplasm

neoplasm ( J:181546 )

N • mice are protected from Lmp1-driven lymphomagenesis

Genotype
MGI:6393270

cn90

• Allelic Composition: Dhx15^{tm1c(EUCOMM)Wtsi}/Dhx15^{tm1c(EUCOMM)Wtsi}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C3H * C57BL/6N

immune system

decreased B cell proliferation ( J:284624 )

• in a competitive fitness assay upon activation

abnormal B cell differentiation ( J:284624 )

decreased B cell number ( J:284624 )

• 4-fold reduction, not restricted to a particular B cell subtype

• 4-fold reduction of CD3+ splenic B cells

decreased pre-B cell number ( J:284624 )

• in the bone marrow

decreased spleen weight ( J:284624 )

spleen hypoplasia ( J:284624 )

cellular

decreased B cell proliferation ( J:284624 )

• in a competitive fitness assay upon activation

hematopoietic system

decreased B cell proliferation ( J:284624 )

• in a competitive fitness assay upon activation

abnormal B cell differentiation ( J:284624 )

decreased B cell number ( J:284624 )

• 4-fold reduction, not restricted to a particular B cell subtype

• 4-fold reduction of CD3+ splenic B cells

decreased pre-B cell number ( J:284624 )

• in the bone marrow

decreased spleen weight ( J:284624 )

spleen hypoplasia ( J:284624 )

Genotype
MGI:5517353

cn91

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Ptpn22*)Draw}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

Renal abnormalities in Gt(ROSA)26Sor^{tm1(Ptpn22*)Draw}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mice

immune system

enlarged spleen ( J:201448 )

• at 10 months

spleen hyperplasia ( J:201448 )

• at 10 months

increased B cell number ( J:201448 )

• of age-dependent B cells

increased germinal center B cell number ( J:201448 )

• in aged mice

increased autoantibody level ( J:201448 )

• broad range of autoantibodies in aged mice

increased anti-double stranded DNA antibody level ( J:201448 )

• in aged mice

glomerulonephritis ( J:201448 )

• in aged mice with increased cellularity and mesangial matrix and infiltration of Mac1+ cells

renal/urinary system

glomerulonephritis ( J:201448 )

• in aged mice with increased cellularity and mesangial matrix and infiltration of Mac1+ cells

expanded mesangial matrix ( J:201448 )

• in aged mice

hematopoietic system

enlarged spleen ( J:201448 )

• at 10 months

spleen hyperplasia ( J:201448 )

• at 10 months

increased B cell number ( J:201448 )

• of age-dependent B cells

increased germinal center B cell number ( J:201448 )

• in aged mice

growth/size/body

enlarged spleen ( J:201448 )

• at 10 months

spleen hyperplasia ( J:201448 )

• at 10 months

Genotype
MGI:2654061

cn92

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Rbpj^tm1Hon/Rbpj^tm1Hon
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality ( J:76240 )

• mutants show high sensitivity to the lethal effects of blood-borne Staphylococcus aureus infection

immune system

abnormal B cell differentiation ( J:76240 )

• affected differentiation of T2 B cells, indicated by a reduced population of marginal zone B (MZB) cells and an increased population of follicular B cells

decreased marginal zone B cell number ( J:76240 , J:121523 )

• loss of marginal zone B cells (J:76240)

• decreased numbers of marginal zone B cells (J:121523)

increased follicular B cell number ( J:76240 , J:121523 )

• increased numbers of follicular B cells in spleen (J:121523)

increased IgG3 level ( J:76240 )

• 3-fold increase in serum IgG3

increased susceptibility to bacterial infection ( J:76240 )

• increased mortality rate after blood-born bacterial infection

increased susceptibility to bacterial infection induced morbidity/mortality ( J:76240 )

• mutants show high sensitivity to the lethal effects of blood-borne Staphylococcus aureus infection

hematopoietic system

abnormal B cell differentiation ( J:76240 )

• affected differentiation of T2 B cells, indicated by a reduced population of marginal zone B (MZB) cells and an increased population of follicular B cells

decreased marginal zone B cell number ( J:76240 , J:121523 )

• loss of marginal zone B cells (J:76240)

• decreased numbers of marginal zone B cells (J:121523)

increased follicular B cell number ( J:76240 , J:121523 )

• increased numbers of follicular B cells in spleen (J:121523)

increased IgG3 level ( J:76240 )

• 3-fold increase in serum IgG3

Genotype
MGI:3639683

cn93

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Cxcr4^tm1Tng/Cxcr4^tm2Tng
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

hematopoietic system

decreased plasma cell number ( J:109147 )

• the number of plasma cells in bone marrow were severely reduced

• the numbers of mature B cells and plasma cells in spleen were normal

immune system

decreased plasma cell number ( J:109147 )

• the number of plasma cells in bone marrow were severely reduced

• the numbers of mature B cells and plasma cells in spleen were normal

Genotype
MGI:3656029

cn94

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ube2n^tm1Aki/Ube2n^tm1Aki
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased B cell number ( J:112287 )

• B cells expressing B220, CD38 and CD21 are present in lower numbers

• fewer B cells enter S phase after stimulation with anti-IgM, anti-CD40, LPS or CpG DNA

abnormal spleen marginal zone morphology ( J:112287 )

• width of marginal zone B cell area is smaller than in controls

decreased marginal zone B cell number ( J:112287 )

• mice have a much lower frequency of B220+CD21^hiCD23^low marginal zone B cells

abnormal B cell physiology ( J:112287 )

• mice show defective MAP kinase activation in B cells

increased B cell apoptosis ( J:112287 )

• more mutant B cells undergo apoptosis ex vivo even after stimulation with LPS, CpG DNA or anti-CD40

decreased B cell proliferation ( J:112287 )

• B cells stimulated with LPS or CpG DNA show a lower proliferative response than controls

decreased immunoglobulin level ( J:112287 )

• all isotypes except IgG2a and IgG2b are significantly lower than in controls

abnormal humoral immune response ( J:112287 )

• after immunization with TNP-ficoll or TNP-chicken gammaglobulin mice produce less serum TNP-specific IgM and IgG3

hematopoietic system

decreased B cell number ( J:112287 )

• B cells expressing B220, CD38 and CD21 are present in lower numbers

• fewer B cells enter S phase after stimulation with anti-IgM, anti-CD40, LPS or CpG DNA

abnormal spleen marginal zone morphology ( J:112287 )

• width of marginal zone B cell area is smaller than in controls

decreased marginal zone B cell number ( J:112287 )

• mice have a much lower frequency of B220+CD21^hiCD23^low marginal zone B cells

abnormal B cell physiology ( J:112287 )

• mice show defective MAP kinase activation in B cells

increased B cell apoptosis ( J:112287 )

• more mutant B cells undergo apoptosis ex vivo even after stimulation with LPS, CpG DNA or anti-CD40

decreased B cell proliferation ( J:112287 )

• B cells stimulated with LPS or CpG DNA show a lower proliferative response than controls

decreased immunoglobulin level ( J:112287 )

• all isotypes except IgG2a and IgG2b are significantly lower than in controls

cellular

increased B cell apoptosis ( J:112287 )

• more mutant B cells undergo apoptosis ex vivo even after stimulation with LPS, CpG DNA or anti-CD40

decreased B cell proliferation ( J:112287 )

• B cells stimulated with LPS or CpG DNA show a lower proliferative response than controls

Genotype
MGI:3664610

cn95

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Map3k7^tm1Aki/Map3k7^tm1.1Aki
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased B-1 B cell number ( J:112597 )

• decrease in the number of B220+CD5+ B-1 B cells in the peritoneal cavity

abnormal B cell physiology ( J:112597 )

• impaired B cell survival following LPS or CpG DNA stimulation or B cell receptor crosslinking

decreased B cell proliferation ( J:112597 )

• decreased LPS- and/or CpG DNA-induced proliferation in follicular and marginal zone B-2 cells with impaired entry in S phase; however, LPS- and/or CpG DNA-induced IL6 production is similar to wild-type

• decreased proliferation in response to B cell receptor and CD40 stimulation with impaired entry into S phase and impaired survival following B cell receptor crosslinking

decreased immunoglobulin level ( J:112597 )

• decrease for all isotypes except IgM

decreased IgG level ( J:112597 )

• decreased levels of IgG1 and IgG3 following T cell dependent or T cell independent antigen stimulation, respectively; however, levels of IgM are similar to control following T cell dependent antigen stimulation

decreased IgG1 level ( J:112597 )

decreased IgG3 level ( J:112597 )

hematopoietic system

decreased B-1 B cell number ( J:112597 )

• decrease in the number of B220+CD5+ B-1 B cells in the peritoneal cavity

abnormal B cell physiology ( J:112597 )

• impaired B cell survival following LPS or CpG DNA stimulation or B cell receptor crosslinking

decreased B cell proliferation ( J:112597 )

• decreased LPS- and/or CpG DNA-induced proliferation in follicular and marginal zone B-2 cells with impaired entry in S phase; however, LPS- and/or CpG DNA-induced IL6 production is similar to wild-type

• decreased proliferation in response to B cell receptor and CD40 stimulation with impaired entry into S phase and impaired survival following B cell receptor crosslinking

decreased immunoglobulin level ( J:112597 )

• decrease for all isotypes except IgM

decreased IgG level ( J:112597 )

• decreased levels of IgG1 and IgG3 following T cell dependent or T cell independent antigen stimulation, respectively; however, levels of IgM are similar to control following T cell dependent antigen stimulation

decreased IgG1 level ( J:112597 )

decreased IgG3 level ( J:112597 )

cellular

decreased B cell proliferation ( J:112597 )

• decreased LPS- and/or CpG DNA-induced proliferation in follicular and marginal zone B-2 cells with impaired entry in S phase; however, LPS- and/or CpG DNA-induced IL6 production is similar to wild-type

• decreased proliferation in response to B cell receptor and CD40 stimulation with impaired entry into S phase and impaired survival following B cell receptor crosslinking

Genotype
MGI:3687509

cn96

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺; Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:113365 )

N • normal numbers of mature B cells including follicular and marginal zone B cells are produced

N • spleens contain well-organized lymphoid architecture with normal follicles and distinct marginal zone

Genotype
MGI:3687542

cn97

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

cellular

decreased B cell apoptosis ( J:113365 )

• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures

increased cell proliferation ( J:113365 )

• 1-2 days after crosslinking with BCR, there are more cells is S phase than in wild-type B cell cultures

immune system

increased B cell number ( J:113365 )

• B cell numbers are increased in spleens (130 x 10⁶) compared to wild-type (56 x 10⁶)

abnormal splenic cell ratio ( J:113365 )

• B cell hyperplasia is observed, with a significantly expanded population of marginal zone B cells

abnormal B cell physiology ( J:113365 )

• cells on average have a longer lifespan than wild-type B cells

decreased B cell apoptosis ( J:113365 )

• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures

hematopoietic system

increased B cell number ( J:113365 )

• B cell numbers are increased in spleens (130 x 10⁶) compared to wild-type (56 x 10⁶)

abnormal splenic cell ratio ( J:113365 )

• B cell hyperplasia is observed, with a significantly expanded population of marginal zone B cells

abnormal B cell physiology ( J:113365 )

• cells on average have a longer lifespan than wild-type B cells

decreased B cell apoptosis ( J:113365 )

• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures

Genotype
MGI:3688724

cn98

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Spi1^tm2Dgt/Spi1^tm2Dgt
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

hematopoietic system

hematopoietic system phenotype ( J:114150 )

N • mice have normal numbers of pre-B cells and mature B cells in the bone marrow

N • B cells from the spleen show significant proliferative responses to mitogenic agents

Genotype
MGI:3702091

cn99

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pdia3^tm1Gjh/Pdia3^tm1Gjh
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

abnormal B cell physiology ( J:112606 )

• naive B cells express 50% - 90% less H-2K^b and have decreased H-2D^b expression

• however, B cell development, survival, and proliferative responses are similar to control mice and mice raise normal titers of IgG

hematopoietic system

abnormal B cell physiology ( J:112606 )

• naive B cells express 50% - 90% less H-2K^b and have decreased H-2D^b expression

• however, B cell development, survival, and proliferative responses are similar to control mice and mice raise normal titers of IgG

Genotype
MGI:3720197

cn100

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ptpn6^tm1Rsky/Ptpn6^tm1Rsky
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

abnormal leukocyte cell number ( J:123568 )

increased granulocyte number ( J:123568 )

• at 7 to 11 months of age

decreased follicular B cell number ( J:123568 )

• fewer CD23+CD21+IgM+ follicular B cells are detected

decreased marginal zone B cell number ( J:123568 )

• fewer CD211^hiIgM^hiCD1d^hi marginal zone B cells are detected

increased B cell number ( J:123568 )

• at 7 to 11 months of age

increased B-1a cell number ( J:123568 )

increased plasma cell number ( J:123568 )

• at 7 to 11 months of age

increased T cell number ( J:123568 )

• at 7 to 11 months of age

increased macrophage cell number ( J:123568 )

• at 7 to 11 months of age

abnormal lymph organ size ( J:123568 )

enlarged spleen ( J:123568 )

• at 7 to 11 months of age

enlarged lymph nodes ( J:123568 )

• at 7 to 11 months of age

abnormal immune system physiology ( J:123568 )

decreased B cell proliferation ( J:123568 )

• following stimulation by anti-IgM or anti-CD40 antibodies, B cell proliferation is reduced

• however, proliferation stimulated by LPS is normal

abnormal humoral immune response ( J:123568 )

• antibody-mediated response to NP-CG is not as strong ad in wild-type mice

• antibody-mediated response to NP-ficoll is severely impaired

increased susceptibility to systemic lupus erythematosus ( J:123568 )

• at 7 to 11 months of age, mice develop an autoimmune disease with features similar to systemic lupus erythematosus

hematopoietic system

decreased B cell proliferation ( J:123568 )

• following stimulation by anti-IgM or anti-CD40 antibodies, B cell proliferation is reduced

• however, proliferation stimulated by LPS is normal

enlarged spleen ( J:123568 )

• at 7 to 11 months of age

abnormal leukocyte cell number ( J:123568 )

increased granulocyte number ( J:123568 )

• at 7 to 11 months of age

decreased follicular B cell number ( J:123568 )

• fewer CD23+CD21+IgM+ follicular B cells are detected

decreased marginal zone B cell number ( J:123568 )

• fewer CD211^hiIgM^hiCD1d^hi marginal zone B cells are detected

increased B cell number ( J:123568 )

• at 7 to 11 months of age

increased B-1a cell number ( J:123568 )

increased plasma cell number ( J:123568 )

• at 7 to 11 months of age

increased T cell number ( J:123568 )

• at 7 to 11 months of age

increased macrophage cell number ( J:123568 )

• at 7 to 11 months of age

growth/size/body

enlarged spleen ( J:123568 )

• at 7 to 11 months of age

cellular

decreased B cell proliferation ( J:123568 )

• following stimulation by anti-IgM or anti-CD40 antibodies, B cell proliferation is reduced

• however, proliferation stimulated by LPS is normal

Genotype
MGI:3768340

cn101

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ltb^tm1Avt/Ltb^tm1Avt
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased marginal zone B cell number ( J:79129 )

abnormal spleen B cell follicle morphology ( J:79129 )

• following immunization, fewer peanut agglutinin positive (PNA+) clusters are present and very few IgD- areas typical of germinal centers are identified

• B cell follicle disruption is not as severe as in Ltb null mice

• however, some follicular dendritic cells are present and immune complex binding is observed

abnormal spleen follicular dendritic cell network ( J:79129 )

• follicular dendritic cell (FDC) networks are reduced to 15% to 20% of the number found in wild-type mice

decreased spleen germinal center number ( J:79129 )

decreased spleen germinal center size ( J:79129 )

small Peyer's patches ( J:79129 )

abnormal adaptive immunity ( J:79129 )

• following exposure to sheep red blood cells (SRBC) mice fail to develop normal specific IgG responses

• memory IgG responses are reduced compared to wild-type but not as much as in Ltb null mice

• affinity maturation is only slightly reduced

• however, unlike Ltb null mice IgM levels are normal

hematopoietic system

decreased marginal zone B cell number ( J:79129 )

abnormal spleen B cell follicle morphology ( J:79129 )

• following immunization, fewer peanut agglutinin positive (PNA+) clusters are present and very few IgD- areas typical of germinal centers are identified

• B cell follicle disruption is not as severe as in Ltb null mice

• however, some follicular dendritic cells are present and immune complex binding is observed

abnormal spleen follicular dendritic cell network ( J:79129 )

• follicular dendritic cell (FDC) networks are reduced to 15% to 20% of the number found in wild-type mice

decreased spleen germinal center number ( J:79129 )

decreased spleen germinal center size ( J:79129 )

Genotype
MGI:3768341

cn102

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ltb^tm1Avt/Ltb^tm1Avt; Tg(Lck-cre)1Jtak/?
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

absent follicular dendritic cells ( J:79129 )

• mice lack follicular dendritic cells and no immune complex binding is observed

Genotype
MGI:3775442

cn103

• Allelic Composition: Sh2d1a^tm2Vei/Sh2d1a^tm2Vei; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:131618 )

♀N • unlike other conditional knockouts of Apcs, mice exhibit normal numbers of NK T cells, normal antibody response and normal germinal center B cell numbers

Genotype
MGI:3777342

cn104

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Traf2^tm1Rbr/Traf2^tm1Rbr
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

increased follicular B cell number ( J:132877 )

• there is almost a 2-fold increase in the number of follicular B cells found in the spleen

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

lymph node hyperplasia ( J:132877 )

• about a 3-fold increase in the number of cells present in lymph nodes

• increase is due to expansion of the B cell compartment

hematopoietic system

increased follicular B cell number ( J:132877 )

• there is almost a 2-fold increase in the number of follicular B cells found in the spleen

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

Genotype
MGI:3809748

cn105

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

enlarged spleen ( J:139293 )

increased mature B cell number ( J:139293 )

• the number of mature peripheral B cells is increased resulting enlargement of the spleen and lymph nodes

• however, B cell proliferation is normal

increased marginal zone B cell number ( J:139293 )

enlarged lymph nodes ( J:139293 )

hematopoietic system

enlarged spleen ( J:139293 )

increased mature B cell number ( J:139293 )

• the number of mature peripheral B cells is increased resulting enlargement of the spleen and lymph nodes

• however, B cell proliferation is normal

increased marginal zone B cell number ( J:139293 )

growth/size/body

enlarged spleen ( J:139293 )

Genotype
MGI:3809749

cn106

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm6(Map3k14*)Rsky}/Gt(ROSA)26Sor^{tm6(Map3k14*)Rsky}
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

enlarged spleen ( J:139293 )

decreased B-1 B cell number ( J:139293 )

• in the peritoneal cavity

increased mature B cell number ( J:139293 )

• the spleen contains 6-fold more AA4.1-B cells than in control mice due to enhanced survival

• however, B cell proliferation is normal

abnormal spleen B cell follicle morphology ( J:139293 )

abnormal Peyer's patch morphology ( J:139293 )

• lymphoid cells appear to spill over their normal confines into surrounding tissue unlike in wild-type mice

enlarged lymph nodes ( J:139293 )

hematopoietic system

enlarged spleen ( J:139293 )

decreased B-1 B cell number ( J:139293 )

• in the peritoneal cavity

increased mature B cell number ( J:139293 )

• the spleen contains 6-fold more AA4.1-B cells than in control mice due to enhanced survival

• however, B cell proliferation is normal

abnormal spleen B cell follicle morphology ( J:139293 )

growth/size/body

enlarged spleen ( J:139293 )

Genotype
MGI:3809750

cn107

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}; Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased lymphocyte cell number ( J:139293 )

decreased mature B cell number ( J:139293 )

hematopoietic system

decreased lymphocyte cell number ( J:139293 )

decreased mature B cell number ( J:139293 )

Genotype
MGI:3809751

cn108

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm6(Map3k14*)Rsky}/Gt(ROSA)26Sor^{tm6(Map3k14*)Rsky}; Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

increased lymphocyte cell number ( J:139293 )

increased mature B cell number ( J:139293 )

hematopoietic system

increased lymphocyte cell number ( J:139293 )

increased mature B cell number ( J:139293 )

Genotype
MGI:3814891

cn109

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

abnormal B cell physiology ( J:140751 )

• B cells, but not dendritic cells or macrophages, are capable of inducing proliferation of CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch in vitro unlike wild-type cells

• unlike in vitro, when CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch are transferred into mice they fail to exhibit proliferation and instead undergo cell death

• mice are capable of inducing proliferation of memory T cells expressing Tg(Tcra2D2,Tcrb2D2)1Kuch unlike wild type mice

• mice are capable of inducing proliferation of Tg(Tcra2D2,Tcrb2D2)1Kuch T cells also deficient in Pdcd1 (Pdcd1^tm1Hon) up to 71% or following treatment with anti-CTLA-4 antibodies up to 79% and proliferation is increased to 97% when both are used

• B cells induce peripheral tolerance by sensitizing T cells to antigen induced cell death in adoptive transfer experiments

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:140751 )

• mice are resistant to direct and passive MOG-induced experimental autoimmune encephalomyelitis (EAE) and can confer some resistance upon adoptive transfer of B cells into wild-type micemice are resistant to direct and passive MOG-induced experimental encephalomyelitis (EAE) and can confer some resistance upon adoptive transfer of B cells into wild-type mice

• resistance to EAE is not affected by depletion of T regulatory cells

• however, mice inoculated with C57BL/6 spinal cord fluid develop EAE

hematopoietic system

abnormal B cell physiology ( J:140751 )

• B cells, but not dendritic cells or macrophages, are capable of inducing proliferation of CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch in vitro unlike wild-type cells

• unlike in vitro, when CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch are transferred into mice they fail to exhibit proliferation and instead undergo cell death

• mice are capable of inducing proliferation of memory T cells expressing Tg(Tcra2D2,Tcrb2D2)1Kuch unlike wild type mice

• mice are capable of inducing proliferation of Tg(Tcra2D2,Tcrb2D2)1Kuch T cells also deficient in Pdcd1 (Pdcd1^tm1Hon) up to 71% or following treatment with anti-CTLA-4 antibodies up to 79% and proliferation is increased to 97% when both are used

• B cells induce peripheral tolerance by sensitizing T cells to antigen induced cell death in adoptive transfer experiments

Genotype
MGI:3814893

cn110

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/Gt(ROSA)26Sor⁺; Il10^tm1Roer/Il10^tm1Roer
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

abnormal B cell physiology ( J:140751 )

• unlike in vitro, when CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch are transferred into mice they fail to exhibit proliferation

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:140751 )

• mice are resistant to direct and passive MOG-induced experimental autoimmune encephalomyelitis

hematopoietic system

abnormal B cell physiology ( J:140751 )

• unlike in vitro, when CD4+ T cells containing Tg(Tcra2D2,Tcrb2D2)1Kuch are transferred into mice they fail to exhibit proliferation

Genotype
MGI:3851693

cn111

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ikbkb^tm1Cgn/Ikbkb^tm1.1Cgn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

increased B cell proliferation ( J:79132 )

• B cell turnover over a one week period is almost twice that of controls

decreased immature B cell number ( J:79132 )

• immature B cell numbers in the spleen are reduced by about a half

decreased mature B cell number ( J:79132 )

• there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

• the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

• B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

• B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

• follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

• marginal zone B cell numbers are reduced about 4-fold

hematopoietic system

increased B cell proliferation ( J:79132 )

• B cell turnover over a one week period is almost twice that of controls

decreased immature B cell number ( J:79132 )

• immature B cell numbers in the spleen are reduced by about a half

decreased mature B cell number ( J:79132 )

• there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

• the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

• B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

• B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

• follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

• marginal zone B cell numbers are reduced about 4-fold

cellular

increased B cell proliferation ( J:79132 )

• B cell turnover over a one week period is almost twice that of controls

Genotype
MGI:3851694

cn112

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ikbkb^tm2Cgn/Ikbkb^tm2.1Cgn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

hematopoietic system

decreased mature B cell number ( J:79132 )

• there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

• the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

• B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

• B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

• follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

• marginal zone B cell numbers are reduced about 4-fold

immune system

decreased mature B cell number ( J:79132 )

• there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

• the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

• B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

• B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

• follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

• marginal zone B cell numbers are reduced about 4-fold

Genotype
MGI:3851695

cn113

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ikbkg^tm1.1Mpa/Y
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

increased B cell proliferation ( J:79132 )

♂ • B cell turnover over a one week period is twice that of controls

decreased immature B cell number ( J:79132 )

♂ • immature B cell numbers in the spleen are reduced by about a third

decreased mature B cell number ( J:79132 )

♂ • there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

♂ • the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

♂ • B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

♂ • B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

♂ • follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

♂ • marginal zone B cell numbers are reduced about 4-fold

hematopoietic system

increased B cell proliferation ( J:79132 )

♂ • B cell turnover over a one week period is twice that of controls

decreased immature B cell number ( J:79132 )

♂ • immature B cell numbers in the spleen are reduced by about a third

decreased mature B cell number ( J:79132 )

♂ • there is a 2- to 4- fold reduction in the number of mature recirculating B cells found in the bone marrow

♂ • the IgM^lowIgD⁺ mature B cell population is strongly diminished in the spleen by 3- to 4- fold

♂ • B cell numbers in the lymph nodes are also strongly reduced

decreased B-1 B cell number ( J:79132 )

♂ • B-1 B cell numbers are strongly decreased in the peritoneum cavity

decreased follicular B cell number ( J:79132 )

♂ • follicular B cells are the most diminished B cell population in the spleen

decreased marginal zone B cell number ( J:79132 )

♂ • marginal zone B cell numbers are reduced about 4-fold

cellular

increased B cell proliferation ( J:79132 )

♂ • B cell turnover over a one week period is twice that of controls

Genotype
MGI:4831002

cn114

• Allelic Composition: Tnfaip3^tm2Ama/Tnfaip3^tm2Ama; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

increased T cell number ( J:163917 )

• moderate expansion of T cells

abnormal B cell morphology ( J:163917 )

• increase in the number and size of anti-DNA producing B cells

decreased B cell number ( J:163917 )

• small decrease in the percentage of IgM+B cells in the bone marrow, reflecting a reduction in mature or recirculating B cells

increased B cell number ( J:163917 )

• moderate increase in B cells

increased immature B cell number ( J:163917 )

increased germinal center B cell number ( J:163917 )

increased plasma cell number ( J:163917 )

• increase in percentage of splenic plasma cells

abnormal B-1a B cell morphology ( J:163917 )

• percentage of B-1a cells in the peritoneal cavity is lower than in controls but the absolute numbers are not different

abnormal B cell activation ( J:163917 )

• spontaneous B cell activation becomes apparent at 6 months of age

increased B cell proliferation ( J:163917 )

• B cells are hyperresponsive to multiple stimuli

• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals

increased immunoglobulin level ( J:163917 )

• increase in glomerular immunoglobulin deposits

increased IgG level ( J:163917 )

• modest increase in IgGs

increased IgM level ( J:163917 )

increased interleukin-6 secretion ( J:163917 )

• increase in IL-6 production by B cells after treatment with LPS and CpG

increased susceptibility to autoimmune disorder ( J:163917 )

• CpG treatment enhances production of IgG dsDNA antibodies in serum as well as deposition of IgG in renal glomeruli, indicating development of autoimmune disease

• IgM deposits are seen in the kidneys

increased autoantibody level ( J:163917 )

• mice develop autoimmunity; antibodies to over 46 self-antigens are detected, including antibodies to nuclear antigens

hematopoietic system

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

increased T cell number ( J:163917 )

• moderate expansion of T cells

abnormal B cell morphology ( J:163917 )

• increase in the number and size of anti-DNA producing B cells

decreased B cell number ( J:163917 )

• small decrease in the percentage of IgM+B cells in the bone marrow, reflecting a reduction in mature or recirculating B cells

increased B cell number ( J:163917 )

• moderate increase in B cells

increased immature B cell number ( J:163917 )

increased germinal center B cell number ( J:163917 )

increased plasma cell number ( J:163917 )

• increase in percentage of splenic plasma cells

abnormal B-1a B cell morphology ( J:163917 )

• percentage of B-1a cells in the peritoneal cavity is lower than in controls but the absolute numbers are not different

abnormal B cell activation ( J:163917 )

• spontaneous B cell activation becomes apparent at 6 months of age

increased B cell proliferation ( J:163917 )

• B cells are hyperresponsive to multiple stimuli

• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals

increased immunoglobulin level ( J:163917 )

• increase in glomerular immunoglobulin deposits

increased IgG level ( J:163917 )

• modest increase in IgGs

increased IgM level ( J:163917 )

cellular

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

increased B cell proliferation ( J:163917 )

• B cells are hyperresponsive to multiple stimuli

• B cells exhibit exaggerated NF-kappaB responses to CD40-induced signals

Genotype
MGI:4831003

cn115

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tnfaip3^tm2Ama/Tnfaip3⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

increased germinal center B cell number ( J:163917 )

increased plasma cell number ( J:163917 )

• increase in percentage of splenic plasma cells

increased immunoglobulin level ( J:163917 )

• IgM and IgG deposits are seen in the kidneys

increased susceptibility to autoimmune disorder ( J:163917 )

• CpG treatment enhances production of IgG dsDNA antibodies in serum as well as deposition of IgG in renal glomeruli, indicating development of autoimmune disease

increased autoantibody level ( J:163917 )

hematopoietic system

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

increased germinal center B cell number ( J:163917 )

increased plasma cell number ( J:163917 )

• increase in percentage of splenic plasma cells

increased immunoglobulin level ( J:163917 )

• IgM and IgG deposits are seen in the kidneys

cellular

decreased B cell apoptosis ( J:163917 )

• B cells are resistant to Fas-mediated programmed cell death compared to controls

Genotype
MGI:4850098

cn116

• Allelic Composition: Pik3cd^tm2.1Tnr/Pik3cd^tm2.1Tnr; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:164283 )

N • mice exhibit normal germinal center B cell numbers, NP-specific IgG1 titers, and immune memory response after immunization

increased IgE level ( J:164283 )

• after NP-CGG immunization, antigen-specific IgE titers are increased 30-fold compared to in similarly treated wild-type mice

hematopoietic system

increased IgE level ( J:164283 )

• after NP-CGG immunization, antigen-specific IgE titers are increased 30-fold compared to in similarly treated wild-type mice

Genotype
MGI:4939594

cn117

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Irf8^tm1.1Hm/Irf8^tm1.1Hm
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:168923 )

N • spleen and lymph node sizes are normal

N • mice exhibit normal T-dependent and T-independent antibody responses

decreased follicular B cell number ( J:168923 )

• the proportion of AA4-B220+IgM^low CD19+ follicular B cells is decreased compared to in control mice

increased B cell number ( J:168923 )

• the frequency of CD19+B220+ B cells is increased compared to in control mice

• the number of total peritoneal B cells is increased compared to in control mice

increased transitional stage B cell number ( J:168923 )

• the frequency of B220+AA4+ transitional B cells is increased compared to in control mice

• the absolute number of transitional B cells is increased compared to in control mice

increased B-2 B cell number ( J:168923 )

• in the peritoneum

increased follicular B cell number ( J:168923 )

• the absolute number of follicular B cells is increased compared to in control mice

abnormal spleen marginal zone morphology ( J:168923 )

• mice exhibit enlarged marginal zones surrounding white pulp follicles compared with control mice

increased marginal zone B cell number ( J:168923 )

• the frequency of AA4-B220+IgM^hi CD19+ marginal zone B cells is increased compared to in control mice

• the absolute number of marginal zone B cells is increased compared to in control mice

hematopoietic system

decreased follicular B cell number ( J:168923 )

• the proportion of AA4-B220+IgM^low CD19+ follicular B cells is decreased compared to in control mice

increased B cell number ( J:168923 )

• the frequency of CD19+B220+ B cells is increased compared to in control mice

• the number of total peritoneal B cells is increased compared to in control mice

increased transitional stage B cell number ( J:168923 )

• the frequency of B220+AA4+ transitional B cells is increased compared to in control mice

• the absolute number of transitional B cells is increased compared to in control mice

increased B-2 B cell number ( J:168923 )

• in the peritoneum

increased follicular B cell number ( J:168923 )

• the absolute number of follicular B cells is increased compared to in control mice

abnormal spleen marginal zone morphology ( J:168923 )

• mice exhibit enlarged marginal zones surrounding white pulp follicles compared with control mice

increased marginal zone B cell number ( J:168923 )

• the frequency of AA4-B220+IgM^hi CD19+ marginal zone B cells is increased compared to in control mice

• the absolute number of marginal zone B cells is increased compared to in control mice

Genotype
MGI:5314087

cn118

• Allelic Composition: Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Klrk1^tm1Dhr/Klrk1^tm1Dhr; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

neoplasm

neoplasm ( J:181546 )

N • mice are protected from Lmp1-driven lymphomagenesis

Genotype
MGI:5314104

cn119

• Allelic Composition: Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

immune system

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal immune system physiology ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

abnormal CD4-positive, alpha-beta T cell physiology ( J:181546 )

• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells

• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells

• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer

increased interferon-gamma secretion ( J:181546 )

• minor in T cells co-cultured with tumor or B cells

increased tumor necrosis factor secretion ( J:181546 )

• minor in T cells co-cultured with tumor or B cells

hematopoietic system

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal CD4-positive, alpha-beta T cell physiology ( J:181546 )

• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells

• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells

• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer

growth/size/body

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

cellular

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

Genotype
MGI:5502352

cn120

• Allelic Composition: Nabp2^tm1.1Kkha/Nabp2^tm1.1Kkha; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:195140 )

N • mice exhibit normal class switch recombination

Genotype
MGI:5502699

cn121

• Allelic Composition: Tab2^tm2.1Aki/Tab2^tm2.1Aki; Tab3^tm1Aki/Tab3^tm1Aki; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased mature B cell number ( J:195289 )

decreased B-1a cell number ( J:195289 )

• peritoneal B-1a cell numbers are further reduced over reduction seen in Tab2 KO mice

decreased plasma cell number ( J:195289 )

• plasma cell populations are reduced

abnormal B cell physiology ( J:195289 )

increased B cell apoptosis ( J:195289 )

• undergo apoptosis more rapidly in response to CpG DNA and anti-IgM but not anti-CD40 stimulation

decreased B cell proliferation ( J:195289 )

• impaired proliferation in response to CpG DNA, anti-IgM, and anti-CD40 stimulation

abnormal immune serum protein physiology ( J:195289 )

decreased immunoglobulin level ( J:195289 )

decreased IgD level ( J:195289 )

decreased IgE level ( J:195289 )

decreased IgG level ( J:195289 )

decreased circulating interleukin-6 level ( J:195289 )

• impaired production

cellular

increased B cell apoptosis ( J:195289 )

• undergo apoptosis more rapidly in response to CpG DNA and anti-IgM but not anti-CD40 stimulation

decreased B cell proliferation ( J:195289 )

• impaired proliferation in response to CpG DNA, anti-IgM, and anti-CD40 stimulation

hematopoietic system

decreased mature B cell number ( J:195289 )

decreased B-1a cell number ( J:195289 )

• peritoneal B-1a cell numbers are further reduced over reduction seen in Tab2 KO mice

decreased plasma cell number ( J:195289 )

• plasma cell populations are reduced

abnormal B cell physiology ( J:195289 )

increased B cell apoptosis ( J:195289 )

• undergo apoptosis more rapidly in response to CpG DNA and anti-IgM but not anti-CD40 stimulation

decreased B cell proliferation ( J:195289 )

• impaired proliferation in response to CpG DNA, anti-IgM, and anti-CD40 stimulation

decreased immunoglobulin level ( J:195289 )

decreased IgD level ( J:195289 )

decreased IgE level ( J:195289 )

decreased IgG level ( J:195289 )

homeostasis/metabolism

decreased circulating interleukin-6 level ( J:195289 )

• impaired production

Genotype
MGI:5780067

cn122

• Allelic Composition: Kmt2d^tm1.1Kaig/Kmt2d^tm1.1Kaig; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:228913 )

♀N • unimmunized mice exhibit normal numbers of bone marrow B cell subpopulations, splenic follicular B cells and marginal zone B cells

♀N • mice immunized with sheep red blood cell exhibit normal numbers of transitional and marginal zone B cells

increased B cell proliferation ( J:228913 )

♀

abnormal B cell differentiation ( J:228913 )

♀ • modest impairment in affinity maturation

♀ • however, somatic hypermutation is normal

increased germinal center B cell number ( J:228913 )

♀ • 3-fold in the spleen and also in the mesenteric lymph nodes of mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

decreased B cell number ( J:228913 )

♀ • in the spleen and lymph nodes of mice immunized with sheep red blood cell

decreased mature B cell number ( J:228913 )

♀ • in the bone marrow of mice immunized with sheep red blood cell

decreased follicular B cell number ( J:228913 )

♀

increased spleen germinal center number ( J:228913 )

♀ • in mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

increased spleen germinal center size ( J:228913 )

♀ • in mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

decreased IgG1 level ( J:228913 )

♀ • 10-fold less in mice challenged with NP-KLH

decreased IgM level ( J:228913 )

♀ • 10-fold less in mice challenged with NP-KLH

hematopoietic system

increased B cell proliferation ( J:228913 )

♀

abnormal B cell differentiation ( J:228913 )

♀ • modest impairment in affinity maturation

♀ • however, somatic hypermutation is normal

increased germinal center B cell number ( J:228913 )

♀ • 3-fold in the spleen and also in the mesenteric lymph nodes of mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

decreased B cell number ( J:228913 )

♀ • in the spleen and lymph nodes of mice immunized with sheep red blood cell

decreased mature B cell number ( J:228913 )

♀ • in the bone marrow of mice immunized with sheep red blood cell

decreased follicular B cell number ( J:228913 )

♀

increased spleen germinal center number ( J:228913 )

♀ • in mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

increased spleen germinal center size ( J:228913 )

♀ • in mice immunized with sheep red blood cell

♀ • in mice challenged with NP-KLH

decreased IgG1 level ( J:228913 )

♀ • 10-fold less in mice challenged with NP-KLH

decreased IgM level ( J:228913 )

♀ • 10-fold less in mice challenged with NP-KLH

cellular

increased B cell proliferation ( J:228913 )

♀

Genotype
MGI:5780069

cn123

• Allelic Composition: Kmt2d^tm1.1Kaig/Kmt2d⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

increased germinal center B cell number ( J:228913 )

♀ • intermediate at 3 and 6 months in mice immunized with sheep red blood cell

increased spleen germinal center size ( J:228913 )

♀ • intermediate at 3 and 6 months in mice immunized with sheep red blood cell

hematopoietic system

increased germinal center B cell number ( J:228913 )

♀ • intermediate at 3 and 6 months in mice immunized with sheep red blood cell

increased spleen germinal center size ( J:228913 )

♀ • intermediate at 3 and 6 months in mice immunized with sheep red blood cell

Genotype
MGI:5825356

cn124

• Allelic Composition: Tcf3^tm1(PBX1)Mlc/Tcf3⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

neoplasm

increased B cell acute lymphoblastic leukemia incidence ( J:226241 )

• mice develop acute leukemia with an incidence of 7% at 12 months of age

• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS

• 94% of leukemias have a B cell precursor phenotype

hematopoietic system

enlarged spleen ( J:226241 )

• in leukemic mice

abnormal pro-B cell morphology ( J:226241 )

• progenitor B cells proliferate extensively in methylcellulose culture supplemented with IL-7, SCF, and FLT3 and are severely compromised in the their ability to differentiate into CD43- cells compared with progenitor B cells from controls indicating enhanced proliferation of progenitor B cells

abnormal pro-B cell differentiation ( J:226241 )

• mice show perturbed early B cell progenitor cell differentiation

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

anemia ( J:226241 )

• in leukemic mice

thrombocytopenia ( J:226241 )

• in leukemic mice

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

abnormal B cell physiology ( J:226241 )

• enhanced proliferation of progenitor B cells

• preleukemic mice irradiated sublethally to deplete the endogenous B cell populations show regeneration of B cell progenitors with a dramatic expansion of B220^lo progenitor cell population indicating enhanced B cell progenitor self-renewal

immune system

enlarged spleen ( J:226241 )

• in leukemic mice

abnormal pro-B cell morphology ( J:226241 )

• progenitor B cells proliferate extensively in methylcellulose culture supplemented with IL-7, SCF, and FLT3 and are severely compromised in the their ability to differentiate into CD43- cells compared with progenitor B cells from controls indicating enhanced proliferation of progenitor B cells

abnormal pro-B cell differentiation ( J:226241 )

• mice show perturbed early B cell progenitor cell differentiation

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

abnormal B cell physiology ( J:226241 )

• enhanced proliferation of progenitor B cells

• preleukemic mice irradiated sublethally to deplete the endogenous B cell populations show regeneration of B cell progenitors with a dramatic expansion of B220^lo progenitor cell population indicating enhanced B cell progenitor self-renewal

enlarged lymph nodes ( J:226241 )

• in leukemic mice

liver/biliary system

enlarged liver ( J:226241 )

• in leukemic mice

growth/size/body

enlarged liver ( J:226241 )

• in leukemic mice

enlarged spleen ( J:226241 )

• in leukemic mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
acute lymphoblastic leukemia		DOID:9952	OMIM:247640 OMIM:613065	J:226241

Genotype
MGI:5825360

cn125

• Allelic Composition: Pax5^tm3Mbu/Pax5⁺; Tcf3^tm1(PBX1)Mlc/Tcf3⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

neoplasm

increased B cell acute lymphoblastic leukemia incidence ( J:226241 )

• mice exhibit increased penetrance and accelerated acute leukemia development compared to single Tcf3^tm1(PBX1)Mlc conditional mutants

hematopoietic system

decreased immature B cell number ( J:226241 )

• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3^tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation

abnormal pro-B cell morphology ( J:226241 )

• preleukemic mice show expansion of GFP+ progenitor cells of the Lin-CD19+CD43+ fractions at younger ages compared to single Tcf3^tm1(PBX1)Mlc conditional mutants, indicating accelerated preleukemic progenitor B cell expansion

arrested B cell differentiation ( J:226241 )

• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3^tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation

immune system

decreased immature B cell number ( J:226241 )

• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3^tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation

abnormal pro-B cell morphology ( J:226241 )

• preleukemic mice show expansion of GFP+ progenitor cells of the Lin-CD19+CD43+ fractions at younger ages compared to single Tcf3^tm1(PBX1)Mlc conditional mutants, indicating accelerated preleukemic progenitor B cell expansion

arrested B cell differentiation ( J:226241 )

• preleukemic mice show a greater decrease of immature B cells of the Lin-CD19+CD43- fractions compared to Tcf3^tm1(PBX1)Mlc conditional mutants, indicating a more severe block of B cell differentiation at this stage of maturation

Genotype
MGI:6731079

cn126

• Allelic Composition: Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

decreased plasma cell number ( J:307366 )

• a reduction between 30 and 50% in IgA-secreting cells in spleen and bone marrow

• a reduction between 30 and 50% in IgG-secreting cells in the bone marrow

• marker analysis shows a 50% reduction of splenic CD138/Taci+ plasmablast/plasma cell numbers; this decrease is attributed to the approximate 60% decrease in the late CD19-negative mature plasma cell subset

• the number of late CD19-negative P3-plasma cells is reduced in the bone marrow by approximately 50%, but only in the Taci+ plasma cell subset with a high abundance of surface CD138

increased memory B cell number ( J:307366 )

• 42 days after NP-KLH immunization, mice show a trend of increased numbers of NP-specific memory B cells (CD38-sIgG+) cells in the spleen and bone marrow

• numbers of pro-B cells, pre-B cells, immature B cells, and recirculating mature B cells in the bone marrow are unaltered in non-immunized mice

abnormal plasmablast number ( J:307366 )

• differentiation of germinal center B cells into plasmablasts is impaired resulting in a decrease in numbers of newly formed plasmablasts after immunization with NP-KLH

• however, the number of germinal center B cells is not altered

decreased IgA level ( J:307366 )

• serum IgA levels are reduced by roughly 50% in non-immunized mice

decreased IgG level ( J:307366 )

• serum IgG levels are reduced by roughly 50% in non-immunized mice

• mice immunized with the thymus-dependent model antigen TNP-KLH show reduced TNP-specific IgG titers

decreased IgM level ( J:307366 )

• serum IgM levels are reduced by roughly 50% in non-immunized mice

impaired humoral immune response ( J:307366 )

• mice show reduced antigen-specific antibody responses

• TNP-KLH-immunized mice show a 50% reduction in the number of TNP-specific IgG- or IgM-secreting cells in the spleen and bone marrow 70 days after primary immunization

• TNP-KLH-immunized mice show a reduction in the CD138/Taci+ plasmablast/plasma cell population in the spleen and bone marrow, indicating fewer mature P3-plasma cells

• however, the number of P1-plasmablasts and P2-plasma cells in the spleen and bone marrow are not reduced in TNP-KLH-immunized mice

• mice show lower numbers of P1-plasmablasts in the blood 14 days after primary immunization with TNP-KLH

• TNP-KLH immunized mice show a more pronounced shift to CD19+ cells in CD138/Taci+ populations under homeostatic conditions

• the number of CD138^low early P2-plasma cells in the bone marrow is elevated in TNP-KLH immunized mice

hematopoietic system

decreased plasma cell number ( J:307366 )

• a reduction between 30 and 50% in IgA-secreting cells in spleen and bone marrow

• a reduction between 30 and 50% in IgG-secreting cells in the bone marrow

• marker analysis shows a 50% reduction of splenic CD138/Taci+ plasmablast/plasma cell numbers; this decrease is attributed to the approximate 60% decrease in the late CD19-negative mature plasma cell subset

• the number of late CD19-negative P3-plasma cells is reduced in the bone marrow by approximately 50%, but only in the Taci+ plasma cell subset with a high abundance of surface CD138

increased memory B cell number ( J:307366 )

• 42 days after NP-KLH immunization, mice show a trend of increased numbers of NP-specific memory B cells (CD38-sIgG+) cells in the spleen and bone marrow

• numbers of pro-B cells, pre-B cells, immature B cells, and recirculating mature B cells in the bone marrow are unaltered in non-immunized mice

abnormal plasmablast number ( J:307366 )

• differentiation of germinal center B cells into plasmablasts is impaired resulting in a decrease in numbers of newly formed plasmablasts after immunization with NP-KLH

• however, the number of germinal center B cells is not altered

decreased IgA level ( J:307366 )

• serum IgA levels are reduced by roughly 50% in non-immunized mice

decreased IgG level ( J:307366 )

• serum IgG levels are reduced by roughly 50% in non-immunized mice

• mice immunized with the thymus-dependent model antigen TNP-KLH show reduced TNP-specific IgG titers

decreased IgM level ( J:307366 )

• serum IgM levels are reduced by roughly 50% in non-immunized mice

Genotype
MGI:4438893

cn127

• Allelic Composition: Adam10^tm1.1Dhc/Adam10^tm1.1Dhc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL

hematopoietic system

abnormal B cell differentiation ( J:158127 )

• severely abrogated development of precursors to MZBs in the spleen

decreased transitional stage T2 B cell number ( J:158127 )

• decreased level of T2 B cells in the spleen

increased transitional stage T1 B cell number ( J:158127 )

• modestly increased percentage of T1 cells in the spleen compared with heterozygotes

• normal percentage of total B cells

absent marginal zone B cells ( J:158127 )

• absent marginal zone B cell (MZB) lineage in the spleen

• complete absence of MZBs surrounding the marginal sinus, labeled with the metallophilic macrophage marker 1 in the spleen

increased follicular B cell number ( J:158127 )

• increased level of follicular B cells in the spleen

immune system

abnormal B cell differentiation ( J:158127 )

• severely abrogated development of precursors to MZBs in the spleen

decreased transitional stage T2 B cell number ( J:158127 )

• decreased level of T2 B cells in the spleen

increased transitional stage T1 B cell number ( J:158127 )

• modestly increased percentage of T1 cells in the spleen compared with heterozygotes

• normal percentage of total B cells

absent marginal zone B cells ( J:158127 )

• absent marginal zone B cell (MZB) lineage in the spleen

• complete absence of MZBs surrounding the marginal sinus, labeled with the metallophilic macrophage marker 1 in the spleen

increased follicular B cell number ( J:158127 )

• increased level of follicular B cells in the spleen

Genotype
MGI:3804187

cn128

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tcf3^tm1Mbu/Tcf3^tm1.2Mbu; Tg(Vav-BCL2)69Jad/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL

hematopoietic system

decreased pre-B cell number ( J:137719 )

• GFP+ pre-B cells are absent in the bone marrow

immune system

decreased pre-B cell number ( J:137719 )

• GFP+ pre-B cells are absent in the bone marrow

Genotype
MGI:6387015

cn129

• Allelic Composition: Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
• Cell Lines: HEPD0539_8_A05

immune system

enlarged spleen ( J:280549 )

decreased immature B cell number ( J:280549 )

• decrease in the frequency and absolute number of immature B cells

decreased B-1 B cell number ( J:280549 )

• decrease in the frequency of B1 cells in the peritoneal cavity

increased B cell number ( J:280549 )

• increase in B-cell frequencies in spleen, inguinal lymph nodes, and peritoneal cavity

• increase in absolute numbers of B cells

increased mature B cell number ( J:280549 )

• increase in the frequency and absolute number of mature B cells

increased B-2 B cell number ( J:280549 )

• increase in the frequency of B2 cells in the peritoneal cavity

increased marginal zone B cell number ( J:280549 )

• within the mature B-cell population, marginal zone (MZ) B cells are increased

decreased T cell number ( J:280549 )

• decrease in T-cell frequencies in spleen, inguinal lymph nodes, and peritoneal cavity

abnormal follicular B cell morphology ( J:280549 )

• while the reduced frequency of follicular B cells is due to the expansion of MZ cell population, the absolute number of follicular B cells is not reduced, but is even increased

abnormal B cell activation ( J:280549 )

• B cells exhibit increased expression of surface molecules (MHCII, CD86, CD23, CD21, and ICOSL) associated with B-cell activation

increased immunoglobulin level ( J:280549 )

• antibody deposition to kidney glomeruli is seen in 10 month old mice, but not in 8 week old mice

increased IgA level ( J:280549 )

• increase in serum and fecal IgA concentration

• increase in frequencies of IgA+ B cells in both the spleen and Peyers patches

increased IgG2a level ( J:280549 )

• increase in serum IgG2a concentration

increased IgG2b level ( J:280549 )

• increase in serum IgG2b concentration

increased IgM level ( J:280549 )

• increase in serum IgM concentration

increased circulating interleukin-6 level ( J:280549 )

• increase in serum IL-6 concentration at 10 months of age

increased susceptibility to autoimmune disorder ( J:280549 )

• mutant recipient mice transferred with BM12 CD4 T cells show a stronger autoimmune response than wild-type mice, have a higher frequency of germinal center B cells and plasma cells, a higher titer of serum autoantibodies against dsDNA and nuclear antigen, and higher levels of kidney glomerular deposition with IgG

increased susceptibility to systemic lupus erythematosus ( J:280549 )

• mice develop a lupus-like autoimmune disease

increased anti-nuclear antigen antibody level ( J:280549 )

• mice exhibit higher concentration of serum autoantibodies against nuclear antigen at 10 months of age

increased anti-double stranded DNA antibody level ( J:280549 )

• mice exhibit higher concentration of serum autoantibodies against double-stranded DNA (dsDNA) at 10 months of age

hematopoietic system

enlarged spleen ( J:280549 )

decreased immature B cell number ( J:280549 )

• decrease in the frequency and absolute number of immature B cells

decreased B-1 B cell number ( J:280549 )

• decrease in the frequency of B1 cells in the peritoneal cavity

increased B cell number ( J:280549 )

• increase in B-cell frequencies in spleen, inguinal lymph nodes, and peritoneal cavity

• increase in absolute numbers of B cells

increased mature B cell number ( J:280549 )

• increase in the frequency and absolute number of mature B cells

increased B-2 B cell number ( J:280549 )

• increase in the frequency of B2 cells in the peritoneal cavity

increased marginal zone B cell number ( J:280549 )

• within the mature B-cell population, marginal zone (MZ) B cells are increased

decreased T cell number ( J:280549 )

• decrease in T-cell frequencies in spleen, inguinal lymph nodes, and peritoneal cavity

abnormal follicular B cell morphology ( J:280549 )

• while the reduced frequency of follicular B cells is due to the expansion of MZ cell population, the absolute number of follicular B cells is not reduced, but is even increased

abnormal B cell activation ( J:280549 )

• B cells exhibit increased expression of surface molecules (MHCII, CD86, CD23, CD21, and ICOSL) associated with B-cell activation

increased immunoglobulin level ( J:280549 )

• antibody deposition to kidney glomeruli is seen in 10 month old mice, but not in 8 week old mice

increased IgA level ( J:280549 )

• increase in serum and fecal IgA concentration

• increase in frequencies of IgA+ B cells in both the spleen and Peyers patches

increased IgG2a level ( J:280549 )

• increase in serum IgG2a concentration

increased IgG2b level ( J:280549 )

• increase in serum IgG2b concentration

increased IgM level ( J:280549 )

• increase in serum IgM concentration

homeostasis/metabolism

increased circulating interleukin-6 level ( J:280549 )

• increase in serum IL-6 concentration at 10 months of age

growth/size/body

enlarged spleen ( J:280549 )

Genotype
MGI:6717128

cn130

• Allelic Composition: Pdap1^em1Rkuhn/Pdap1^em1Rkuhn; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N

immune system

abnormal somatic hypermutation frequency ( J:298705 )

• germinal center B cells sorted from Peyer's patches of aged mice show a significantly lower mutation frequency at both JH4 and JK5 intronic regions, with a higher proportion of sequences harboring zero or less than 5 mutations and a concomitant decrease in the number of highly mutated clones relative to control mice

decreased mature B cell number ( J:298705 )

• mice show a marked reduction in the number of splenic resting mature B cells

decreased germinal center B cell number ( J:298705 )

• unimmunized mice show a reduced percentage of germinal center B cells (and IgA+ germinal center cells) in Peyer's patches

abnormal B cell physiology ( J:298705 )

• activated B cells exhibit sustained expression of the integrated stress response (ISR) effector activating transcription factor 4 (Atf4) and induction of the ISR transcriptional program, increased cell death, and reduced AID (activation-induced cytidine deaminase) expression relative to control cells

• resting B cells show phosphorylation of Perk and its downstream target eIF2alpha as well as Atf4 expression, indicating constitutive activation of the Perk-mediated ISR pathway

• however, plasma cell differentiation and function are normal under steady-state conditions

increased B cell apoptosis ( J:298705 )

• CaspGLOW staining of cultured splenocytes revealed increased caspase activity at 24 and 48 h after activation with LPS + IL-4 or LPS-BAFF-TGFbeta

• number of live cells in splenocyte cultures is significantly decreased at 48 and 72 h after activation with LPS + IL-4

abnormal class switch recombination ( J:298705 )

• primary splenic B cells show lower levels of class switch recombination (CSR) for all tested isotypes under in vitro conditions that induce switching to IgG1, IgG3, IgG2b or IgA

• CSR defect is due to impaired formation of AID-induced DNA double-strand breaks (DSBs), caused by defective induction of AID expression with further contribution of impaired germline transcription (GLT) in an isotype-specific manner

• percentage of switched IgA germinal center B cells is significantly reduced in Peyer's patches

• however, B cell proliferation is normal under all stimulation conditions, and class switching is reduced independently of the number of cell divisions

cellular

increased B cell apoptosis ( J:298705 )

• CaspGLOW staining of cultured splenocytes revealed increased caspase activity at 24 and 48 h after activation with LPS + IL-4 or LPS-BAFF-TGFbeta

• number of live cells in splenocyte cultures is significantly decreased at 48 and 72 h after activation with LPS + IL-4

abnormal mitochondrial physiology ( J:298705 )

• splenocyte cultures show an increased proportion of cells with low mitochondrial membrane potential at 24 and 48 h after activation with LPS + IL-4

• however, no changes are observed in mitochondrial mass or respiration capacity

hematopoietic system

abnormal somatic hypermutation frequency ( J:298705 )

• germinal center B cells sorted from Peyer's patches of aged mice show a significantly lower mutation frequency at both JH4 and JK5 intronic regions, with a higher proportion of sequences harboring zero or less than 5 mutations and a concomitant decrease in the number of highly mutated clones relative to control mice

decreased mature B cell number ( J:298705 )

• mice show a marked reduction in the number of splenic resting mature B cells

decreased germinal center B cell number ( J:298705 )

• unimmunized mice show a reduced percentage of germinal center B cells (and IgA+ germinal center cells) in Peyer's patches

abnormal B cell physiology ( J:298705 )

• activated B cells exhibit sustained expression of the integrated stress response (ISR) effector activating transcription factor 4 (Atf4) and induction of the ISR transcriptional program, increased cell death, and reduced AID (activation-induced cytidine deaminase) expression relative to control cells

• resting B cells show phosphorylation of Perk and its downstream target eIF2alpha as well as Atf4 expression, indicating constitutive activation of the Perk-mediated ISR pathway

• however, plasma cell differentiation and function are normal under steady-state conditions

increased B cell apoptosis ( J:298705 )

• CaspGLOW staining of cultured splenocytes revealed increased caspase activity at 24 and 48 h after activation with LPS + IL-4 or LPS-BAFF-TGFbeta

• number of live cells in splenocyte cultures is significantly decreased at 48 and 72 h after activation with LPS + IL-4

abnormal class switch recombination ( J:298705 )

• primary splenic B cells show lower levels of class switch recombination (CSR) for all tested isotypes under in vitro conditions that induce switching to IgG1, IgG3, IgG2b or IgA

• CSR defect is due to impaired formation of AID-induced DNA double-strand breaks (DSBs), caused by defective induction of AID expression with further contribution of impaired germline transcription (GLT) in an isotype-specific manner

• percentage of switched IgA germinal center B cells is significantly reduced in Peyer's patches

• however, B cell proliferation is normal under all stimulation conditions, and class switching is reduced independently of the number of cell divisions

Genotype
MGI:6387022

cn131

• Allelic Composition: Map3k14^tm1.1Gne/Map3k14^tm1.1Gne; Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac
• Cell Lines: HEPD0539_8_A05

immune system

immune system phenotype ( J:280549 )

N • mice show a rescue of the B-cell defect seen in Otub1 conditional mice, with mice showing enhanced frequency and absolute number of peritoneal B2 cells

N • mice show a rescue of the defect in B-cell maturation, with increased splenic mature B cells, particularly the MZ B cells

Genotype
MGI:5911410

cn132

• Allelic Composition: Rnaseh2b^{tm1c(EUCOMM)Wtsi}/Rnaseh2b^{tm1c(EUCOMM)Wtsi}; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL
• Cell Lines: EPD0087_4_A02

immune system

immune system phenotype ( J:186986 )

N • mice exhibit normal numbers of B cells in the spleen

decreased B cell proliferation ( J:186986 )

• LPS-induced

hematopoietic system

decreased B cell proliferation ( J:186986 )

• LPS-induced

cellular

decreased B cell proliferation ( J:186986 )

• LPS-induced

Genotype
MGI:6387020

cn133

• Allelic Composition: Map3k14^tm1.1Gne/Map3k14^tm1.1Gne; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac

hematopoietic system

decreased B cell number ( J:280549 )

• reduction in peripheral B cell numbers

immune system

decreased B cell number ( J:280549 )

• reduction in peripheral B cell numbers

Genotype
MGI:3710554

cn134

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Rbpj^tm1Hon/Rbpj^tm1Hon; Spen^tm2.1Hon/Spen^tm2.1Hon
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

immune system

decreased marginal zone B cell number ( J:121523 )

• severely decreased numbers of marginal zone B cells in spleen

increased follicular B cell number ( J:121523 )

• increased numbers of follicular B cells in spleen

hematopoietic system

decreased marginal zone B cell number ( J:121523 )

• severely decreased numbers of marginal zone B cells in spleen

increased follicular B cell number ( J:121523 )

• increased numbers of follicular B cells in spleen

Genotype
MGI:3710553

cn135

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Spen^tm2.1Hon/Spen^tm2.1Hon
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

immune system

decreased follicular B cell number ( J:121523 )

• decreased numbers of follicular B cells in spleen

increased marginal zone B cell number ( J:121523 )

• increased numbers of marginal zone B cells in spleen

hematopoietic system

decreased follicular B cell number ( J:121523 )

• decreased numbers of follicular B cells in spleen

increased marginal zone B cell number ( J:121523 )

• increased numbers of marginal zone B cells in spleen

Genotype
MGI:4843145

cn136

• Allelic Composition: Pcid2^tm1Imku/Pcid2^tm1Imku; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

immune system

decreased mature B cell number ( J:166080 )

• severely reduced numbers of splenic B cells in the T1(Cd21^loCd24^hi) and T2 (Cd21^hiCd24^hi) stages

• B220+ cells markedly reduced, particularly in the follicular regions of the spleen

decreased follicular B cell number ( J:166080 )

• reduced numbers of Cd21^intCd24^lo cells

decreased marginal zone B cell number ( J:166080 )

• reduced numbers of Cd21^hiCd23^lo cells

abnormal spleen B cell follicle morphology ( J:166080 )

• reduced follicular region size

hematopoietic system

decreased mature B cell number ( J:166080 )

• severely reduced numbers of splenic B cells in the T1(Cd21^loCd24^hi) and T2 (Cd21^hiCd24^hi) stages

• B220+ cells markedly reduced, particularly in the follicular regions of the spleen

decreased follicular B cell number ( J:166080 )

• reduced numbers of Cd21^intCd24^lo cells

decreased marginal zone B cell number ( J:166080 )

• reduced numbers of Cd21^hiCd23^lo cells

abnormal spleen B cell follicle morphology ( J:166080 )

• reduced follicular region size

Genotype
MGI:2663723

cn137

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Notch2^tm2Hhi/Notch2^tm1.1Hhi
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

hematopoietic system

decreased transitional stage B cell number ( J:83476 )

• decrease in the number of T2 B cells

• almost complete absence of CD1d T2 B cells, the precursors of marginal zone B cells (pre-MZB)

abnormal spleen marginal zone morphology ( J:83476 )

• complete absence of the perifollicular rim consisting of IgM^hiIgD^lo cells in the spleen

absent marginal zone B cells ( J:83476 )

• near complete absence of marginal zone B cells in the spleen

immune system

decreased transitional stage B cell number ( J:83476 )

• decrease in the number of T2 B cells

• almost complete absence of CD1d T2 B cells, the precursors of marginal zone B cells (pre-MZB)

abnormal spleen marginal zone morphology ( J:83476 )

• complete absence of the perifollicular rim consisting of IgM^hiIgD^lo cells in the spleen

absent marginal zone B cells ( J:83476 )

• near complete absence of marginal zone B cells in the spleen

Genotype
MGI:3584126

cn138

• Allelic Composition: Mcm3ap^tm1Imku/Mcm3ap^tm1Imku; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

immune system

decreased B cell proliferation ( J:88276 )

• B cell proliferation is slightly impaired in response to CD40/CD50 stimulation but not in response to LPS stimulation

abnormal memory B cell number ( J:88276 )

• decrease in the memory B cell population

decreased B cell number ( J:88276 )

decreased germinal center B cell number ( J:88276 )

• decrease in the germinal center B cell population

abnormal spleen germinal center morphology ( J:88276 )

• germinal center formation is delayed in response to T cell dependent antigen stimulation

abnormal germinal center B cell physiology ( J:88276 )

• after antigen stimulation increased apoptosis is seen in germinal center B cells

decreased IgG level ( J:88276 )

• antibody response (IgG1) to NP25-BSA is markedly reduced with the decrease occurring because of a decrease in the germinal center B cell and memory B cell populations

hematopoietic system

decreased B cell proliferation ( J:88276 )

• B cell proliferation is slightly impaired in response to CD40/CD50 stimulation but not in response to LPS stimulation

abnormal memory B cell number ( J:88276 )

• decrease in the memory B cell population

decreased B cell number ( J:88276 )

decreased germinal center B cell number ( J:88276 )

• decrease in the germinal center B cell population

abnormal spleen germinal center morphology ( J:88276 )

• germinal center formation is delayed in response to T cell dependent antigen stimulation

abnormal germinal center B cell physiology ( J:88276 )

• after antigen stimulation increased apoptosis is seen in germinal center B cells

decreased IgG level ( J:88276 )

• antibody response (IgG1) to NP25-BSA is markedly reduced with the decrease occurring because of a decrease in the germinal center B cell and memory B cell populations

cellular

decreased B cell proliferation ( J:88276 )

• B cell proliferation is slightly impaired in response to CD40/CD50 stimulation but not in response to LPS stimulation

Genotype
MGI:4360762

cn139

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Notch2^tm1.1Hhi/Notch2⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

hematopoietic system

decreased marginal zone B cell number ( J:83476 )

• numbers of marginal zone B cells in the spleen are 1/6 to 1/4 of those in the control mice

• IgM⁺IgD^- marginal zone B cells are reduced in the spleen

immune system

decreased marginal zone B cell number ( J:83476 )

• numbers of marginal zone B cells in the spleen are 1/6 to 1/4 of those in the control mice

• IgM⁺IgD^- marginal zone B cells are reduced in the spleen

Genotype
MGI:3690553

cn140

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^lpr/Fas^tm1Cgn; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL

immune system

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

increased double-negative T cell number ( J:114948 )

• similar to mice with recombination only in T cells

enlarged lymph nodes ( J:114948 )

• similar to mice with recombination only in T cells

hematopoietic system

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

increased double-negative T cell number ( J:114948 )

• similar to mice with recombination only in T cells

growth/size/body

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

Genotype
MGI:5448645

cn141

• Allelic Composition: Nabp2^tm1.1Nfel/Nabp2^tm1.2Nfel; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL

immune system

immune system phenotype ( J:190019 )

N • mice exhibit normal B and T cell development, immunoglobulin class-switch recombination and genomic stability in dividing B lymphocytes

Genotype
MGI:7540616

cn142

• Allelic Composition: Bod1l^em1Bltn/Bod1l^em1Bltn; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J

immune system

decreased IgG level ( J:337726 )

• pre-immune IgG in the serum

decreased IgG1 level ( J:337726 )

• anti-NP27 IgG1 following immunization

hematopoietic system

decreased IgG level ( J:337726 )

• pre-immune IgG in the serum

decreased IgG1 level ( J:337726 )

• anti-NP27 IgG1 following immunization

Genotype
MGI:5614487

cn143

• Allelic Composition: Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺; Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J

immune system

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

increased B cell number ( J:217520 )

• CD19+ B cells in tamoxifen-treated mice

• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion

increased CD4-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased CD8-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased activated T cell number ( J:217520 )

• in tamoxifen-treated mice

• however, T cell numbers decrease 8 days after tamoxifen application

abnormal T cell physiology ( J:217520 )

• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

hematopoietic system

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

increased B cell number ( J:217520 )

• CD19+ B cells in tamoxifen-treated mice

• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion

increased CD4-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased CD8-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased activated T cell number ( J:217520 )

• in tamoxifen-treated mice

• however, T cell numbers decrease 8 days after tamoxifen application

abnormal T cell physiology ( J:217520 )

• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

growth/size/body

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

Genotype
MGI:7550775

cn144

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tbl1xr1^{tm1c(EUCOMM)Hmgu}/Tbl1xr1^{tm1c(EUCOMM)Hmgu}; Tg(Vav-BCL2)69Jad/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N

hematopoietic system

abnormal lymphocyte morphology ( J:292118 )

• large immunoblasts with irregularly shaped nuclei and moderate cytoplasm in lymphoid and other tissues such as kidney and liver when immunized periodically

abnormal B cell differentiation ( J:292118 )

• increased number of B220- cells, expressing more CD138 when immunized periodically

• the few remaining B220+ cells mostly (pre)memory B cells (MBs) and not germinal center B cells (GCBs) when immunized periodically

• normal mature B cell numbers in bone marrow when immunized periodically

abnormal spleen morphology ( J:292118 )

• large immunoblasts with irregularly shaped nuclei and moderate cytoplasm mostly outside follicles in red pulp when immunized periodically

immune system

abnormal lymphocyte morphology ( J:292118 )

• large immunoblasts with irregularly shaped nuclei and moderate cytoplasm in lymphoid and other tissues such as kidney and liver when immunized periodically

abnormal B cell differentiation ( J:292118 )

• increased number of B220- cells, expressing more CD138 when immunized periodically

• the few remaining B220+ cells mostly (pre)memory B cells (MBs) and not germinal center B cells (GCBs) when immunized periodically

• normal mature B cell numbers in bone marrow when immunized periodically

abnormal spleen morphology ( J:292118 )

• large immunoblasts with irregularly shaped nuclei and moderate cytoplasm mostly outside follicles in red pulp when immunized periodically

mortality/aging

premature death ( J:292118 )

• when immunized periodically

neoplasm

increased organ/body region tumor incidence ( J:292118 )

• in kidney, lung, liver, intestines and other organs when immunized periodically

Genotype
MGI:3690552

cn145

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^lpr/Fas^tm1Cgn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * MRL

immune system

enlarged spleen ( J:114948 )

• 5-fold enlargement

enlarged lymph nodes ( J:114948 )

• 17-fold enlargement in the lymph nodes

• weight of the enlarged lymph nodes is still 200- to 300-fold less than in Fas^tm1.1Cgn Fas^lpr trans-heterozygous mice

hematopoietic system

enlarged spleen ( J:114948 )

• 5-fold enlargement

growth/size/body

enlarged spleen ( J:114948 )

• 5-fold enlargement

Genotype
MGI:7281485

cn146

• Allelic Composition: Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺; Myd88^em1.1Rsky/Myd88⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6NTac

hematopoietic system

increased plasma cell number ( J:308792 )

• 15x increase in spleen 10 days after tamoxifen tre

• persistently high number of IgM+ plasma cells in spleen and bone marrow for at least 70 weeks after tamoxifen treatment

increased IgM level ( J:308792 )

• high total IgM serum levels for at least 70 weeks after tamoxifen treatment, displaying discrete paraprotein bands in the gamma-globulin zone upon serum protein electrophoresis

immune system

increased plasma cell number ( J:308792 )

• 15x increase in spleen 10 days after tamoxifen tre

• persistently high number of IgM+ plasma cells in spleen and bone marrow for at least 70 weeks after tamoxifen treatment

increased IgM level ( J:308792 )

• high total IgM serum levels for at least 70 weeks after tamoxifen treatment, displaying discrete paraprotein bands in the gamma-globulin zone upon serum protein electrophoresis

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
monoclonal gammopathy of uncertain significance		DOID:7442		J:308792

Genotype
MGI:5013716

cn147

• Allelic Composition: Birc2^tm1Rbr/Birc2^tm1Rbr; Birc3^tm1Rbr/Birc3^tm1Rbr; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * NZB

immune system

immune system phenotype ( J:172843 )

N • mice exhibit no differences in spleen or lymph node size or in the numbers or phenotype of the B cells within these peripheral lymphoid tissues compared with wild-type mice

Genotype
MGI:5013717

cn148

• Allelic Composition: Birc2^tm1Rbr/Birc2^tm1Rbr; Birc3^tm1.1Rbr/Birc3^tm1.1Rbr; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * NZB

immune system

decreased B cell apoptosis ( J:172843 )

enlarged spleen ( J:172843 )

decreased germinal center B cell number ( J:172843 )

• in response to CD40L, mice exhibit 10-fold lower germinal center B cells compared with wild-type mice

increased B cell number ( J:172843 )

• in the lymph nodes, follicular, and marginal zone

increased follicular B cell number ( J:172843 )

increased marginal zone B cell number ( J:172843 )

decreased spleen germinal center size ( J:172843 )

• in response to CD40L

enlarged lymph nodes ( J:172843 )

hematopoietic system

decreased B cell apoptosis ( J:172843 )

enlarged spleen ( J:172843 )

decreased germinal center B cell number ( J:172843 )

• in response to CD40L, mice exhibit 10-fold lower germinal center B cells compared with wild-type mice

increased B cell number ( J:172843 )

• in the lymph nodes, follicular, and marginal zone

increased follicular B cell number ( J:172843 )

increased marginal zone B cell number ( J:172843 )

decreased spleen germinal center size ( J:172843 )

• in response to CD40L

cellular

decreased B cell apoptosis ( J:172843 )

growth/size/body

enlarged spleen ( J:172843 )

Genotype
MGI:5013718

cn149

• Allelic Composition: Birc2^tm1Rbr/Birc2^tm1Rbr; Birc3^tm1.1Rbr/Birc3^tm1.1Rbr; Cd19^tm1(cre)Cgn/Cd19⁺; Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * NZB

immune system

immune system phenotype ( J:172843 )

N • mice exhibit normal B cell development in the spleen and lymph node unlike in Tnfrsf13c^tm1Mass homozygotes

Genotype
MGI:5301604

cn150

• Allelic Composition: Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL

immune system

enlarged spleen ( J:177784 )

• due to expansion of B cells, regulatory T cells, CD4 and CD8 effector-like T cell, and eosinophils

increased spleen weight ( J:177784 )

increased eosinophil cell number ( J:177784 )

• in the spleen

increased B cell number ( J:177784 )

• in the spleen

increased regulatory T cell number ( J:177784 )

• in the spleen

abnormal effector T cell morphology ( J:177784 )

• mice exhibit an increase in CD4 and CD8 effector-like T cells in the spleen compared with control mice

hematopoietic system

enlarged spleen ( J:177784 )

• due to expansion of B cells, regulatory T cells, CD4 and CD8 effector-like T cell, and eosinophils

increased spleen weight ( J:177784 )

increased eosinophil cell number ( J:177784 )

• in the spleen

increased B cell number ( J:177784 )

• in the spleen

increased regulatory T cell number ( J:177784 )

• in the spleen

abnormal effector T cell morphology ( J:177784 )

• mice exhibit an increase in CD4 and CD8 effector-like T cells in the spleen compared with control mice

growth/size/body

enlarged spleen ( J:177784 )

• due to expansion of B cells, regulatory T cells, CD4 and CD8 effector-like T cell, and eosinophils

increased spleen weight ( J:177784 )

Genotype
MGI:3777347

cn151

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Traf2^tm1Rbr/Traf2^tm1Rbr; Traf3^tm1Rbr/Traf3^tm1Rbr
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

hematopoietic system

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

Genotype
MGI:3777344

cn152

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Traf3^tm1Rbr/Traf3^tm1Rbr
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

increased follicular B cell number ( J:132877 )

• there is almost a 2-fold increase in the number of follicular B cells found in the spleen

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

lymph node hyperplasia ( J:132877 )

hematopoietic system

increased follicular B cell number ( J:132877 )

• there is almost a 2-fold increase in the number of follicular B cells found in the spleen

increased marginal zone B cell number ( J:132877 )

• there are greatly increased numbers of marginal zone B cells in both spleen and lymph nodes

• surface expression of CD21 on these cells is enhanced

abnormal B cell physiology ( J:132877 )

• 50% of B cells remain viable in unsupplemented culture for up to 10 days compared to no survival of wild-type cells

Genotype
MGI:3804190

cn153

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tcf3^tm1Mbu/Tcf3^tm1.2Mbu
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

decreased pro-B cell number ( J:137719 )

• in the bone marrow, pro-B and re-circulating B cell numbers are decreased by half compared to in wild-type mice

decreased B cell number ( J:137719 )

• in the bone marrow, total B cell number in the bone marrow is reduced to 30% of wild-type

• the spleen contains half the number of B cells as in wild-type mice

decreased immature B cell number ( J:137719 )

• in the bone marrow, immature B cells are decreased to 18% of wild-type numbers

• in the spleen, immature B cells are reduced by 50% compared to in wild-type mice

decreased transitional stage B cell number ( J:137719 )

• in the spleen, transitional B cells are reduced by 50% compared to in wild-type mice

decreased mature B cell number ( J:137719 )

• in the spleen, mature B cells are reduced by 50% compared to in wild-type mice

decreased pre-B cell number ( J:137719 )

• in the bone marrow, pre-B cells are decreased to 18% of wild-type numbers

• GFP+ pre-B cells are absent in the bone marrow

hematopoietic system

decreased pro-B cell number ( J:137719 )

• in the bone marrow, pro-B and re-circulating B cell numbers are decreased by half compared to in wild-type mice

decreased B cell number ( J:137719 )

• in the bone marrow, total B cell number in the bone marrow is reduced to 30% of wild-type

• the spleen contains half the number of B cells as in wild-type mice

decreased immature B cell number ( J:137719 )

• in the bone marrow, immature B cells are decreased to 18% of wild-type numbers

• in the spleen, immature B cells are reduced by 50% compared to in wild-type mice

decreased transitional stage B cell number ( J:137719 )

• in the spleen, transitional B cells are reduced by 50% compared to in wild-type mice

decreased mature B cell number ( J:137719 )

• in the spleen, mature B cells are reduced by 50% compared to in wild-type mice

decreased pre-B cell number ( J:137719 )

• in the bone marrow, pre-B cells are decreased to 18% of wild-type numbers

• GFP+ pre-B cells are absent in the bone marrow

Genotype
MGI:5795711

cn154

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

hematopoietic system

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

immune system

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

cellular

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

Genotype
MGI:5316373

cn155

• Allelic Composition: Ebf1^tm1.1Rug/Ebf1^tm1.1Rug; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

hematopoietic system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

Genotype
MGI:5543897

cn156

• Allelic Composition: H2-Ab1^b-tm1Wug/H2-Ab1^b-tm1Wug; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129S2/SvPas * C57BL/6

immune system

immune system phenotype ( J:204951 )

N • mice exhibit normal B cell development

abnormal B cell physiology ( J:204951 )

• B cells prime MOG-specific 2D2 TCR transgenic CD4 T cell proliferation to a lesser extent than wild-type cells

abnormal dendritic cell physiology ( J:204951 )

• bone marrow-derived dendritic cells fail to generate an antigen-specific response unlike wild-type cells

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:204951 )

• resistant in a passive or active model

hematopoietic system

abnormal B cell physiology ( J:204951 )

• B cells prime MOG-specific 2D2 TCR transgenic CD4 T cell proliferation to a lesser extent than wild-type cells

Genotype
MGI:3584440

cn157

• Allelic Composition: Lmo2^tm3Thr/Lmo2^tm4Thr; Cd19^tm1(cre)Thr/Cd19⁺
• Genetic Background: involves: 129S/SvEv

hematopoietic system

hematopoietic system phenotype ( J:86869 )

N • mutant mice are viable and exhibit no hematopoietic defects, with normal bone marrow, spleen and thymus cell counts

immune system

immune system phenotype ( J:86869 )

N • normal T and B lymphoid development

Genotype
MGI:2657004

cn158

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ikbkb^tm2Mka/Ikbkb^tm2Mka
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * C57BL/6

hematopoietic system

increased B cell apoptosis ( J:82995 )

• decrease in survival of B cells

decreased B cell number ( J:82995 )

• reduction in populations of some peripheral B cell subsets, particularly the lymph node compartment

• B cell generation is not impaired

decreased B-1 B cell number ( J:82995 )

• reduced number of peritoneal B-1 cells

decreased marginal zone B cell number ( J:82995 )

abnormal B cell activation ( J:82995 )

• mutants fail to mount effective antibody responses to T cell-dependent and independent antigens

decreased B cell proliferation ( J:82995 )

• hypoproliferation in response to anti-IgM, LPS, and anti-Tnfrsf5 (anti9-CD40)

decreased IgG level ( J:82995 )

• decrease in basal IgG levels

decreased IgM level ( J:82995 )

• decrease in basal IgM levels

immune system

increased B cell apoptosis ( J:82995 )

• decrease in survival of B cells

decreased B cell number ( J:82995 )

• reduction in populations of some peripheral B cell subsets, particularly the lymph node compartment

• B cell generation is not impaired

decreased B-1 B cell number ( J:82995 )

• reduced number of peritoneal B-1 cells

decreased marginal zone B cell number ( J:82995 )

abnormal B cell activation ( J:82995 )

• mutants fail to mount effective antibody responses to T cell-dependent and independent antigens

decreased B cell proliferation ( J:82995 )

• hypoproliferation in response to anti-IgM, LPS, and anti-Tnfrsf5 (anti9-CD40)

decreased IgG level ( J:82995 )

• decrease in basal IgG levels

decreased IgM level ( J:82995 )

• decrease in basal IgM levels

cellular

increased B cell apoptosis ( J:82995 )

• decrease in survival of B cells

decreased B cell proliferation ( J:82995 )

• hypoproliferation in response to anti-IgM, LPS, and anti-Tnfrsf5 (anti9-CD40)

Genotype
MGI:3843174

cn159

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ep300^tm2Reck/Ep300⁺
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * C57BL/6

mortality/aging

premature death ( J:147840 )

• all mice die by prematurely, but female mice exhibit a shorter life span than male mice (median survival of 29 weeks for females compared with 43 weeks for males)

• Background Sensitivity: mice have a shorter life span than mice on a mixed background containing C57BL/6

immune system

arteritis ( J:147840 )

• mice exhibit paravascular cell infiltration and thickening of the artery walls unlike in wild-type mice

enlarged spleen ( J:147840 )

increased spleen weight ( J:147840 )

• at 4 to 6 months

abnormal B cell differentiation ( J:147840 )

• mature B cells in aged mice lack CD23 expression unlike in wild-type mice indicating an age-dependent loss of part of the normal B cell differentiation program

abnormal transitional stage B cell morphology ( J:147840 )

• fewer transitional B cells with the AA4.1+ phenotype are detected compared to in wild-type mice

• however, the number of total transitional B cells is normal

decreased marginal zone B cell number ( J:147840 )

increased B cell number ( J:147840 )

• the number of activated B cells in the spleen is more than in wild-type mice

increased activated T cell number ( J:147840 )

• in the spleen

abnormal spleen marginal zone macrophage morphology ( J:147840 )

• decreased in number

intermingled spleen red and white pulp ( J:147840 )

enlarged lymph nodes ( J:147840 )

• in some mice

abnormal adaptive immunity ( J:147840 )

• following ovalbumin immunization, the memory response upon boosting with ovalbumin is 3-fold less than in similarly treated wild-type mice

increased B cell apoptosis ( J:147840 )

• following IgM stimulation, apoptosis of transitional B cells is greater than in wild-type mice

• however, mature B cells exhibit normal apoptosis rates

decreased B cell proliferation ( J:147840 )

• in response to BCR engagement by anti-IgM, B cell proliferation is less than in wild-type mice

• however, B cells exhibit normal proliferation in response to LPS, IL4, anti-CD40 and ODN1668, and IgM proliferation can be restored by co-stimulation with anto-CD40 or IL4

abnormal humoral immune response ( J:147840 )

• prior to ovalbumin immunization, mice exhibit 3-fold more ovalbumin-specific immunoglobins compared to in wild-type mice

• however, the humoral response 14 days after immunization is normal

increased immunoglobulin level ( J:147840 )

• 1.6-fold at 10 months of age

increased IgG2b level ( J:147840 )

• 3.7-fold

increased susceptibility to systemic lupus erythematosus ( J:147840 )

• Background Sensitivity: mice develop systemic lupus erythematosus symptoms earlier in life than when mice are on a mixed background containing FVB/N

increased anti-double stranded DNA antibody level ( J:147840 )

kidney inflammation ( J:147840 )

• interstitial

glomerulonephritis ( J:147840 )

renal/urinary system

kidney inflammation ( J:147840 )

• interstitial

glomerulonephritis ( J:147840 )

abnormal renal glomerulus morphology ( J:147840 )

• glomeruli are enlarged and often filled with homogeneous protein deposits in the kidney, spleen, liver, and lungs unlike in wild-type mice

renal glomerular protein deposits ( J:147840 )

renal fibrosis ( J:147840 )

cardiovascular system

arteritis ( J:147840 )

• mice exhibit paravascular cell infiltration and thickening of the artery walls unlike in wild-type mice

hematopoietic system

increased B cell apoptosis ( J:147840 )

• following IgM stimulation, apoptosis of transitional B cells is greater than in wild-type mice

• however, mature B cells exhibit normal apoptosis rates

decreased B cell proliferation ( J:147840 )

• in response to BCR engagement by anti-IgM, B cell proliferation is less than in wild-type mice

• however, B cells exhibit normal proliferation in response to LPS, IL4, anti-CD40 and ODN1668, and IgM proliferation can be restored by co-stimulation with anto-CD40 or IL4

enlarged spleen ( J:147840 )

increased spleen weight ( J:147840 )

• at 4 to 6 months

abnormal B cell differentiation ( J:147840 )

• mature B cells in aged mice lack CD23 expression unlike in wild-type mice indicating an age-dependent loss of part of the normal B cell differentiation program

abnormal transitional stage B cell morphology ( J:147840 )

• fewer transitional B cells with the AA4.1+ phenotype are detected compared to in wild-type mice

• however, the number of total transitional B cells is normal

extramedullary hematopoiesis ( J:147840 )

• with islands of granulopoiesis

increased megakaryocyte cell number ( J:147840 )

• 4- to 20-fold in the spleen

decreased marginal zone B cell number ( J:147840 )

increased B cell number ( J:147840 )

• the number of activated B cells in the spleen is more than in wild-type mice

increased activated T cell number ( J:147840 )

• in the spleen

abnormal spleen marginal zone macrophage morphology ( J:147840 )

• decreased in number

intermingled spleen red and white pulp ( J:147840 )

increased immunoglobulin level ( J:147840 )

• 1.6-fold at 10 months of age

increased IgG2b level ( J:147840 )

• 3.7-fold

cellular

increased B cell apoptosis ( J:147840 )

• following IgM stimulation, apoptosis of transitional B cells is greater than in wild-type mice

• however, mature B cells exhibit normal apoptosis rates

decreased B cell proliferation ( J:147840 )

• in response to BCR engagement by anti-IgM, B cell proliferation is less than in wild-type mice

• however, B cells exhibit normal proliferation in response to LPS, IL4, anti-CD40 and ODN1668, and IgM proliferation can be restored by co-stimulation with anto-CD40 or IL4

growth/size/body

enlarged spleen ( J:147840 )

increased spleen weight ( J:147840 )

• at 4 to 6 months

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
systemic lupus erythematosus		DOID:9074	OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420	J:147840

Genotype
MGI:3843175

cn160

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Ep300^tm2Reck/Ep300⁺
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * FVB/N

mortality/aging

premature death ( J:147840 )

• Background Sensitivity: mice have a longer life span than mice on a mixed background containing C57BL/6

• all mice die prematurely, but female mice exhibit a shorter life span than male mice (median survival of 73 weeks for females compared with over 90 weeks for males)

immune system

increased susceptibility to systemic lupus erythematosus ( J:147840 )

• Background Sensitivity: mice develop systemic lupus erythematosus symptoms later in life than when mice are on a mixed background containing C57BL/6

Genotype
MGI:5446431

cn161

• Allelic Composition: Tbk1^tm1Arte/Tbk1^tm1Arte; Map3k14^tm1Rds/Map3k14^tm1Rds; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129/SvEv * 129P2/OlaHsd * C57BL/6

immune system

abnormal B cell differentiation ( J:188560 )

• no significant increase in the production of IgA+ compared to mice homozygous for Map3k14^tm1Rds alone

abnormal immunoglobulin level ( J:188560 )

• unlike mutant mice wild-type for Map3k14 the serum titer of IgA is not elevated

hematopoietic system

abnormal B cell differentiation ( J:188560 )

• no significant increase in the production of IgA+ compared to mice homozygous for Map3k14^tm1Rds alone

abnormal immunoglobulin level ( J:188560 )

• unlike mutant mice wild-type for Map3k14 the serum titer of IgA is not elevated

Genotype
MGI:5446428

cn162

• Allelic Composition: Tbk1^tm1Arte/Tbk1^tm1Arte; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129/SvEv * 129P2/OlaHsd * C57BL/6

immune system

increased mature B cell number ( J:188560 )

• much greater frequency of IgA+ B cells in mesenteric lymph nodes and Peyer's patches compared to age matched controls

• significantly greater frequency and number of IgA+ B cells in the spleen in young mice immunized with a T cell dependent antigen

abnormal B cell physiology ( J:188560 )

• moderate increase in NKKB activation following induction

abnormal class switch recombination ( J:188560 )

• expression analysis indicates a defect in the negative regulation of class switching to IgA

increased IgA level ( J:188560 )

• production of antigen specific IgA in immunized mice is enhanced compared to similarly treated controls

• starting at 12 weeks of age serum IgA levels are increased in unimmunized mice compared to aged match controls

increased IgM level ( J:188560 )

• production of antigen specific IgM in immunized mice is moderately enhanced compared to similarly treated controls

increased anti-nuclear antigen antibody level ( J:188560 )

• higher serum titers of the autoantibody antinuclear antigen at 8 months of age

increased anti-double stranded DNA antibody level ( J:188560 )

• at 8 months of age

renal/urinary system

increased urine protein level ( J:188560 )

• at 8 months of age

abnormal kidney physiology ( J:188560 )

• prominent deposition of antibodies in the kidney glomeruli at 8 months of age a sign of nephropathy

homeostasis/metabolism

increased circulating creatinine level ( J:188560 )

• at 8 months of age

increased blood urea nitrogen level ( J:188560 )

• at 8 months of age

increased urine protein level ( J:188560 )

• at 8 months of age

hematopoietic system

increased mature B cell number ( J:188560 )

• much greater frequency of IgA+ B cells in mesenteric lymph nodes and Peyer's patches compared to age matched controls

• significantly greater frequency and number of IgA+ B cells in the spleen in young mice immunized with a T cell dependent antigen

abnormal B cell physiology ( J:188560 )

• moderate increase in NKKB activation following induction

abnormal class switch recombination ( J:188560 )

• expression analysis indicates a defect in the negative regulation of class switching to IgA

increased IgA level ( J:188560 )

• production of antigen specific IgA in immunized mice is enhanced compared to similarly treated controls

• starting at 12 weeks of age serum IgA levels are increased in unimmunized mice compared to aged match controls

increased IgM level ( J:188560 )

• production of antigen specific IgM in immunized mice is moderately enhanced compared to similarly treated controls

Genotype
MGI:7281480

cn163

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Myd88^em1.1Rsky/Myd88^em1.1Rsky
• Genetic Background: involves: C57BL/6NTac

cellular

increased B cell proliferation ( J:308792 )

• transient expansion of B cells in absence or presence of added mitogens in vitro

hematopoietic system

increased B cell proliferation ( J:308792 )

• transient expansion of B cells in absence or presence of added mitogens in vitro

immune system

increased B cell proliferation ( J:308792 )

• transient expansion of B cells in absence or presence of added mitogens in vitro

Genotype
MGI:7281482

cn164

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Myd88^em1.1Rsky/Myd88⁺
• Genetic Background: involves: C57BL/6NTac

hematopoietic system

hematopoietic system phenotype ( J:308792 )

N • normal B cell development in bone marrow

N • normal Ig class switching in B cells in spleen, mesenteric lymph nodes and Peyers patches

enlarged spleen ( J:308792 )

• from age 30 weeks

increased germinal center B cell number ( J:308792 )

• increased frequency and number from age 30 weeks, increasing over time

increased plasma cell number ( J:308792 )

• increased number of IgM+ plasma cells

• increased plasma cell compartment in spleen and bone marrow

• increased frequency and number of TACI+ CD138+ plasma cells from age 50 weeks

abnormal splenic cell ratio ( J:308792 )

• increased frequency and number of germinal center B cells from age 30 weeks, increasing over time

• normal frequency of follicular and marginal zone B cells

increased IgM level ( J:308792 )

• increased serum levels from age 10 weeks, increasing over time

immune system

enlarged spleen ( J:308792 )

• from age 30 weeks

increased germinal center B cell number ( J:308792 )

• increased frequency and number from age 30 weeks, increasing over time

increased plasma cell number ( J:308792 )

• increased number of IgM+ plasma cells

• increased plasma cell compartment in spleen and bone marrow

• increased frequency and number of TACI+ CD138+ plasma cells from age 50 weeks

abnormal splenic cell ratio ( J:308792 )

• increased frequency and number of germinal center B cells from age 30 weeks, increasing over time

• normal frequency of follicular and marginal zone B cells

increased IgM level ( J:308792 )

• increased serum levels from age 10 weeks, increasing over time

growth/size/body

enlarged spleen ( J:308792 )

• from age 30 weeks

Genotype
MGI:5013719

cx165

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

hematopoietic system

abnormal B cell differentiation ( J:172843 )

• in the spleen and lymph node

immune system

abnormal B cell differentiation ( J:172843 )

• in the spleen and lymph node